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Abstract 
Drug Induced Liver Injury (DILI) is of major concern to both clinicians and the 
pharmaceutical industry due to the attrition of lead compounds during preclinical 
development and the incidence of hepatotoxicity and/or the withdrawal of drugs post 
marketing. It has been hypothesised that drug-induced mitochondrial dysfunction (DIMD) 
could be a causative factor of DILI.  
The nucleoside analogue fialuridine (FIAU) was withdrawn from use following a clinical trial 
in 1993 in which 5 patients died of hepatic failure. Subsequent research has shown that 
FIAU induces toxicity via mitochondrial DNA damage. However, current in vitro screening 
methods do not identify these compounds as toxic and thus this poses a problem to pre-
clinical safety assessments. Three methods of metabolic modification, utilising glucose or 
galactose supplemented media and 2DG were compared to define and monitor 
mitochondrial toxicity induced by FIAU, and positive control adefovir (ADEF), in HepG2 
(human hepatocellular carcinoma) cells. The structural isomer of fialuridine, (FIAU 2’ 
epimer) was included as a negative control. Mitochondrial toxicity could not be 
demonstrated in HepG2 cells over a 7-day period by any of these drugs. 
The HepaRG line is evident to be more hepatocyte-like than HepG2 cells and therefore can 
overcome the limitations of the widely used HepG2 cells. It is hypothesised that their 
increased primary human hepatocyte (PHH) like phenotypic characteristics may be more 
suitable for drug toxicity studies. Here, the utility of HepaRG based models in the detection 
of mitotoxicants was compared with previous research using a HepG2 model. Bioenergetic 
phenotyping revealed that the HepaRG line is less metabolically active when compared to 
HepG2 cells. HepaRG cells have the capacity to undergo metabolic modification using a 
short term glucose/galactose switch method and thus detect compounds with 
mitochondrial liabilities (EC50-ATPglu/EC50-ATPgal >2). Following the assessment of 12 
hepatotoxins it was concluded that the HepaRG line offered no increased sensitivity for the 
detection of mitotoxicants compared with HepG2 cells. However, their stability in culture 
over extended periods (1 to 4 weeks) may be advantageous for the study of delayed 
toxicity. Therefore, HepaRG cells were further utilised in the assessment of FIAU induced 
mitochondrial toxicity, using an acute metabolic screen. Mitochondrial toxicity in the 
absence of cell death was demonstrated following 2-week drug incubation. The 
measurement of cellular respiration (using Seahorse technology) demonstrated a dose-
dependent decrease in mitochondrial respiration in the absence of a decrease in 
mitochondrial mass. Further studies demonstrated significant drug-dependent decreases in 
the expression of nuclear encoded complex II, mitochondria-encoded complex IV, plus a 
decrease in mitochondrial DNA (mtDNA). The studies have demonstrated that the HepaRG 
cell model is a suitable model for the study of mitochondrial toxicity induced by nucleoside 
antivirals with evidence indicating that the mechanism of action via effects upon 
mitochondrial DNA matches the clinical mechanism of hepatotoxicity.  
Further studies utilising HepaRG were performed to assess the chemical and molecular 
pathways of toxicity induced by paracetamol. The studies provided evidence that HepaRG 
cells have the metabolic capacity for the turnover of parent compound to the toxic 
metabolite NAPQI. Furthermore, acute metabolic screening demonstrated that following 
short term incubations the parent compound paracetamol contains a mitochondrial liability 
in the absence of NAPQI-induced GSH depletion.  
The studies within this thesis have highlighted that the HepaRG line is suitable for the 
detection of mitotoxicants in which toxicity is delayed or which is mediated via CYP P450 
catalysed-metabolites. Additionally, the studies provide much evidence as to the power of 
in vitro screening models in providing fine and detailed mechanistic information. 
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1.1. Adverse Drug Reactions 
As defined by the World Health Organisation an adverse drug reaction (ADR) is an event 
which is both noxious, unintended and occurs at doses intended for prophylaxis, therapy 
and diagnosis (Organisation, 1966). However, this definition does not include events caused 
by drug abuse, therapeutic failures, intentional or accidental poisoning plus drug 
noncompliance (Lazarou et al., 1998). In 2000 the number of deaths caused by ADRs, as 
recorded on death certificates, stood at 206 within the United States of America. However 
the post marketing surveillance system, MedWatch reported a figure of 6,894 (Chyka, 
2000). While both figures are grossly different it’s important to remember that whatever 
the true figure mortality can be attributed to ADRs. It has been reported that 6.5% of all 
admissions to the National Health Service (NHS) of the UK are due to ADRs with an 
associated financial cost of £466m per annum (Pirmohamed et al., 2004). The severity of 
unexpected ADR is exemplified by a phase II clinical trial involving the 2
nd
 generation anti-
viral agent fialuridine (FIAU) when a number of unanticipated reactions were observed 
amongst the volunteers. Of these, the most serious were hepatic failure with the 
subsequent death of 5 out of the 15 volunteers (Honkoop et al., 1997). Even more recently 
in the Avandia event, a meta-analysis revealed a link between rosiglitazone and an 
increased risk of myocardial infarction  (Nissen et al., 2007). While the drug is still in use for 
the treatment of diabetes serious questions have been raised about pharmacovigilance and 
reporting (Psaty et al., 2007). ADRs can result in drug attrition even before clinical trials 
have been approved. This was seen in the case of the blockage of human ether-a-go-go-
related gene (hERG) potassium channels leading to life-threatening prolonged QT 
syndrome (Torsades de pointes) (Sanguinetti et al., 2006). Both Cisapride which is a 
gastroprokinetic agent and the antipsychotic drug Sertindole have been withdrawn  over 
concerns of prolonged QT syndrome (Yap et al., 2003). 
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1.2. Drug Induced Liver Injury (DILI) 
ADR specific to the liver is termed drug-induced liver injury (DILI) and can be described as 
liver injury due to a drug or medicinal product resulting in abnormal tests and or liver 
dysfunction while all other aetiologies have been ruled out. It should be noted that DILI 
does not include hepatic injury caused by non-medicinal, complimentary and or herbal 
products (Bleibel et al., 2007; Björnsson, 2010). Presently DILI is both the leading cause of 
acute liver failure in the United States of America (USA) and also a leading factor in liver 
injury worldwide (Tujios et al., 2011). DILI is the most frequent single reason for the 
removal of drugs from the market and is likely the single toxicity leading to withdrawal or 
significant modification of labelling, such as black box warnings (Temple et al., 2002). 
According to the NIH LIVERTOX database, approximately 1,100 drugs and or medicinal 
products have hepatic liabilities (National Institutes of Health (NIH), 2012). Additionally, 
between 1953 and 2013, 81 drugs were withdrawn across different pharmaceutical 
markets due to DILI (Suzuki et al., 2010). It can thus be appreciated that DILI is a major 
cause of concern both clinically  and during the development of new drugs due to both 
financial and legal ramifications (Devarbhavi, 2012). 
While the incidence of DILI is relatively unknown, a French study estimated that DILI occurs 
at a rate of approximately 14 in 100,000 patients (Bagheri et al., 2000; Sgro et al., 2002). 
Interestingly, while this figure is low, the researchers discovered that the number of 
spontaneous reporting occasions to the French regulatory authorities was actually 16x 
lower, thus highlighting the unreported nature of DILI. Even though it is evident that under 
reporting is prevalent, DILI is still responsible for fewer incidences of hepatotoxicity/liver 
dysfunction compared with alcohol abuse, viral hepatitis and diabetes (Ostapowicz et al., 
2002) . One clinical study has reported that 9% of abnormal liver function tests can be 
attributed to DILI (Bagheri et al., 2000). DILI is relatively rare and uncommon within the 
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young however its incidence increases within the elderly, potentially due to the increased 
number of medications being taken (Pessayre et al., 2008a).  
 In the most basic sense DILI can be divided into two types, intrinsic and idiosyncratic. 
Intrinsic reactions generally occur in a dose-dependent manner whereby the toxicity is 
reproducible in animal models. On the contrary idiosyncratic reactions are very rare, are 
not dose related plus the time from administration to the manifestation of symptoms often 
varies. Additionally, it very difficult to model these reactions within animal studies (Roth et 
al., 2010). However, the classification between intrinsic and idiosyncratic reactions is not 
clear cut with overlap between both types. For example, paracetamol can be classified as 
an intrinsic hepatotoxin although in some individuals hepatotoxicity is seen at doses of <4 
g/day while others can tolerate dosages of 10-15 g/day (Shayiq et al., 1999; Krähenbuhl et 
al., 2007).  
1.2.1. Diagnosis of DILI 
Within the clinic, symptoms of DILI can appear similar to those seen in non-drug induced 
hepatic conditions such as acute viral hepatitis, hepatic steatosis, acute cholangitis, and 
primary biliary cirrhosis, amongst many others (Bleibel et al., 2007). The most common 
form of hepatic injury resulting from DILI is acute hepatitis. With the utilisation of a liver 
biopsy 3 subtypes can be further classified; cholestatic, hepatocellular and mixed (Pessayre 
et al., 2008a). Cholestatic injury is associated with inflammation and brown bile deposits 
within the hepatocytes. Hepatocellular is associated with inflammation plus signs of 
apoptotic and necrosis led cell death. Lastly, mixed injury is associated with inflammation, 
necrosis plus cholestatic injury (Pessayre et al., 2008b). While diagnosis using biopsy is not 
always possible or practical, biochemical analysis can be utilised in cases of mild or 
moderate hepatitis (Pessayre et al., 2008b). For example, readings of 2 x the upper limit of 
normal (ULN) of alkaline phosphatase (AP) or a ratio of alanine aminotransferase (ALT):AP 
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≤2 then the injury can be classified as cholestatic; 2 x ULN ALT or ALT:AP ratio ≥ 5 then the 
injury can be classified as hepatocellular or mixed injury can be established when both 2 x 
of ALT and AP or ALT:AP ratio is between 2 and 5 (Benichou, 1990). Through the utilisation 
of biochemical analysis and by assessment of the aforementioned ratio’s a greater insight 
into the mechanism of injury and its severity can be established.   
1.2.2. The molecular mechanisms underlying DILI 
The pathogenesis of DILI is believed to be multifactorial involving numerous pathways and 
components, one mechanism alone cannot fully explain the hepatic injury observed.  The 
following section will discuss three components and their interplay which have been 
proposed as critical elements within DILI; xenobiotic metabolism, the immune system and 
mitochondrial dysfunction.  
Metabolism is an important factor in the pathogenesis of DILI. Drugs are metabolised in the 
liver to become more polar to enable their subsequent excretion (David et al., 2010).The 
ultimate goal in the metabolism of an exogenous compound is to render the compound 
more hydrophilic, thus more water soluble, therefore the compound can undergo renal 
excretion.  The process of converting an exogenous, potentially toxic compound into a 
compound with greater hydrophilic character often occurs in two phases; phase I 
metabolism, which involves the addition or subtraction of a functional group and phase II 
metabolism, in which the exogenous compound or its intermediary is conjugated to a 
charged, polar group and so becomes more excretable (Hodgson, 2004; Timbrell, 2009). 
The liver receives 80 % of its blood flow directly from the gastrointestinal tract (Park et al., 
2005). Thus, the liver receives high concentrations of drugs, and or metabolites, after 
administration in order to minimise or eliminate systemic drug exposure (Antoine et al., 
2008). Phase I metabolism can lead to the formation of reactive metabolites through 
oxidative reactions catalysed by the cytochrome P450 (CYP450) family of enzymes. These 
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reactive metabolites can bind to macromolecules and form protein adducts (Hodgson, 
2004; Antoine et al., 2008; Timbrell, 2009).  
The roles of both the adaptive and innate immune system have been assessed as important 
components within DILI. It has been demonstrated that reactive metabolites can bind to 
intracellular proteins forming haptens, with subsequent activation of cytotoxic T-cells 
leading to the release of pro-inflammatory cytokines. An example of this can be seen with 
halothane induced hepatitis resulting from an immune reaction against the CYP2E1-
halothane complex (Njoku et al., 2002). A study carried out by Daly et al, 2009 
demonstrated that individuals with the human leukocyte antigen HLA-B*5701 genotype are 
more likely to develop cholestatic injury following administration of the antimicrobial agent 
flucloxacillin. It was suggested by the authors of the study that flucloxacillin induced liver 
injury may have a T-cell and thus adaptive immune component to its toxicity (Daly et al., 
2009). Similar studies have demonstrated associations between the HLA-DQA1*02:01 
genotype and lapatinib-induced liver injury in women with advanced breast cancer (Spraggs 
et al., 2011). While haptenisation is a useful concept questions remain. For example, many 
drugs form reactive metabolites yet are not associated with a clear immune element during 
toxicity. 
The role of the innate immune system has also been assessed with many studies 
highlighting that underlying stress and inflammation may potentiate drug toxicity.  Two 
studies, one retrospective and one controlled, discovered that patients with acquired 
immunodeficiency syndrome (AIDS) who were treated with trimethoprim- 
sulfamethoxazole for Pneumocystis carinii had higher incidences of hepatitis (Gordin et al., 
1984; Medina et al., 1990). Furthermore, it has been demonstrated that patients with viral 
hepatitis C may be at increased risk of acute liver injury following paracetamol overdose. 
Whilst the mechanism is not fully understood it is postulated that during periods of 
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inflammation the innate immune system is activated resulting in the release of pro-
inflammatory mediators leading to the depletion of cellular defences such as GSH (Nguyen 
et al., 2008). This theory is supported by a study which demonstrated that the induction of 
inflammatory stress using lipopolysaccharide rendered mice sensitive to the antibiotic 
trovafloxacin, a hepatotoxin with a significant elevation in the cytokine tumor necrosis 
factor-α (TNFα) plasma concentration prior to hepatic injury. The same study also 
demonstrated that levofloxacin, which is not thought to possess a hepatic liability, did not 
cause liver injury after induction of inflammatory stress (Shaw et al., 2007). It is evident that 
the immune system plays a role within DILI and that inflammatory stress may potentiate 
liver injury. 
From these observations stress signalling has been suggested as having a role in mediating 
DILI. During an inflammatory event, the pro-survival activity of NF-κB suppresses C-Jun N-
terminal kinase (JNK) activation which is induced by TNFα (Papa et al., 2004). Many 
intracellular stressors such as UV light, reactive oxygen species (ROS) and cytokines can 
activate this pathway (Shen et al., 2006). Additionally, it has been demonstrated that the 
depletion of hepatic glutathione (GSH) stores using methyl-2-cyano-3, 12-dioxooleana-1, 9-
dien-28-oate (CDDO-Me) activates the JNK pathway (Yue et al., 2006). It has suggested that 
sustained activation of the JNK pathway is required to enable translocation of 
phosphorylated JNK to the mitochondria where it binds to SH3 domain-binding protein 
(SAB). This process results in further amplification of cellular stress, increased mitochondrial 
dysfunction resulting in the formation of MPTP, depolarisation of the mitochondrial 
membrane potential and lastly necrotic cell death. Cell death has been prevented using the 
JNK inhibitor leflunomide thus further supporting the view that the JNK pathway is also an 
important factor within DILI (Latchoumycandane et al., 2007; Win et al., 2011).  
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It is evident that, during DILI, different pathways converge at the site of mitochondria 
leading to either apoptosis or necrosis. The following section will further explore the 
mitochondrial component and its relevance to DILI. 
1.2.3. The Mitochondrion 
It is widely believed that mitochondria have a bacterial origin which arose from a symbiotic 
relationship between early ancestral eukaryotic cells and bacteria (Yoon et al., 2010). 
Researchers using a 2',3'-dideoxynucleotide chain termination method determined the 16S 
ribosomal RNA sequences of both Agrobacterium tumefaciens and Pseudomonas 
testosterone (Yang et al., 1985). Both are prokaryotes that belong to the α and β 
subdivisions respectively. Further sequence analysis revealed that mitochondria originate 
from an endosymbiont of the α subdivision (Yang et al., 1985). In fact the idea that 
mitochondria are bacteria and that the scientific community should endorse mitochondria 
being given their own taxonomic family, the Mitochondriaceae has been argued (Pallen, 
2011). Strong arguments for their reclassification stating that molecular phylogenetic 
studies when applied to mitochondrial encoded macromolecules reveal an 
alphaproteobacterial association with bacteria are discussed by the author.  Together with 
protein biosynthesis, genetic and structural similarities a robust argument for the 
establishment of the Mitochondriaceae family is set forth (Pallen, 2011).   
1.2.3.1. Mitochondrion Structure 
The mitochondrion comprises two membranes, an inner and outer, which leads to the 
creation of two distinct compartments; the matrix and intermembrane space (Frey et al., 
2000; Yoon et al., 2010) (Fig. 1.1). The inner mitochondrial membrane is largely 
impermeable, however, the outer membrane is permeable to small molecules less than 5 
kDa in size due to the presence of porin molecules (Frey et al., 2000; Yoon et al., 2010). The 
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impermeable inner membrane contains cristae which form projections into the 
mitochondrial matrix and it is here where key biochemical reactions take place including 
the tricarboxylic acid cycle (TCA/Krebs cycle) and fatty acid breakdown (β-oxidation) (Frey 
et al., 2000; Baltzer et al., 2010). The intermembrane space is situated between both the 
inner and outer membranes and there lies the electron carrying protein, Cytochrome C 
while the apparatus of OXPHOS, the electron transport chain (ETC) plus transport proteins 
are situated within the cristae of  the inner membrane (Lesnefsky et al., 2006). The 
impermeability of the inner membrane results in a chemical gradient of protons between 
the inner membrane and matrix. The resultant chemical imbalance is utilised as the driving 
force behind the synthesis of ATP (Yoon et al., 2010).  
 
 
Figure 1.1. The Baffle model depicting the structure of a mitochondrion and key structural 
features including the electron transport chain embedded within the inner membrane 
(Frey et al., 2000). 
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1.2.3.2. The mitochondrial genome 
 
Due to its bacterial origin, the mitochondrion contains its own DNA. Mitochondria DNA 
(mtDNA) encodes  for the proteins and enzymes utilised within OXPHOS plus rRNAs and 
tRNAs used for mitochondrial translation (Baltzer et al., 2010). The human mitochondrial 
genome is a small circular double stranded DNA molecule composed of 16,569 base pairs 
(Brandon et al., 2005). The genome contains no introns apart from a noncoding region 
within the D-Loop, therefore, all 37 genes are arranged in a compacted assembly. 13 of the 
37 genes encode the enzymes responsible for the energy production process OXPHOS 
(Table 1.1). The remaining 24 genes encode 22 tRNAs plus 2 rRNAs which are responsible 
for Mt genome translational processes (Yoon et al., 2010).  
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Map Locus Description 
MT-CYB Cytochrome b (Anderson et al., 1981) 
MT-ND6 NADH dehydrogenase subunit 6 (Anderson et al., 1981; 
Chomyn et al., 1986) 
MT-ND5 NADH dehydrogenase subunit 5 (Anderson et al., 1981; 
Chomyn et al., 1985) 
MT-ND4 NADH dehydrogenase subunit 4 (Anderson et al., 1981; 
Chomyn et al., 1985) 
MT-ND4L NADH dehydrogenase subunit 4L (Anderson et al., 1981; 
Chomyn et al., 1985) 
MT-ND3 NADH dehydrogenase subunit 3 (Anderson et al., 1981; 
Chomyn et al., 1985) 
MT-CO3 Cytochrome c oxidase subunit III (Anderson et al., 1981) 
MT-ATP6 ATP synthase F0 subunit 6 (Anderson et al., 1981) 
MT-ATP8 ATP synthase F0 subunit 8 (Anderson et al., 1981; 
Macreadie et al., 1983) 
MT-CO2 Cytochrome c oxidase subunit II (Anderson et al., 1981) 
MT-CO1 Cytochrome c oxidase subunit I (Anderson et al., 1981; 
Guan et al., 1998) 
MT-ND2 NADH dehydrogenase subunit 2 (Anderson et al., 1981; 
Chomyn et al., 1985) 
MT-ND1 NADH Dehydrogenase subunit 1 (Anderson et al., 1981; 
Earley et al., 1987) 
Table 1.1. The 13 mitochondrial genes which encode for protein subunits of the enzymes 
involved in oxidative phosphorylation. 
 
The mitochondria transcribes and translates proteins from its own mtDNA, however, a vast 
majority of its proteins are nuclear in origin. These proteins are initially translated in the 
cytoplasm before being imported into the mitochondria (Bolender et al., 2008).  
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1.2.3.3. The function of the mitochondrion      
Mitochondria have many diverse roles in cell vitality and cell death, the most prominent of 
which include energy production through oxidative phosphorylation (OXPHOS) and 
apoptosis plus intermediary metabolism (Yoon et al., 2010; Pallen, 2011).  
Oxidative Phosphorylation 
Within the matrix, the TCA enzymes are responsible for the creation of the electron donors 
NADH and  FADH2 which feed into the  ETC (Lesnefsky et al., 2006). The ETC comprises 4 
subunits, complexes I - IV. These subunits function to shuttle electrons along the ETC 
resulting in the reduction of molecular water to oxygen and generation of ATP via 
mitochondrial ATP synthase (complex V) (Saraste, 1999) (Fig. 1.2).  
 
Figure 1.2. The structure of the electron transport chain. Electrons migrate from complex I 
to complex V and ultimately result in the molecular reduction of oxygen to water with the 
subsequent generation of ATP. 
 
OXPHOS is initiated via the oxidation of NADH by the 46 subunit protein NADH-
dehydrogenase (complex I) with the concomitant reduction of coenzyme Q (CoQ10).  In turn, 
reduced coenzyme Q is oxidised by Cytochrome c reductase (Complex III) thus powering the 
reduction of cytochrome c. Complex III has 11 subunits per monomer but acts as a dimer. 
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Additionally, its catalysing role in the transfer of electrons also results in the migration of 
protons across the inner mitochondrial membrane thus contributing to the mitochondrial 
membrane potential. Complex IV, also known by the name cytochrome c oxidase, then 
transfers the electron from cytochrome c to oxygen resulting in the molecular reduction of 
oxygen to water. Additionally, succinate dehydrogenase (complex II) is able to feed into the 
ETC at coenzyme Q. Complex II oxidises succinate to fumarate thus reducing coenzyme Q 
and the transfer of an electron to complex III. While complex II is part of the Krebs cycle it 
does not pump protons across the inner mitochondrial membrane and therefore does not 
contribute to the generation of mitochondrial membrane potential. As a result of the 
transfer of electrons, complexes I, III and IV translocate protons from the matrix to the 
cytosol of the inner membrane leading to the production of an electrochemical gradient, 
Ψm, across the inner mitochondrial membrane. This process of electron flow, from FADH2 
or NAD to oxygen, coupled to the active transport of protons is known as the chemiosmotic 
theory. In order to preserve the chemical energy, Ψm mitochondrial membrane potential, 
the inner membrane has a strict permeability, controlled by transporters and ion channels 
which control the migration of protons, ions plus small molecules into and out of the matrix 
(Senior, 1988; Lesnefsky et al., 2006; Hüttemann et al., 2007).  
The last step involves complex V, also known as the mitochondrial ATP synthase (Fig. 1.3). 
The protein is composed of 2 domains, F1, composed of subunits, α β,γ,δ, and ε, which 
functions as a catalytic domain and F0, a membrane domain. Both F1 and F0 domains are 
coupled by a central stalk comprised of subunits γ, δ and ε plus a peripheral stalk. The 
catalytic activity of the β subunits of the F1 domain is conditional upon the rotation of both 
the central stack plus F1 domain (Carbajo et al., 2005). The proton motive force is created 
by protons migrating from the intermembrane space to the matrix through a boundary 
between the F0 subunit α and a c-ring (Carbajo et al., 2005). The rotation of the F1   domain 
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enables the phosphorylation of adenosine diphosphate (ADP) thus generating adenosine 
triphosphate (ATP) (Lesnefsky et al., 2006).    
 
 
Figure 1.3. A simplified depiction of mitochondrial ATP synthase. The protein is composed 
of domains F1 and F0. The proton motive force generated by the migration of hydrogen ions 
results in the rotation of subunit F1 resulting in the generation of ATP from the 
phosphorylation of ADP. 
 
1.2.3.4. Mitochondrial permeability transition pore (MPTP), apoptosis and necrosis 
In addition to the production of ATP, a further important role of the mitochondria is that it 
is a key regulator of apoptotic cell death (Wallace, 1999). Apoptosis is a way in which the 
cell can actively remove damaged and dying cells while allowing healthy cells to survive 
(Evan et al., 2001).   
The mitochondrial permeability transition pore consists of a complex of the voltage-
dependent anion channel (VDAC) and the adenine nucleotide translocase and cyclophilin-D 
(CyP-D) proteins located at exchange points between the inner and outer mitochondrial 
membrane (Crompton, 1999). In normal states the pore is closed however events such as 
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increased ROS production, JNK activation, and the presence of bile acids plus TNF-a 
signalling can cause an increase in the permeability of the mitochondrial membrane to 
compounds with a molecular weight less than 1.5 KDA. The subsequent entry of protons 
into the mitochondria causes expansion of the matrix and eventual rupture leading to the 
release of pro-apoptotic factors cytochrome c and apoptosis-inducing factor (AIF) (Labbe et 
al., 2008). The released cytochrome c plus dATP allows caspase-9 and Apaf-1 to bind via 
NH2-terminal CED-3 domains. Following binding Caspase-9 becomes activated and is then 
able to cleave and activate Caspase-3. Activated Caspase-3 is then able to set in track a 
proteolytic cascade resulting in cell death  (Li et al., 1997) (Fig. 1.4). Cytochrome c release, 
however, can be inhibited by Bcl-2, in essence, Bcl-2 can be seen as anti-apoptotic and 
allows the cell to survive (Green et al., 1998).  While Bcl-2 can be seen as anti-apoptotic the 
over expression of Bax, UV radiation plus staurosporine are all apoptogenic agents, they 
promote Cytochrome c release and thus apoptosis (Green et al., 1998). Further work 
carried out by Qian et al (1999) on hepatocytes exposed to Br-A23187 demonstrated that 
prior to ΔΨm collapse the Mitochondrial Permeability Transition (MPT) pore opened thus 
would explain the ΔΨm decrease (Qian et al., 1999).   
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Figure 1.4.  An overview of the caspase cascade and necrosis. Intracellular stressors induce 
result in the release of cytochrome c from the mitochondria leading to activation of the 
caspase cascade.  As apoptosis is an energy requiring process insufficient ATP levels will 
instead result in necrotic cell death.  
 
The mechanism of cell death via either apoptosis or necrosis is dependent upon cellular 
ATP levels. As apoptosis is an ATP requiring process should MPTP occur in a small number 
of cells sufficient ATP will steer the pathway in favour of apoptosis. Conversely, if a majority 
of cells undergo MPTP opening with a concomitant decrease in OXPHOS then necrosis will 
be the overriding mechanism of cell death (Leist et al., 1997; Qian et al., 1999) . 
1.2.4. Drug induced mitochondrial dysfunction and DILI 
Numerous drugs which have been associated with DILI have also been demonstrated to 
possess mitochondrial liabilities (Boelsterli et al., 2007). It is thus evident that a link exists 
between drug induced mitochondrial dysfunction (DIMD) and DILI. The following section 
will explore the link between DILI, the mitochondria and DIMD. 
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Figure 1.5. A diagram summarising the key locations of the mitochondrion which are 
implicated in DIMD adapted from Dykens et al (Dykens et al., 2007a). The mtDNA and ETC 
are targets of mitochondrial insult while the MPT pore mediates injury. 
 
The mitochondrion has many structures and features which are either possible targets for 
injury (direct) or able to further mediate injury following an initial toxic insult elsewhere 
(indirect). These include the mtDNA, the ETC and the MPT pore (Fig. 1.5). Importantly, 
many drugs may have several targets within the mitochondria.  
The mitochondrion is additionally attractive to drugs due to the high presence of the 
phospholipid cardiolipin within the inner membrane. This is a unique feature of the 
mitochondrondrial inner membrane and has two major consequences; many drugs bind to 
cardiolipin and thus will be brought into close contact with both the ETC and mtDNA and 
lastly cardiolipin contains much unsaturated bonds which can be targeted in oxidative 
reactions by ROS (Boelsterli et al., 2007; Houtkooper et al., 2008).  
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1.2.4.1. Reactive oxidant stress 
The production of ATP via OXPHOS along the ETC results in the production of reactive 
oxygen species (ROS) (Turrens, 2003). These highly reactive oxygen species in the form of 
the superoxide anion (O2
−•
) and hydroxyl radical (OH
•
) are capable of reacting and/or 
forming adducts with macromolecular structures such as DNA and protein causing damage 
including DNA single strand breaks, DNA and protein adducts and DNA base damage (Bayr, 
2005). It has been postulated that the most prevalent ROS-mediated DNA modification is 
the hydroxylation of a guanine base leading to the formation of 8-hydroxyl-2'-
deoxyguanosine (Cadet et al., 1994). Increased levels of ROS are believed to cause opening 
of the MPTP thus leading to either apoptosis of necrosis. As aforementioned the 
mitochondrial genome is small and in tandem with the nuclear genome encodes the 
machinery of the ETC. The mitochondrial genome is also highly susceptible to drug induced 
damage due to the close proximity to ROS from the ETC generation and lack of both repair 
mechanisms and histones (Boelsterli et al., 2007).  
1.2.4.2. Drug-induced inhibition of the electron transport chain 
 The ETC can be targeted directly by drugs at many points along the respiratory chain. 
Certain drugs are known to accumulate within the mitochondria due to their chemical 
structure. For example, perhexiline and amiodarone can be termed cationic amphiphilic 
drugs. In their uncharged form their lipophilicity enables them to cross the outer 
mitochondrial membrane, however, once inside they are deprotonated within the 
mitochondrial intermembrane space and then transported to the mitochondrial matrix due 
to the ΔΨm. Their electrochemical transportation across the inner mitochondrial membrane 
disrupts ΔΨm leading to the uncoupling of oxidative phosphorylation and a consequential 
increase in respiration, although this is not coupled to ATP production (Fromenty et al., 
1995). While perhexiline and amiodarone uncouple OXPHOS at low concentrations it has 
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been found that higher concentrations can further inhibit of complexes I and II leading to a 
decrease in OXPHOS and subsequent reduction in ATP (Fromenty et al., 1990; Deschamps 
et al., 1994). Furthermore, it has been demonstrated that perhexiline can disrupt the beta 
oxidation of fatty acids and more specifically inhibit carnitine palmitoyltransferase-1 (CPT-1 
(Deschamps et al., 1994; Kennedy et al., 1996b).  In this manner perhexiline can be seen to 
have a dual toxicity; an uncoupler and an inhibitor of beta oxidation. 
In addition to uncoupling respiration, drugs can inhibit respiration via inhibition of the 
activity of the electron transport chain via the blockade of migrating electrons leading to 
eventual decreases in ATP production. Furthermore, the accumulation of electrons results 
in an increase in the production of ROS and subsequent mtDNA damage (Indo et al., 2007; 
Shokolenko et al., 2009). Work carried out using HepG2 cells and isolated rat liver have 
demonstrated that nefazodone and buspirone both inhibit complex I with nefazodone 
further inhibiting complex IV (Dykens et al., 2008b). An increase in ROS exposure, excessive 
Ca
2+ 
uptake plus a decrease in energetic capacity can all lead to MPT opening resulting in 
the onset of apoptosis (Wallace, 1999). It has been demonstrated that both paracetamol 
and troglitazone activate the JNK pathway leading to MPT pore formation and subsequent 
cell death (Bae et al., 2003; Latchoumycandane et al., 2007; Win et al., 2011). 
The inhibition of respiration and subsequent blockade of electron flow can also impact 
upon the re-oxidation of NADH to NAD+. This can lead to a decrease in pyruvate oxidation 
by pyruvate dehydrogenase. Instead, pyruvate undergoes reduction to lactate (Pessayre et 
al., 2010). Lactic acidosis is a hallmark of DIMD and it was observed following the failed 
phase II clinical trial involving the  nucleoside analog reverse-transcriptase inhibitor (NRTI) 
FIAU (McKenzie et al., 1995a). 
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1.2.4.3. Bile acids and mitochondrial dysfunction 
Bile salts are a component of bile which are produced for the emulsification of fats during 
normal digestion. Additionally, bile is used to dispose of metabolic by products and 
xenobiotics via its excretion into the bowel.  This process involves the synthesis of bile salts 
within the hepatocytes from cholesterol, secretion into the canaliculi where it flows and is 
stored within the gallbladder ahead of secretion into the bowel (Stieger, 2010). Bile salt 
secretion into the canaliculi is mediated by the bile salt export pump (BSEP), a member of 
bile salt ATP-binding cassette (ABC) transporter family. It flows against a concentration 
gradient thereby ensuring that the concentration of bile salts within the hepatocytes is kept 
low (Stieger et al., 2007). As bile is formed against a gradient via BSEP it has been conceived 
that inhibition of this transporter may result in accumulation of bile within hepatocytes 
thus resulting in cholestatic injury (Padda et al., 2011). It has been demonstrated that a 
mutation within the  PFIC2 gene results in under expression of BSEP and subsequent 
cholestatic injury (Strautnieks et al., 1998). Both drugs and their metabolites have been 
demonstrated to inhibit BSEP thus leading to cholestatic injury. Bosentan, tolcapone and 
troglitazone have been demonstrated to inhibit BSEP (Fattinger et al., 2001; Funk et al., 
2001b; Kostrubsky et al., 2003; Dawson et al., 2012). Research in isolated rat mitochondria 
has demonstrated that bile salts can also inhibit complex I and III (Krähenbühl et al., 1994).  
Thus a dual toxicity of both inhibition of BSEP and inhibition of electron flow is feasible 
therefore suggesting BSEP mediated mitochondrial toxicity is indirect. Furthermore, it has 
been demonstrated that bile acids cause the opening of MPTP within human hepatocyte 
mitochondria (Sokol et al., 2005). 
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1.2.4.4. MtDNA associated mitochondrial toxicity 
Nucleotide analog reverse-transcriptase inhibitors (NtRTI) drugs are antiviral agents. Their 
nucleoside-based structure has been designed with a hydroxyl group at the 5′-hydroxyl end 
of deoxyribose but not at the 3’ end. This means that once the drug is incorporated into the 
growing DNA chain then no further elongation can take place owing to the lack of the 3’ 
hydroxyl group (Mitsuya et al., 1986; Yarchoan et al., 1989). Mitsuya et al. demonstrated 
that HIV polymerase is very efficient at incorporation of the NRTI while work carried out by 
Yarchoan et al. demonstrated that human polymerases operating within the nucleus are 
very inefficient in the same process, thus providing viral selectivity (Mitsuya et al., 1986; 
Yarchoan et al., 1989). However, research has demonstrated that human DNA polymerase 
γ, the mitochondrial DNA polymerase,  can be inhibited by many nucleoside analogues, 
including azidothymidine (AZT) (Lewis et al., 1994a). It is believed that this inhibitory action 
on polymerase γ and/or incorporation into mtDNA during elongation leads to the depletion 
of mtDNA and a subsequent reduction in the expression of mitochondria-encoded 
polypeptides and subsequent mitochondrial dysfunction due to a reduction in ETC activity 
(Chen et al., 1989). Specifically, mtDNA depletion results in a decrease in some of the 
subunits of complexes I, III, IV and V but not complex II which is encoded by the nuclear 
genome (Brivet et al., 2000). It is believed that the decrease in respiratory complex 
expression and disruption of electron flow may also increase ROS production (Indo et al., 
2007; Shokolenko et al., 2009). As aforementioned, the proximity of ROS production in 
relation to the mtDNA means that further DNA damage is likely with further cellular stress 
and amplification of cell death pathways.  
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1.2.5. Important drugs associated with mitochondrial dysfunction and DILI 
 
1.2.5.1. Fialuridine (FIAU) 
 
FIAU, developed as an antiviral agent, is one of the clearest examples of where clinical 
hepatotoxicity can be attributed solely to direct mitochondrial toxicity. Chronic Hepatitis B 
(CHB) infection is a major cause of both mortality and morbidity on a global scale. Infection 
can result in an increased risk of cirrhosis, hepatic compensation and hepatocellular 
carcinoma (HCC) (Aspinall et al., 2011). It is estimated that approximately 350 million 
people worldwide are chronically infected with Hepatitis B virus (HBV) (Lok et al., 2007). 
Across the USA it is estimated that approximately 1,000,000 people are infected with the 
virus and thus are carriers (McKenzie et al., 1995a). While not all carriers will develop 
hepatic complications from CHB approximately 15 to 40 % will develop serious hepatic 
disease (Lok et al., 2007). The first generation nucleoside analogues adenine arabinoside 
(vidarabine) and its monophosphate, acyclovir, didanosine, AZTand ribavirin have been 
extensively studied for use as an anti-viral in chronic hepatitis B therapy, however, they 
were deemed either ineffective or too toxic during prolonged dosing regimes. A short time 
later a new generation of nucleoside analogues which were orally bioavailable were 
identified following their marked anti HBV activity in both in vivo and in-vitro models 
(McKenzie et al., 1995a). The second generation included lamivudine, adefovir, entecavir, 
tenofovir, telbivudine and FIAU (McKenzie et al., 1995a; Aspinall et al., 2011). 
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The chemical structure of FIAU 
During initial clinical testing FIAU was seen to cause a reduction in serum HBV DNA levels by 
65 and 95 % following 2 and 4 weeks of treatment respectively. However, whilst these 
reductions were impressive they were only sustained in a few patients. The investigators 
decided to extend the trial to six months with the idea that a longer dosing period would 
increase drug efficacy (McKenzie et al., 1995a). The trial went ahead however in June 1993 
the trial was unexpectedly terminated when one of 15 participants developed hepatic 
failure 13 weeks into the trial. Although the patient had stopped taking FIAU 17 days 
before, they began to feel unwell and were subsequently admitted to hospital with liver 
failure, shock and lactic acidosis. Even after the termination of the trial 6 patients 
developed severe hepatic toxicity over the subsequent weeks (Medicine, 1995). Overall, 5 
patients died and a further 2 only survived following emergency liver transplantations 
(Medicine, 1995).  
Histological examination of the two patients who underwent liver transplantation following 
the phase II clinical trial, revealed microvesicular and macrovesicular steatosis and 
cholestasis alongside abnormal mitochondria, even though hepatocellular necrosis and 
inflammation was relatively unchanged in samples gathered before treatment (McKenzie et 
al., 1995b). Additionally, hepatocellular glycogen depletion and a marked bile ductular 
proliferation was evident within the biopsy samples (Kleiner et al., 1997). In both the 
clinical trial and groundhog (wood chuck) animal model the severe hepatic injury 
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manifestations such as liver failure and lactic acidosis occurred approximately 11 weeks 
after FIAU treatment was started thus providing evidence of a delayed onset of 
hepatotoxicity (Colacino, 1996; Tennant et al., 1998). None of the patients during the PPPC 
phase II clinical trial which were administered FIAU for less than 4 weeks demonstrated 
neither biochemical nor physical manifestations of hepatotoxicity, again reinforcing the 
theory that a delayed onset of  hepatotoxicity had occurred (1995b; Honkoop et al., 1997).  
Subsequent research, mainly using in vitro studies, has provided evidence of FIAU having an 
effect upon mtDNA due to its structure as a nucleoside analogue. It has been postulated 
that once phosphorylated to the triphosphate form, FIAU inhibits mtDNA replication by its 
insertion into the growing chain, rather than an inhibition of DNA polymerase γ for which it 
lacks affinity. The eventual presence of several consecutive FIAU units within the DNA chain 
leads to the inability of mitochondrial DNA polymerase γ to replicate the DNA (Martin et al., 
1994; Lewis et al., 1995; Lewis et al., 1996a).  It is believed that FIAU undergoes multiple 
phosphorylation steps leading to FIAU-monophosphate (FIAU-MP), FIAU-diphosphate 
(FIAU-DP) and lastly FIAU-triphosphate (FIAU-TP) by the enzymes thymidine kinase (TK), 
thymidylate kinase (TMPK) and nucleoside diphosphate kinase (DPK) respectively (Fig. 1.6) 
(Colacino, 1996).  
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Figure 1.6. The metabolic pathway of FIAU. FIAU is transported from the cytoplasm to the 
mitochondria via ENT1. FIAU then undergoes phosphorylation to FIAU-monophosphate 
(FIAU-MP), FIAU-diphosphate (FIAU-DP) and lastly FIAU-triphosphate (FIAU-TP) by the 
enzymes thymidine kinase (TK), thymidylate kinase (TMPK) and nucleoside diphosphate 
kinase (DPK). FIAU incorporation into the growing DNA chain is believed to result in mtDNA 
damage and depletion. 
 
Structurally, unlike the other members of the nucleoside analogues, FIAU contains a 3’-
hydroxyl group (Cui et al., 1995a). It has been postulated that it is this structural change 
which allows FIAU incorporation into mtDNA resulting in the production of unfunctional 
DNA.  Ultimately, this effect on mtDNA would lead to a reduction in ATP-generating activity 
via the electron transport chain, and the subsequent increase in lactate production due to 
the compensatory up-regulation in glycolysis as demonstrated by Colacino et.al (1994) 
using a hepatocellular carcinoma cell line (HepG2) (Colacino et al., 1994).  
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One of the most important aspects of FIAU toxicity to highlight is the complete lack of its 
prediction, despite full preclinical in vitro and in vivo testing and several prior clinical trials. 
It has been discovered that the in vivo failure to predict toxicity was due to the uptake of 
FIAU from the cytoplasm into the mitochondria via the human equilibrative nucleoside 
transporter-1 (hENT-1, SLC29A1) (Lai et al., 2004b). In humans hENT-1 is found both on the 
outer mitochondrial membrane and the plasma membrane, however, there is low 
homology across species for the mitochondrial localisation signal (PEXN).  The 
mitochondrial localisation signal was identified as amino acid residues Pro (71), Glu (72), 
and Asn (74) which are crucial for the in mitochondrial targeting of hENT-1 (Lee et al., 
2006b). Therefore, in most animals apart from the woodchuck, FIAU cannot enter the 
mitochondria leading to a complete lack of adverse effects (Tennant et al., 1998).   
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1.2.5.2. Paracetamol 
 
 
The chemical structure of paracetamol 
 
Paracetamol, also known as acetaminophen (APAP), is an over–the-counter medication 
used for its analgesic and antipyretic properties (Moyer et al., 2011). In 1966 Davidson et al 
was the first author to report that paracetamol possesses a hepatic liability and thus is a 
hepatotoxin in overdose. It was reported that two individuals, a woman aged 30 and a man 
aged 28, died on the third day following overdose. Both individuals had reportedly 
overdosed on 50 and 150 paracetamol tablets respectively (Davidson et al., 1966). 
Currently across the USA paracetamol is responsible for the highest number of 
pharmaceutical product poisonings; resulting in approximately 500 deaths and 78,000 
people requiring emergency room treatment per annum (Litovitz et al., 2002; Budnitz et al., 
2011).  Despite therapeutic doses being generally considered safe, overdose causes 
centrilobular hepatic necrosis which may be fatal (James et al., 2003). Seminal work carried 
out by Mitchell et al. discovered that a toxic metabolite, called N-acetyl-p-benzoquinone 
imine (NAPQI) was formed following the administration of paracetamol to mice (Mitchell et 
al., 1973b; Mitchell et al., 1973a; Moyer et al., 2011). Taken at recommended doses, 90% of 
the drug is detoxified by phase II metabolic pathways, conjugating to glucuronate or sulfate 
molecules before excretion in the urine (See Fig. 1.8). However, a small proportion of APAP 
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(10 %) is metabolised by phase I hepatic enzymes, mostly CYP2E1 and to a lesser extent by 
CYPs 3A4, 2D6 and CYP1A2. At non-toxic doses of paracetamol, the NAPQI formed is 
scavenged and detoxified by glutathione (GSH) forming paracetamol-GSH adducts 
(Hodgman et al., 2012), which are safely excreted as cysteine and mercapturic acid 
conjugates.  However, in overdose, excess NAPQI formation leads to the depletion of 
glutathione and the onset of hepatotoxicity (Potter et al., 1973; Fernando et al., 1980).   
Proposed mechanisms of paracetamol hepatotoxicity  
Paracetamol-induced hepatotoxicity can be considered multi mechanistic, with numerous 
pathways all converging to induce predominantly necrotic cell death. The key events of 
toxicity (Fig. 1.8) include NAPQI mediated GSH depletion, NAPQI protein binding, reactive 
oxidant stress, formation of MPTP and the activation (phosphorylation) of c-jun NH2-
terminal protein kinase (JNK). 
As part of the detoxification pathway during overdose, paracetamol can undergo sulphation 
and glucuronide conjugation reactions, however, these pathways can become saturated 
(Chen et al., 2008; Ben-Shachar et al., 2012) (Fig.1.8). A further route of detoxification 
involves glutathione conjugation to the aforementioned reactive metabolite NAPQI, which 
is formed from only a small fraction of paracetamol (Mitchell et al., 1973a; Burcham et al., 
1991; Ben-Shachar et al., 2012; McGill et al., 2012b). Work carried out by Mitchell et al. 
demonstrated that administration of cysteine inhibits toxicity thus providing an antidote to 
paracetamol overdose (Mitchell et al., 1973b; Mitchell et al., 1973a). This breakthrough led 
to the development and introduction of N-acetylcysteine to treat APAP overdose. Even 
today NAC is still the antidote of choice as it can be administered up to 48 h post APAP 
ingestion (Saito et al., 2010). The mechanism of action involves the promotion of hepatic 
GSH synthesis  thus replenishing depleted hepatic GSH reserves and preventing any further 
NAPQI induced hepatotoxicity (Lauterburg et al., 1983). NAPQI binds to sulfhydryl groups 
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within various hepatic proteins, including mitochondrial ones. Research carried by Qiu et al. 
using radiolabelled paracetamol administered to mice with subsequent two-dimensional 
polyacrylamide gel electrophoresis and matrix-assisted laser desorption ionization mass 
spectrometry enabled the identification of 20 drug-adduct hepatic proteins. Some of these 
included Glutathione peroxidase, Thioether S-methyltransferase, Selenium-binding liver 
protein (124602), Methionine adenosyltransferase, Aldehyde dehydrogenase cytosolic class 
I , ATP synthase α-subunit (416677) and Carbonic anhydrase III (226778) (Qiu et al., 1998). It 
has been suggested that the covalent binding of NAPQI to protein is insufficient to fully 
explain the toxicity observed within paracetamol overdose (Masubuchi et al., 2005).  
Work carried out by Boobis et al. demonstrated that paracetamol toxicity may have an 
oxidative stress component as dithiothreitol, which prevents oxidation of sulfhydryl groups, 
protected against paracetamol-induced toxicity (Boobis et al., 1986). It is believed that 
superoxide formation may occur following a number of events such as the uncoupling of 
mitochondrial respiration and or through normal mitochondrial function (Koop, 1992; 
Casteilla et al., 2001; Brand et al., 2004). Since superoxide can form hydrogen peroxide (Fig. 
1.7) and GSH is a cofactor of glutathione peroxidase, the depletion of GSH enables further 
possible intracellular toxicity (Gaetani et al., 1989). The role of cellular iron in the formation 
of reactive oxidant species during paracetamol toxicity has been implicated (Fig. 1.7). It is 
believed that iron molecules (Fe
2+
) are released from damaged lysosomes and translocate 
into mitochondria to induce mitochondria dysfunction, further oxidative stress, the 
generation of the highly reactive hydroxyl group (●OH), MPT onset, mitochondrial 
depolarization and ultimately cellular necrosis. It was demonstrated that the use of an iron 
chelator, deferoxamine (DFO), protected against toxicity while toxicity was potentiated 
with the use of an iron donor, 3,5,5-trimethyl-hexanoyl ferrocene (TMHF) (Moon et al., 
2010). It has been proposed that iron may take part in the Fenton reaction thus facilitating 
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the conversion of superoxide into the highly reactive hydroxyl radical (Fig. 1.7) leading to 
lipid peroxidation as well as oxidation of proteins and nucleic acids (Burk et al., 1980).  
O2
-•
+ O2
-• 
+ 2H
+  
→ H2O2 + O2 
 
O2
-•
+ H2O2
  
→ + OH
- 
+ OH
• 
+ O2 
 
Fe
2+
 + H2O2 → Fe
3+
 + OH
-
 + OH
• 
Figure 1.7. Equations detailing the formation of hydrogen peroxide and the hydroxyl 
radical in both a non Fenton and Fenton reaction. Two superoxide molecules can react to 
form hydrogen peroxide. Superoxide and hydrogen peroxide can react to form the hydroxyl 
radical in a non-Fenton reaction. Iron (Fe
2+
) can react with hydrogen peroxide to form the 
hydroxyl radical in a Fenton reaction. 
 
Another closely related mechanism involves the formation of the reactive species 
peroxynitrite. Nitric oxide reacts with superoxide to form peroxynitrite within the 
mitochondria which, similarly to the hydroxyl anion, is able to bind to macromolecules but 
can additionally cause DNA strand breaks (Radi et al., 1994; Szabo et al., 1997). 
Physiological amounts of peroxynitrite are detoxified by GSH, however, when produced in 
the GSH-depleted environment of paracetamol overdose the cellular environment is 
vulnerable to peroxynitrite damage (Sies et al., 1997; Hinson et al., 1998; Radi et al., 2002). 
Such a mechanism has been demonstrated during paracetamol overdose when 
peroxynitrite formation resulted in the fragmentation of mtDNA (Cover et al., 2005). 
Other targets within the mitochondrial that have been demonstrated to be targeted during 
paracetamol overdose include complexes I and II; It has been demonstrated that NAPQI 
inhibition can inhibit their activity (Burcham et al., 1991). Additionally, In vitro and in vivo 
research using mice hepatocytes and mice have demonstrated mitochondrial permeability 
transition pore (MPTP) opening as a possible further mechanism of paracetamol 
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hepatotoxicity (Kon et al., 2004; Masubuchi et al., 2005).  The onset of an MPTP event can 
be caused by the presence of oxidants such as superoxide and peroxynitrite and calcium 
(Ca
2+
). The subsequent pathway involves membrane depolarisation, the uncoupling of 
OXPHOS, the swelling of the mitochondria and eventual release of the cell contents and 
necrosis (Reid et al., 2005). Supporting the view that MPTP is involved in paracetamol 
hepatotoxicity is the finding that Cyclosporin A, which blocks MPTP, also is protective 
against paracetamol-mediated cell death (Kon et al., 2004; Kon et al., 2007). 
Finally, It is also believed that activation (phosphorylation) of the c-jun NH2-terminal 
protein kinase (JNK) pathway can initiate an MPT event leading to necrosis and cell death 
during paracetamol overdose (Latchoumycandane et al., 2007; Win et al., 2011). Research 
has demonstrated that depletion of GSH causes an activation of the pathway (Yue et al., 
2006). This initial process activates JNK signalling pathway through the formation of p-JNK, 
which translocates to the mitochondria where it binds to its essential ligand SAB (SH3 
domain-binding protein) located on the cytoplasmic side of the outer mitochondrial 
membrane (Win et al., 2011).   The resultant vicious cycle of ROS formation, sustained 
activation of JNK pathway and mitochondrial dysfunction finalises the fate of cell by 
initiating opening of the MPTP and cell necrosis (Latchoumycandane et al., 2007; Win et al., 
2011).  
It is thus apparent that many interconnected pathways are involved in the onset of 
paracetamol-induced hepatotoxicity, which predominantly arise from the formation of 
NAQPI following GSH depletion, NAPQI covalent binding, and oxidative stress all converging 
on the mitochondria and formation of an MPTP event.   
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Figure 1.8. Schematic representing the metabolism of paracetamol during toxicity. 
Paracetamol undergoes detoxification via the sulphation or glucuronidation pathways. At 
non-toxic doses a small proportion of paracetamol is metabolised by phase I hepatic 
enzymes mostly CYP2E1 and to a lesser extent by CYPs 3A4, 2D6 and CYP1A2 to the toxic 
metabolic NAPQI. NAPQI is detoxified at non-toxic doses by GSH. However, at toxic doses 
the GSH detoxification pathway becomes saturated allowing NAPQI to bind to 
macromolecules, an increase in reactive oxidant stress, JNK activation, formation of MPTP 
and lastly toxicity in the form of necrosis. 
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Inter-species differences  
While much research regarding paracetamol hepatotoxicity has been undertaken, the 
majority of this data has been gathered from rodent in vivo and primary culture models, 
predominantly mice (Jaeschke et al., 2006; Jemnitz et al., 2008; Jaeschke et al., 2012). Rats 
are generally resistant to paracetamol hepatotoxicity as demonstrated by lower levels of 
oxidative stress and mitochondrial protein adduct formation and thus the extrapolation of 
these findings to humans remains questionable (McGill et al., 2012a). The pattern of 
toxicity seen within mouse models is similar to that seen within the clinic, however many 
questions still remain to be answered. For example, liver dysfunction can be observed far 
earlier in mice following an overdose administration of paracetamol compared to humans.; 
following an overdose administration of paracetamol aminotransferase activity can be 
detected in mouse plasma within 2-6 h which in contrast to human is rarely seen within the 
first 12-24 h following an overdose administration (Singer et al., 1995; Knight et al., 2001).   
1.2.6. Cell models used for testing mitochondrial toxicity and DILI 
 
Primary human hepatocytes (PHH) are often referred to as the gold standard for 
investigating DILI with respect to their physiological similarity to liver tissue, particularly in 
terms of energy metabolism and drug-metabolising systems.  However, their isolation 
involves collagenase digestion from either whole livers unsuitable for transplantation or 
from healthy sections during tumour resections which can damage cellular contents and 
both cell junctions and membranes (Guillouzo, 1998; Guguen-Guillouzo et al., 2010). It has 
been demonstrated that collagenase digestion may initiate oxidative stress leading to a 
significant decrease in CYP450 isoform activity with peak losses at 4 to 8 hours post 
isolation (Duval et al., 1995; Wang et al., 1998; Tirmenstein et al., 2000). Inter-variability 
between donors, short life span, the substantial loss of phenotypic features, the lack of bile 
collection plus the scarcity of available livers limits their use in high throughput drug toxicity 
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studies (Sassa et al., 1987; Madan et al., 2003). Therefore, the use of liver cells lines such as 
HepG2 and HepaRG which are less phenotypically similar to that of a functioning human 
liver is often preferred, particularly as such hepatoma derived lines offer the advantage of 
unlimited sub-cultivation plus a high cell number. 
1.2.6.1. HepG2 cells 
 
The HepG2 cell line has been used extensively within drug toxicity studies (Colacino et al., 
1994; Cui et al., 1995b; Tirmenstein et al., 2002; Bova et al., 2005b; Dykens et al., 2008a; 
Dykens et al., 2008b; Kenne et al., 2008; Kim et al., 2012). However, they are associated 
with genetic instability and a reduction in drug metabolising enzymes, particularly CYP 
P450s, when compared to liver tissue or PHH (Hart et al., 2010). While drug metabolising 
capacity is often reduced compared with PHH, phase II enzymes have been demonstrated 
to be expressed at near similar and sometimes higher levels when compared to PHH 
(Westerink et al., 2007). It could be thus postulated that owing to their lack of phase I 
metabolism capacity they are better suited to assessing parent compound toxicity as 
opposed to compounds which require bioactivation. 
Importantly for the study of mitochondrial toxicity is the consideration of their bioenergetic 
phenotype. The tumorigenic origin of HepG2 cells results in an altered bioenergetic 
phenotype in which, due to the Warburg and crabtree effect, anaerobic respiration can 
predominate. Therefore, cell lines of tumourgenic origin may appear resistant to 
mitochondrial toxicants which act directly via ETC toxicity. Through the substitution of 
glucose for galactose HepG2 cells become increasingly aerobically poised and thus sensitive 
to mitochondrial toxicants (Rodríguez-Enríquez et al., 2001; Marroquin et al., 2007; Vander 
Heiden et al., 2009; Diaz-Ruiz et al., 2011). The metabolic modification of HepG2 has been 
reported in numerous studies in the identification of compounds which may have a 
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mitochondrial liability (Marroquin et al., 2007; Dykens et al., 2008a; Dykens et al., 2008b; 
Swiss et al., 2011). 
1.2.6.2. HepaRG cells 
 
 HepaRG cells were developed to circumvent the limitations presented by the use of PHH 
and HepG2 cells; providing a higher metabolic profile than HepG2 cells and a wider 
availability and longevity than PHH. In 2002 cells were isolated from a female patient 
suffering from hepatocarcinoma associated with chronic hepatitis C viral infection.  The 
researchers discovered that the cells, strictly a mixture of hepatocyte-like and biliary-like 
cells, unlike many established human hepatoma cell lines were capable of supporting 
hepatitis B virus (HBV) infection (Marion et al., 2010c; Gerets et al., 2012). It was observed 
that initially, the cells had hepatocyte like morphology but after a few passages they 
acquired an undifferentiated state. Following culturing in the presence of 2% DMSO and 
hydrocortisone for 2 weeks, it was observed that some cells grouped into clusters and once 
again demonstrated hepatocyte like morphology, thus displaying a differentiated state 
(Gripon et al., 2002) .  
The HepaRG line is known for its expression of many CYP isoforms CYP1A2, 2B6, 2C9, 2E1, 
3A4 which the HepG2 line either lacks or are expressed at lower levels (Hart et al., 2010; 
Sison-Young et al., 2015). This advantage is especially important when investigating drugs 
or compounds which require metabolic activation such as paracetamol. Additionally, the 
cells form polarised hepatocyte like colonies surrounded by biliary-epithelial like cells. The 
biliary like status opens up the possibility for use with drugs which are believed to cause 
bile acid mediated mitochondrial toxicity. As well as increased CYP and biliary like status, 
levels of nuclear receptors constitutive androstane receptor (CAR) and pregnane X receptor 
(PXR) are comparable to those found in cultured primary human hepatocytes (Guillouzo et 
al., 2007; Kanebratt et al., 2008; Marion et al., 2010c; McGill et al., 2011a). The cell line is 
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viable in culture for up to 4 weeks following differentiation thus allowing elongated dosing 
periods when assessing drugs such as chronic toxicants such as FIAU (Marion et al., 2010b). 
It is postulated that the HepaRG cell may bridge the gap between PHH and traditional in 
vitro hepatic models.  
1.2.7. Experimental rationale and aims of thesis 
 
DIMD is a major problem in DILI and, due to the potential severity of such mitochondrial 
toxicity, it is of paramount importance to be able to confidently assess the mitochondrial 
liability of compounds early in the drug-discovery process.  Safety testing within the 
pharmaceutical industry has traditionally focussed upon cytotoxicity assessment or cell 
health rather than being mechanistically (e.g. mitochondrial) focussed. However, more 
recent changes in  preclinical strategy have brought safety pharmacology back to the lead 
compound stage which further supports structure–activity relationship (SAR) studies 
(Dykens et al., 2007a). As stated by Dykens et al (2007) the ideal solution would be for a 
first in vitro study for assessing mitochondrial liabilities within lead compounds. It is 
certainly feasible that pharma were unaware of the importance of mitochondrial 
dysfunction when developing their blockbuster drugs. As recently as 1997 and 2001 
troglitazone and cerivastatin were withdrawn from the market because of DILI (Kohlroser et 
al., 2000; Chalasani, 2005). In both cases further work revealed that mitochondrial liabilities 
were evident and were a major factor in the onset of hepatotoxicity although this was not 
predicted during preclinical and clinical drug development phases (Nadanaciva et al., 
2007a). Importantly, it was discovered by the work of Marroquin et al., 2007 that many 
mitochondrial liabilities were missed during cell death assays due to conventional cell 
culture protocols which hinder the identification of compounds with potential 
mitochondrial liabilities (Marroquin et al., 2007). Specifically, the culturing of hepG2 cells in 
high glucose media (standard 4.5 g/L) amplifies both the Warburg and Crabtree effects, 
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which are observations that cells of tumour origin gain a majority of their energy from 
glycolysis and furthermore high glucose media concentrations inhibit OXPHOS (Warburg, 
1956; Rodríguez-Enríquez et al., 2001). In this scenario cells of tumour origin demonstrate 
resistance to mitochondrial insult. This seminal paper described how the Crabtree effect 
could be circumvented by substituting glucose for galactose in the media to force the cells 
to produce ATP solely from OXPHOS and not glycolysis. This simple substitution reveals 
sensitivity to mitochondrial toxicants (Marroquin et al., 2007).  
This form of metabolic modification has revolutionised mitochondrial testing by providing a 
quick and inexpensive assay which can be utilised as a first-pass test for liabilities. However, 
as discussed earlier the widely used HepG2 line does have limitations in terms of CYP450 
expression, thus limiting its use in drugs which require metabolic activation. Additionally, 
the concept of an interplay between the mechanisms of BSEP inhibition and mitochondrial 
dysfunction will not be possible in the HepG2 line due to lack of biliary structures. It could 
thus be postulated that efficient and successful mitochondrial testing requires the 
utilisation of the right assays in the correct cell line. Therefore, this thesis will focus upon 
developing novel methods for assessing mitochondrial toxicity alongside characterising 
HepaRG cells for their utility in identifying mitochondrial toxicants in comparison to HepG2 
cells. To do this, a panel of classic mitochondrial poisons will be used to firstly phenotype 
the cells in terms of bioenergetic activity (OXPHOS vs glycolysis) before using a panel of 
known hepatotoxicants and mitotoxicants. Mechanistic work will be developed to fully 
understand the use of these models to examine the mitochondrial toxicity pathways 
induced by FIAU and paracetamol. FIAU is selected as it is one of the clearest examples of 
where clinical hepatotoxicity can be attributed solely to direct mitochondrial toxicity and is 
a classic case of delayed mitochondrial toxicity. Paracetamol is selected as an example of 
metabolite mediated mitotoxicity. 
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1.2.8. Thesis hypotheses 
 
Hypothesis 1 
NRTIs are believed to cause mitochondrial toxicity via incorporation into mtDNA leading to 
mtDNA depletion and subsequent translation of error prone polypeptides which may 
represent key apparatus of the respiratory chains. With the utilisation of metabolically 
modified HepG2 cells it is hypothesised that nucleoside-mediated mitochondrial toxicity of 
FIAU and ADEF can be demonstrated.  
Hypothesis 2 
HepaRG cells have been developed to circumvent the limitations held by HepG2 cells thus 
may bridge the gap between primary human hepatocytes and hepatoma derived lines for 
the utility of drug toxicity studies. Therefore it can be hypothesised that the HepaRG line is 
a more advantageous and suitable in-vitro hepatoma line for assessing drug induced 
mitochondrial injury  
Hypothesis 3 
It is believed that mitochondrial heteroplasmy and the threshold effect provide evidence as 
to why NRTIs such as FIAU demonstrate a delayed toxicity, with a subsequent rapid 
phenotypic change from healthy to individuals with acute hepatic failure. Thus it can be 
hypothesised that through the utilisation of long term dosing FIAU mediated mitochondrial 
toxicity can be demonstrated. 
Hypothesis 4 
As aforementioned the recently developed HepaRG line may provide  a novel model which 
is physiologically more similar to the in-vivo hepatic environment compared to the 
mainstay HepG2 models. Thus it is hypothesised that the HepaRG line is a more 
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advantageous and suitable in-vitro hepatoma line for assessing paracetamol induced 
mitochondrial injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
 
 
 
 
 
 
Chapter 2 
 
Utilising metabolic modification to develop an in 
vitro assay to identify mitochondrial toxicity 
induced by the nucleoside analogues fialuridine 
and adefovir 
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2.1. Introduction 
 
Drug induced Liver Injury (DILI) is an uncommon but serious off-target reaction to a number 
of pharmaceutical drugs (Boelsterli et al., 2007). It has been postulated that drug-induced 
mitochondrial dysfunction could account for cases of DILI which are not adequately 
explained by the traditional mechanisms. Evidence of drug induced mitochondrial injury 
leading to adverse drug reactions is growing and many drugs are now known to display 
mitochondrial liabilities (McKenzie et al., 1995b; Colacino, 1996; Boelsterli, 2003a; Bova et 
al., 2005a; Chan et al., 2005; Boelsterli et al., 2007). Metformin analogue phenformin was 
withdrawn following the manifestation of lactic acidosis in a number of patients (Kwong et 
al., 1998). Both Metformin and phenformin are believed to be inhibitors of the respiratory  
complex I with the latter being a far more potent inhibitor (Dykens et al., 2008a). Much 
research is beginning to bridge the gap between DILI and mitochondrial dysfunction 
(Colacino et al., 1994; Colacino, 1996; Berson et al., 1998; Kaufmann et al., 2005; Lim et al., 
2006; Masubuchi et al., 2006; Velho et al., 2006).  
Most cases of mitochondrial toxicity only became apparent once the drug/(s) were on the 
market, as was the case with the aforementioned phenformin, with troglitazone and 
cerivastatin also following suit (Marroquin et al., 2007). Mitochondrial dysfunction appears 
to be a substantial factor of drug attrition (Dykens et al., 2007b).   It is thus of great 
importance that industry has the techniques and assays at their disposal in order to identify 
whether a new lead compound has a mitochondrial liability, often only apparent during 
long-term administration or post approval. Taking measures to reduce the chances of late 
stage drug attrition can only be achieved with the use of increasingly mechanistic preclinical 
assays which can recapitulate the clinical situation. 
Primary Human Hepatocytes (PHH) are the current gold standard used to assess whether a 
compound displays DILI due to their metabolic activity (Vander Heiden et al., 2009). 
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Unfortunately, there remain numerous limitations regarding both their isolation and long 
term viability when in culture, plus inter-batch variation such as cytochrome P450 isoform 
expression differences or whether there is evidence of an underlying state of liver disease. 
In vivo rodent models have been proposed as a platform to assess mitochondrial toxicity 
but their large bioenergetic capacity can generally tolerate mitochondrial insult and are 
thus resistant to mitochondrial toxicants (Pereira et al., 2012). Additionally, extrapolation 
issues exist because of rodent to human species differences. It is for these limitations that 
much  drug testing and pre-clinical  development rely on immortalised cells, derived from 
tumours, which are cultured in supraphysiological glucose conditions (Marroquin et al., 
2007). While these lines are generally robust, practical, easy to culture and reproducible 
their metabolic phenotype hinders their use in mitochondrial toxicity research.  
While non-tumourigenic cells under normal physiological conditions obtain energy through 
OXPHOS, cells of cancer origin have the ability to produce energy through the glycolytic 
pathway. Irrespective of oxygen availability and a fully  functioning mitochondria, cancer 
origin cells obtain a majority of their energy supply from glycolysis rather than oxidative 
phosphorylation (OXPHOS) (Rodríguez-Enríquez et al., 2001). This process is called the 
Warburg effect as it was first described by Otto Heinrich Warburg in 1956 (Warburg, 1956). 
Conventional cell culture methods, where cells are typically grown in 25 mM glucose, 
further compound the issue as such elevated glucose concentrations are known to inhibit 
OXPHOS, a process known as the Crabtree effect (Rodríguez-Enríquez et al., 2001). Overall 
these effects lead to a situation whereby cells of a cancerous origin appear resistant to 
mitochondrial toxicants which would normally be toxic within primary cells due to their use 
of anaerobic respiration. If both the Warburg and Crabtree effects hinder the assessment of 
mitochondrial toxicity within cancer origin cells, how can mitochondrial toxicity be 
assessed?  
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In 2007 the area of mitochondrial research was transformed following the publication of an 
elegant concept which involved substituting glucose for galactose culture media 
(Marroquin et al., 2007). Substituting glucose for galactose renders the cell unable to 
produce net ATP via glycolysis and thus pushes the cell metabolic phenotype more towards 
OXPHOS (Fig. 2.1).  
 
 
Figure 2.1. The metabolism of glucose and galactose to produce cellular ATP. Adapted 
from Ostergaard et al (Ostergaard et al., 2007). Glucose is converted to glucose-6- 
phosphate (G6P) and then to pyruvate during glycolysis. Galactose can also undergo 
conversion to G6P but this reaction is inefficient. L-glutamine within the galactose culture 
media feeds directly into the TCA in the form of glutamate, therefore, bypassing the need 
of pyruvate from glycolysis. 
 
During glycolysis glucose is converted to glucose -6- phosphate (G6P) and then to pyruvate 
with a net gain of 2x ATP (Gatenby et al., 2004). In primary cells pyruvate would then enter 
the mitochondria, be converted to acetyl coA which then subsequently feeds into the 
tricarboxylic acid cycle (TCA cycle). Following a round of TCA reactions, NADH is used to 
46 
 
power the complex I reactions within the electron transport chain, located within the inner 
mitochondrial membrane (Hüttemann et al., 2008). As aforementioned, cancer derived 
cells derive the majority of their energy supply from the utilisation of glycolysis, even with a 
fully competent mitochondrial and sufficient oxygen supply. Although galactose can 
undergo conversion to G6P within glycolysis this reaction is inefficient and the net yield of 
ATP is greatly reduced (0.4 ATP) when compared to the metabolism of glucose. Instead, L-
glutamine within the galactose culture media can then power OXPHOS by feeding directly 
into the TCA in the form of glutamate, therefore, bypassing the need of pyruvate from 
glycolysis (Reitzer et al., 1979). In essence the substituted galactose may introduce a 
bottleneck within the glycolytic pathway thus shutting down glycolysis with the onus then 
being switched to OXPHOS for energy production and thus cell survival.  
It has been shown that using this system, and growing cells in the presence of galactose 
instead of glucose, renders cells susceptible to mitochondrial toxicants such as the complex 
I inhibitor rotenone. This simple substitution renders the mitochondria more sensitive to 
mitochondrial toxicants which would otherwise be non-toxic (Marroquin et al., 2007). This 
can be seen clearly in the following figure (Fig. 2.2) taken with permission from (Marroquin 
et al., 2007). 
 
Figure 2.2. Measurement of cellular ATP following incubation of rotenone (0 to 1 µM) for 
24 h in Hepg2 cells cultured in either glucose (open symbol) or galactose (closed symbol). 
The figure was extracted with permission from  Marroquin et al publication (Marroquin et 
al., 2007).  
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Since this seminal work the Glucose-Galactose assay for assessing mitochondrial toxicity is 
both common and routinely used within industry for detecting mitochondrial toxicity (Table 
2.1) (Dykens et al., 2007b; Marroquin et al., 2007; Dykens et al., 2008a; Dykens et al., 
2008b; Will et al., 2008; Swiss et al., 2011; Pereira et al., 2012; Thompson et al., 2012).  
 
Authors Publication details Type of Glu/Gal assay used 
Marroquin et 
al. 2007 
Circumvention of the crabtree effect 
in order to  demonstrate 
mitochondrial toxicity in galactose 
cultured cells 
Chronic modification was used in 
that cells were cultured in 
galactose for a period of 4 weeks 
with bi-weekly passaging and 
maintenance 
Dykens et al. 
2007 
The significance of mitochondrial 
toxicity testing in drug development 
(Review) 
Review describes the chronic 
metabolic modification method 
Dykens et al. 
2008 
In Vitro Assessment of Mitochondrial 
Dysfunction and Cytotoxicity of 
Nefazodone, Trazodone, and 
Buspirone 
Chronic modification was used in 
that cells were cultured in 
galactose for a period of 4 weeks 
with bi-weekly passaging and 
maintenance 
Will et al. 
2008 
Effect of the Multitargeted Tyrosine 
Kinase Inhibitors Imatinib, Dasatinib, 
Sunitinib, and Sorafenib on 
Mitochondrial Function in Isolated 
Rat Heart Mitochondria and H9c2 
Cells 
Chronic modification was used in 
that cells were cultured in 
galactose for a period of 4 weeks 
with bi-weekly passaging and 
maintenance 
Swiss et al. 
2011 
Assessment of Mitochondrial 
Toxicity in HepG2 Cells Cultured in 
High-Glucose- or Galactose-
Containing Media 
Chronic modification was used in 
that cells were cultured in 
galactose for a period of 4 weeks 
with bi-weekly passaging and 
maintenance 
Thompson, 
R. A. et al. 
2012 
In Vitro Approach to Assess the 
Potential for Risk of Idiosyncratic 
Adverse Reactions Caused by 
Candidate Drugs 
Chronic modification was used in 
that cells were cultured in 
galactose for a period of 4 weeks 
with bi-weekly passaging and 
maintenance 
Pereira et al. 
2012 
Mitochondrial bioenergetics and 
drug-induced toxicity in a panel of 
mouse embryonic fibroblasts with 
mitochondrial DNA single nucleotide 
polymorphisms 
Acute modification was used 
whereby cells were dosed with 
either glucose or galactose media 
Table 2.1. Examples of the Glu/Gal assay being used within industry. 
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Marroquin et al. describe performing this metabolic modification using galactose media 
occurring over 4 weeks with bi- weekly passaging. In order to alleviate the long lead time 
for the production of viable galactose type cells two other methods of metabolic 
modification were investigated within this chapter. Both methods significantly shorten the 
period required to illicit the molecular switch and thus brings both economic and cell 
culture advantages when compared to the model pioneered by Marroquin.   
The chapter will thus test the hypothesis that nucleoside-mediated mitochondrial toxicity 
can be demonstrated using metabolic modification within HepG2 cells. Three test 
compounds will be analysed (Fig.2.3); FIAU (1), an inactive epimer of FIAU (2) and adefovir 
(ADEF, 3).  
 
 
 
Figure 2.3. The chemical structures of FIAU, ADEF and inactive FIAU epimer. 
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ADEF is included as a positive mitochondrial toxin as has been shown to cause 
mitochondrial dysfunction within human proximal tubule cells (Tanji et al., 2001). Based 
upon this the following experiment aims will be addressed: 
• The validity of the HepG2 cells to assess toxicity by this class of compounds will be 
verified by the examination of the presence of human Equilibrative nucleoside 
transporter 1 (hENT1) expression. hENT1 has been shown to be important in the 
localisation of FIAU to the mitochondria (Lai et al., 2004a; Govindarajan et al., 
2008b).  
• HepG2 cells will then be assessed for their utility in various metabolic modification 
screens to identify mitochondrial toxicity using rotenone as a positive control. 
These screens will then be used to assess the mitotoxicity of FIAU and ADEF.   
• The downstream effects of mitochondrial dysfunction will be examined using 
seahorse technology to assess the complex activity of the electron transport chain.  
• Endpoint analysis will involve the measurement of cellular ATP and LDH reserve (a 
measure of cell death) underpinned by protein quantification.  
Should a drug/compound have an IC50-ATP glu/ IC50-ATP gal of >2 it can be deemed to be a 
mitochondrial toxicant as the effect is observed significantly more within the galactose 
cultured cells. Additionally, if a drug/compound had an IC50-LDH Gal/ IC50-ATP Gal of >2 this 
would signify that mitochondrial toxicity/dysfunction occurs before cell death. The chapter 
therefore has the ultimate aim of answering the question ‘Are NRTIs mitochondrially toxic?’ 
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2.2. Methods and Materials 
2.2.1. Materials 
Inactive FIAU epimer was purchased from Carbosynth (Compton, Berkshire, UK) Foetal 
bovine serum (FBS), dialysed foetal bovine serum (DFBS) NUPAGE 4-12% BT GEL 1.5MM 
gels and Collagen I Rat Protein were purchased from LifeTechnologies (Paisley, UK). All 
Seahorse consumables were purchased from Seahorse Bioscience (Boston, USA). HepG2 
cells were acquired from the European Collection of Cell Cultures (Salisbury, UK). Anti-ENT1 
antibody (ab48607), Human ENT1 peptide (ab48606), Anti-beta Actin antibody [AC-15] 
(ab6276), Total OXPHOS Human WB Antibody Cocktail (ab110411), Anti-Rabbit IgG (A9169), 
and Anti-Mouse IgG (A9044) were purchased from Abcam (Cambridge, UK). Western 
Lightning Plus ECL Enhanced Chemiluminesence substrate was purchased from Perkin 
Elmer (Buckinghamshire, UK). Hyperfilm ECL was purchased from Fisher Scientific UK Ltd 
(Loughborough, UK). Precision Plus Protein™ Kaleidoscope was purchase from Bio-Rad 
Laboratories Ltd (Watford, UK). All remaining materials and reagents were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). 
 
2.2.2. Cell culture and experimental preparation 
 
HepG2 cells were cultured in high glucose (4500 mg/L) DMEM supplemented with FBS (10 
% v/v), sodium pyruvate (1% v/v), HEPES (0.5 % v/v), plus penicillin/streptomycin (1 % v/v) 
(wild-type media).Cells were grown in a 37
o
C humidified air incubator containing 5 % CO2. 
Cells were counted using a Hawksley haemocytometer using a light microscope (Leica DME, 
Leica Microsystems, Milton Keynes, UK). A 0.4 % v/v trypan blue solution was used during 
cell counting to stain viable cells.  
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2.2.3. Metabolic modification overview 
In this chapter three forms of metabolic modification have been used to assess whether 
ADEF and FIAU demonstrate mitochondrial liabilities.  Metabolic modification was achieved 
by replacing glucose for galactose within the culture media either within a 2 hour period 
(acute modification), over 4 weeks with bi-weekly passaging (chronic modification) and 
lastly through the utilisation of using 2-Deoxy-D-glucose (2DG) to inhibit glycolysis (Fig. 2.4).  
Figure 2.4. Overview of Acute (A), Chronic (B) and 2DG (C) metabolic modification of 
HepG2 cells.  
 
2.2.3.1. Acute metabolic modification 
 
Complete glucose free conditions were achieved using a dialysed foetal bovine serum 
(DFBS). HepG2 cells were plated out in wild type media and left to adhere overnight. 
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Glucose media 
High glucose (4500 mg/L) DMEM supplemented with DFBS (10 % v/v), sodium pyruvate (1% 
v/v), HEPES (0.5 % v/v),  plus penicillin/streptomycin (1 % v/v). 
No Glucose (Galactose) media 
Zero glucose (0 mg/L) DMEM supplemented with DFBS (10 % v/v), Sodium pyruvate (1 % 
v/v), HEPES (0.5 % v/v), L-Glutamine (1 % v/v), 10 mM galactose plus penicillin 
/streptomycin (1 % v/v). 
HepG2 cells were plated out in a clear, flat bottomed plate at a density of 12 x 10
3
 cells/ 
well in triplicate in a total of 100 µl of wild-type media. The plated cells were left overnight 
(37 
o
C, 5 % CO2) to adhere. For time points longer than 24 hours the seeding density was 
adjusted to account for doubling time (3.5 x 10
3 
cells/well) 
The media were then removed using an aspirator and the cells were washed (HBSS, 200 µL, 
x3). Either glucose or glucose free DFBS media (50 µL) was added to the appropriate wells 
(37
o
C, 5 % CO2, 2h). Compounds were prepared in 0.5 % v/v DMSO in glucose or glucose 
free DFBS media (Rotenone, 0 to 100 µM), ADEF, 0 to 100 µM and FIAU, 0 to 665 µM). 
Compounds (50 µL) were added to the cells and returned to the incubator (37 
o
C, 5 % CO2) 
for the appropriate length of incubation   
2.2.3.2. Chronic metabolic modification 
 
Cells were grown in either glucose media (high glucose (4500 mg/L) DMEM supplemented 
with FBS (10 % v/v), sodium pyruvate (1 % v/v), HEPES (0.5 % v/v),  plus 
penicillin/streptomycin (1 % v/v), or galactose media (zero glucose (0 mg/L) DMEM 
supplemented with FBS (10 % v/v), sodium pyruvate (1 % v/v), HEPES (0.5 % v/v), L-
glutamine (1 % v/v), 10mM galactose plus penicillin/streptomycin (1 % v/v) ).  Flasks were 
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maintained in the appropriate media for 4 weeks with bi-weekly passaging of the cells 
before experiments were performed. 
2.2.3.3. Metabolic modification using 2-Deoxy-D-glucose (2DG) 
 
HepG2 cells were plated in 96-well plates (12 x 10
3
 cells/well, 50 µl media) and incubated 
(37 
o
C, 5 % CO2) overnight. Cells were co-dosed with test compounds at a range of 
concentrations plus 2DG at a concentration of 10 mM for the appropriate time period (37 
o
C, 5 % CO2).   
2.2.4. Combined assays for assessing cellular ATP, LDH release and protein quantification 
Determination of cellular ATP 
 
An ATP disodium salt a stock solution (2 mM) was made using nuclease-free H2O. The stock 
solution was then used generate an ATP standard curve (0-0.02 nmoles/µl) using nuclease-
free H2O as the diluent. Following drug incubation 25 µl of supernatant was removed from 
each well of the 96 well test plate. To this 1x somatic cell ATP releasing reagent (100 µl) was 
added to each well to ensure an increase in membrane permeability. The plate was then 
shaken (1 min, 300 rpm). Cell lysate (10 µl) was then transferred to a white flat bottomed 
96-well plate and somatic cell ATP releasing reagent (40 µl) was added. ATP standards (5 µl) 
were added to the plate in duplicate and made up to 50 µl using somatic cell ATP releasing 
reagent. The reaction mix was then prepared according to manufacturer’s instructions and 
added to all wells (50 µl).  The plate was shaken (1min, 300rpm) for 1 minute at 300 rpm 
and read using a Varioskan flask luminescent spectrophotometer manufactured by (Thermo 
Scientific, Loughborough, UK). 
ATP content was calculated from the standard curve and normalised to protein content 
(ATP/mg of protein)  
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Protein determination using  BCA protein assay kit 
A standard curve was prepared using the somatic cell ATP releasing reagent as the diluent. 
Ten standard concentrations were prepared ranging from 2 mg/ml (bovine serum albumin) 
to blank. The working reaction mix was prepared according to the manufacturer’s standard 
protocol 
Lysate samples (25 µl) prepared during ATP assay were transferred to a 96 well clear flat 
bottomed plate in triplicate alongside the prepared protein standards (9 µl) in duplicate. 
Reaction mix (200 µl) was added to the samples and standards before incubation (37 
o
C, 30 
minutes). The plate was read using a Varioskan flask spectrophotometer (Thermo Scientific, 
Loughborough, UK) at an absorbance wavelength of 562 nm. Protein concentration (mg/ml) 
was calculated from the standard curve and used to normalise ATP data. 
Determination of total LDH leakage using cytotoxicity detection kit 
Cytotoxicity was assessed using the cytotoxicity detection kit to quantify lactate 
dehydrogenase (LDH). LDH is a cytoplasmic protein found in all cells. Should a cell become 
damaged LDH is released into the surrounding cell supernatant. LDH is able to reduce NAD
+ 
to NADH
+ 
H
+
 after which lactate is oxidised to pyruvate. NADH
+ 
H
+ 
then transfers 2H
 
to the 
yellow tetrazolium salt 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium 
chloride (INT) through a catalytic reaction. The reduction of INT results in the formation of 
the red formazan salt. The red signal is related to the amount of LDH present and thus is 
directly proportional to the amount of damaged and or lysed cells (Smith et al., 2011) (Fig. 
2.5). 
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Figure 2.5. Formation of Formazan salt through oxidation of Lactate and subsequent 
transfer of H
+
 to INT. 
 
Reagents were prepared using the manufacturer’s standard protocol. Following drug 
incubation supernatant (25 µl) and lysate (25 µl) generated during ATP assay were 
transferred into a clear 96 well flat bottomed plate. Medium (25 µl) was added to either the 
lysates or supernatants alongside medium (50 µl) as a background control. Reaction 
mixture (50 µl) was added to each well and the plate was incubated in the dark (room 
temperature, 30 mins).  The plate was then read using a Varioskan flask spectrophotometer 
(Thermo Scientific, Loughborough, UK) at an absorbance wavelength of 495 nm. 
LDH reserve was expressed as a % of total possible LDH in each culture well:  
		
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2.2.5. Western blot analysis of mitochondrial complexes 
 
HepG2 cells were plated in a clear 6 well plate (5 x 10
5 
cells, 2ml media) and left to adhere 
overnight (37 
o
C, 5 % CO2). Cells were then washed (3x 1ml HBSS). The acute metabolic 
modification method (section 2.2.2.1) was then followed. Cells were incubated with drug; 
ADEF (0-100 µM, 24h), FIAU (0-665 µM, 4 days). Cells were then washed (3 x) before cell 
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lysis with RIPA buffer (100 µl). Wells were scraped and cells/RIPA buffer solution was 
transferred to a 1.5 ml micro centrifuge tube (on ice). This step was repeated to ensure 
complete removal of cells. Samples were then centrifuged (10,000 rpm/ 10 min/4 
o
C) 
Supernatants were retained and stored at -80
o
c before analysis protein content of each 
sample was assessed by BCA assay (section 2.2.3.2). 
 
Buffer preparation 
20x MOPS  buffer 1x MOPS buffer 
MOPS 209.2 g 50ml 20x MOPS buffer 
Tris base 121.2 g 950 ml dH2O 
SDS 20.0 g   
EDTA 6.0 g 
 
Make up to 1L with dH2O 
 
  10x Transfer buffer  1x Transfer buffer 
30.3g Tris base 
100ml 10x transfer 
buffer 
150.2g Glycine 200ml methanol 
Make up to 1L with dH2O Make up to 1L with dH2O 
  20x TBS 1x TBS-Tween 
NaCL 175.2 g 50ml 20x TBS 
KCL 4.48 g 10ml Tween 
Tris base 60.6 g 
Make up to 1L with 
dH2O 
Ph to 7 with conc HCl   
Make up to 1 litre with dH2O   
Table 2.3. Formulation of buffers used within western blot. 
Lysate samples (5 ng) were denatured in LDS sample buffer (lithium dodecyl sulfate at a pH 
of 8.4) and reducing agent (dithiothreitol) mixture (10 µl, 5mins, 90
o
C) prior to loading into 
4-12% Bis-Tris Protein Gel to ensure optimal separation of protein bands. Precision Plus 
Protein™ Kaleidoscope™ (5 µL) was added as a marker. Proteins were separated by 
electrophoresis (10 mins at 90 v and then 170 v for 50 mins) using 1x MOPS buffer (Table 
2.3). Proteins were transferred to nitrocellulose membrane for (1 hr at 230mA) using 1x 
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transfer buffer. Ponceau stain was used to ensure correct protein transfer and loading. 
Membrane was then blocked (overnight, 4
o
C) to ensure minimal unspecific antibody 
binding. All antibodies were made up in 10 % w/v milk powder in 1x TBS-T. Membranes 
were probed using Total OXPHOS Human WB Antibody Cocktail (1:500, 2hr, RT) as primary, 
washing using 1x TBS-T (6x 5min) then anti-mouse (1:10,000, 1hr, RT) as secondary. 
Membranes were washed with 1x TBT-T (6x 5min) and visualised using western blot 
chemiluminescence reagent and imaged using X-ray film.  
2.2.6. Seahorse XF Analysis of Oxygen Consumption rates 
 
The Seahorse XFE96 is a bioanalyser which is capable of real time measurement of both 
oxygen consumption rate (OCR), a measure of oxidative phosphorylation (OXPHOS) and 
extracellular acidification rate (ECAR) which is a measure of glycolysis. Both parameters are 
measured using a fluorescent sensor-containing cartridge which fits above the cell culture 
plate (Fig.2.6) (Horan et al., 2012). 
 
Figure 2.6. Seahorse XFE96 Bioanalyser with the florescent sensor-containing cartridge 
(green) sitting above the culture plate (white). 
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2.2.6.1. Mitochondrial stress tests 
 
Through the sequential injection of four compounds, a bioenergetic profile was determined 
by measuring both oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR). Once a basal oxygen level is established the mitochondrial ATPase inhibitor 
oligomycin is injected causing a decrease in basal oxygen rate due to the cessation of ATP-
energy production from OXPHOS thus allowing ATP-linked respiration to be quantified. The 
mitochondrial uncoupler carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) is 
then injected which causes permeation of the mitochondrial inner membrane to protons. 
The entry of protons causes OCR to reach a maximum as electron movement is no longer 
coupled to the proton gradient, thus allowing maximal respiration to be quantified. Finally, 
a double injection of the inhibitory chain inhibitors Antimycin A and Rotenone results in a 
complete inhibition of the oxidative energy production machinery. Any residual OCR can be 
attributed to non-mitochondrial energy production (Hill et al., 2012). This sequence of 
mitochondrial toxins is termed the mitochondrial stress test and allows several parameters 
of bioenergetic activity to be calculated; basal respiration, ATP-linked respiration, proton 
leak, maximal respiration and spare respiratory capacity to be quantified (Figure 2.7). 
 
Figure 2.7. Representative Seahorse Mitochondrial stress test trace. 
59 
 
Seahorse Procedure 
 
HepG2 cells (2.5 x 10
4
 cells/well or 4 x 10
3 
cells/well for 24 h or 7 day experiments 
respectively) were seeded into a collagen I coated (5 μg/cm
2
) XF Cell Culture Microplate 
(2.5 x 10
4
) and left overnight to adhere (37
o
C, 5% CO2)  
Plates were dosed with either ADEF (0 to 100 µM) or FIAU (0 to 665 µM) in wild-type media 
and were incubated (37 
o
C, 5 % CO2, 24 h or 7 days). The XFe Fluxpak cartridge was 
prepared the evening before the seahorse run: Seahorse calibrant solution (200 µl) was 
added to each well of the fluxpak plate and was incubated overnight (37 
o
C, 0 % CO2). 
Before the assay cell culture media were replaced using pH 7.4 un-buffered glucose (450 
mg /100ml) DMEM supplemented with sodium pyruvate (1 % v/v) and L-Glutamine (1 % 
v/v) and incubated (1 hour, 37 
o
C, 0 % CO2). Oligomycin (1 µM), FCCP (0.25 µM) and 
antimycin/rotenone (1 µM each) were added to ports A, B and C of fluxpak plate to be 
injected by Seahorse XFe96. Both OCR and ECAR were measured every seven minutes for a 
total of twelve cycles.  
Following analysis, media were removed from seahorse wells. ATP somatic lysis reagent (20 
µL) was added to each well and plate was shaken (1 min). Cell lysate (10 µL) was transferred 
to a clear 96 well flat bottomed plate for protein quantification (See section 2.2.3.2). 
Protein values were used to normalise Seahorse data to mg protein. 
2.2.7. Statistical analysis 
 
GraphPad Prism 5 was used for the statistical analysis of data. Data are presented as the 
mean of 3 independent experiments ± standard deviation. The normality of data was tested 
for normality of distribution using the Shapiro-Wilk test. Normal data were tested for 
statistical significance using 1- or 2- way anova as appropriate, non-normal data were 
tested using Mann-Whitney test. A result was deemed significant when p-value <0.05%.  
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2.3. Results 
2.3.1. Western analysis probing for hENT1 
 
Western blot demonstrated that hENT1 is expressed by HepG2 cells (Fig. 2.8). Two 
concentrations of blocking peptide (2 and 8 µg) diminished the band of interest thus 
providing good evidence that the band of interest is hENT1. However, two other bands 
were noted within the blocking condition. 
 
Figure 2.8. Representative Western blot to demonstrate the presence of hENT1 from 
HepG2 whole cell lysates (20 µg). Blocking peptide was utilised at a concentration of 2 and 
8 µg to diminish band of interest. Beta actin was used as a loading control 
 
2.3.2. Validation of metabolic modification for identifying the mitotoxicant rotenone  
 
Rotenone (2 h), a complex I inhibitor, was used as a positive control to test whether each 
method of metabolic modification resulted in changes which enabled mitotoxicity to be 
detected.  
Culturing with galactose media using either the acute or chronic method (8 passages) 
results in a greater sensitivity to rotenone compared with cells grown and thus exposed to 
glucose media when cellular ATP content is measured (Figure 2.9 A and B). Based upon IC50 
values (Table 2.5) both modification methods (acute vs chronic) resulted in cells 42 times 
and 40 times more sensitive when in the presence of galactose compared with the wild-
61 
 
type respectively (cultured in glucose).  When cells were exposed to rotenone in the 
presence of 2-DG sensitivity was also increased (Figure 2.9 C). However, the difference in 
IC50 value compared to wild type was not as great as either galactose experiments, cells 
were 6.9 times more sensitive (Table 2.5).  
Acute (IC50 ± SD) (µM) Chronic (IC50 ± SD) (µM) 2DG (IC50 ± SD) (µM) 
Glucose Galactose Glucose Galactose -2DG +2DG 
ATP LDH ATP LDH ATP LDH ATP LDH ATP LDH ATP LDH 
>100 >100 
2.3 ± 
0.1 
>100 >100 >100 
2.4 ± 
0.3 
>100 >100 >100 
14.4 
± 2.7 
>100 
IC50-ATPglu/ IC50-ATP gal 
>43 (0.0001) >41 (0.0001) >6.9 (0.0001) 
IC50-LDH gal/ IC50-ATP gal 
Not calculated Not calculated Not calculated 
Table 2.5.  IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal ratios for acute, 
chronic and 2DG (10 mM) modified HepG2 cells following treatment with  rotenone (0 – 
100 µM)  for 2 h. Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 ATP gal >2. 
Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 ATP gal >2. 
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Figure 2.9. Cellular ATP determination in HepG2 cells cultured in glucose or galactose plus 
the presence and absence of 2DG (10 mM) following treatment with rotenone (0-100 µM) 
for 2 hours. (A) Acute modification of HepG2 line (B) Chronic modification of HepG2 line (C) 
Modification using 2DG. ATP values are expressed as a % of vehicle control normalised to 
protein content. Results are mean ± S.D. of three or more independent sets of experiments. 
* = P<0.05, **= P<0.01, and *** = p<0.001 significance compared to vehicle control. 
A 
B 
C 
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2.3.3. Assessing the mitotoxicity of ADEF using metabolic modification methods 
2.3.3.1. Acute and chronic modification (7 day incubation) 
 
Following the 7 day incubation it can be seen that the concentrations at which ATP content 
has been reduced by 50 % are also very similar for either modification (Table 2.6, Figure 
2.10 A and B). LDH reserve becomes significant at high concentrations (>33µM) for both 
methods with cell death more apparent when cells are acutely modified. No significant 
differences are observed between IC50-ATP using either the acute or chronic method; 
however, ATP content is decreased in the absence of cell death at lower concentrations. 
Acute (IC50 ± SD) (µM) Chronic (IC50 ± SD) (µM) 
Glucose Galactose Glucose Galactose 
ATP LDH ATP LDH ATP LDH ATP LDH 
8.3 ± 1.0 56.7 ± 12.8 6.3 ± 2.2 75.5 ±15.7 13.6 ± 0.5 >100 14.0 ± 0.1 >100 
IC50-ATPglu/ IC50-ATP gal 
1.3  (p 0.08) 0.73 (p 0.1) 
IC50-LDH gal/ IC50-ATP gal 
11.8 (p 0.01) >7.4 (p <0.0001) 
Table 2.6. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely and chronically modified HepG2 cells following treatment 
with adefovir (0 – 100 µM) for 7 d. Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 
ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 
ATP gal >2. 
 
64 
 
 
Adefovir (µM)A
TP
 
%
 
of
 
ve
hi
cl
e 
co
n
tro
l/m
g 
pr
ot
ei
n
LD
H
 reserve
 %
relative
 to
 co
ntrol
0.1 1 10 100
0
50
100
150
0
50
100
150**
***
***
***
***
 
Adefovir (µM)A
TP
 
%
 
of
 
ve
hi
cl
e 
co
nt
ro
l/m
g 
pr
ot
ei
n
LD
H
 reserve
 %
relative
 to
 co
ntrol
0.1 1 10 100
0
50
100
150
0
50
100
150
Glucose ATP
Galactose ATP
***
***
Glucose LDH
Galactose LDH
**
** ***
***
  
Figure 2.10. Cellular ATP determination and LDH reserve in HepG2 cells cultured in 
glucose or galactose, following acute or chronic modification, and treatment with 
adefovir (0-100 µM) for 7 d. (A) HepG2 with acute modification (B) HepG2 with chronic 
modification. ATP values are expressed as a % of vehicle control normalised to protein 
content. LDH values are expressed as a % of vehicle control. Results are mean ± S.D. of 
three or more independent sets of experiments. * = P<0.05, **= P<0.01, and *** = p<0.001 
significance compared to vehicle control. 
 
 
 
A
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2.3.3.2. Acute and chronic modification (24 hour incubation)  
 
Following 24 h incubation the IC50-ATP values are very similar for either modification with 
no significant difference between the cells exposed to either glucose or galactose. A higher 
concentration of ADEF is required to achieve a 50 % decrease in ATP compared with the 
longer (7 day) incubation (Table 2.7, Figure 2.11 A and B). LDH reserve did not become 
significant in either modification. No significant differences are observed between IC50-ATP 
using either the acute or chronic method in the absence of cell death. 
Acute (IC50 ± SD) (µM) Chronic (IC50 ± SD) (µM) 
Glucose Galactose Glucose Galactose 
ATP LDH ATP LDH ATP LDH ATP LDH 
80.4 ± 
16.0 
>100 
55.2 ± 
31.9 
>100  
91.2 
±14.7 
>100 > 100 >100 
IC50-ATPglu/ IC50-ATP gal 
1.5  (p 0.4) 0.9 (p 0.4) 
IC50-LDH gal/ IC50-ATP gal 
>1.8 (p not calculated) Not calculated 
 
Table 2.7. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely and chronically modified HepG2 cells following treatment 
with adefovir (0 – 100 µM) for 24 h. Mitochondrial toxicity is defined when IC50-ATP glu/ 
IC50 ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ 
IC50 ATP gal >2. 
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Figure 2.11. Cellular ATP determination and LDH reserve in HepG2 cells cultured in 
glucose or  galactose, following acute or chronic modification, and treatment with 
adefovir (0-100µM) for 24 h. (A) HepG2 with acute modification (B) HepG2 with chronic 
modification. ATP values are expressed as a % of vehicle control normalised to protein 
content. LDH values are expressed as a % of vehicle control. Results are mean ± S.D. of 
three or more independent sets of experiments. * = P<0.05, **= P<0.01, and *** = p<0.001 
significance compared to vehicle control. 
  
B 
A 
67 
 
2.3.3.3. Metabolic modification using 2DG (7 day incubation) 
 
The dosing (7 day) of ADEF with and without 2-DG resulted in a significant dose dependent 
decrease in ATP content in both media conditions with similar IC50-ATP values (3.69 ± 0.08 
and 3.75 ± 0.3 µM ) respectively (Table 2.8, Figure 2.12 ). LDH reserve decreased in a 
significant dose dependent manner but did not reach 50% for either media condition. No 
significant differences in IC50-ATP are observed between either media condition in the 
absence of cell death. 
 
 
IC50 ± SD (µM) 
No 2DG With 2DG 
ATP LDH ATP LDH 
3.7 ± 0.3 >100 3.6 ± 0.1 >100  
IC50-ATP No 2DG/ IC50-ATP with 2DG 
1.0  (p 0.4) 
IC50-LDH With 2DG/ IC50-ATP with 2DG 
> 27 (p not calculated) 
 
Table 2.8. IC50-ATP and IC50-LDH values plus IC50-ATP -2DG/ IC50 ATP +2DG and IC50-LDH 
+2DG/ IC50 ATP +2DG ratios for 2DG (10 mM) modified HepG2 cells following treatment 
with adefovir (0 – 100 µM) for 7 d. Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 
ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 
ATP gal >2. 
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Figure 2.12. Cellular ATP determination and LDH reserve in HepG2 cells co-dosed with 
adefovir (0-100 µM) and with and without 2DG (10 mM) for 7 d. ATP values are expressed 
as a % of vehicle control normalised to protein content. LDH values are expressed as a % of 
vehicle control. Results are mean ± S.D. of three or more independent sets of experiments. 
* = P<0.05, **= P<0.01, and *** = p<0.001 significance compared to vehicle control. 
 
2.3.3.4. Metabolic modification using 2DG (24 hour incubation) 
Following 24 h incubation in the presence of 2DG resulted in a significantly increased 
sensitivity of the HepG2 line towards ADEF (IC50-ATP No 2DG/ IC50-ATP with 2DG >4.5) 
compared with just drug alone (Table 2.9, Figure 2.13. LDH reserve did not reach 50% in 
either media conditions as the concentration of drug increased.  
  
69 
 
 
IC50 ± SD (µM) 
No 2DG With 2DG 
ATP LDH ATP LDH 
73.6 ± 28.3 >100 16.3 ± 15.1 >100  
IC50-ATP No 2DG/ IC50-ATP with 2DG 
4.5  (p 0.03) 
IC50-LDH With 2DG/ IC50-ATP with 2DG 
> 6 (p not calculated) 
 
Table 2.9. IC50-ATP and IC50-LDH values plus IC50-ATP -2DG/ IC50 ATP +2DG and IC50-LDH 
+2DG/ IC50 ATP +2DG ratios for 2DG (10 mM) modified HepG2 cells following treatment 
with adefovir (0 – 100 µM) for  24 h. Mitochondrial toxicity is defined when IC50-ATP glu/ 
IC50 ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ 
IC50 ATP gal >2. 
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Figure 2.13. Cellular ATP determination and LDH reserve in HepG2 cells co-dosed with 
adefovir (0-100 µM) and with and without 2-DG (10 mM) for 7 d. ATP values are expressed 
as a % of vehicle control normalised to protein content. LDH values are expressed as a % of 
vehicle control. Results are mean ± S.D. of three or more independent sets of experiments. 
* = P<0.05, **= P<0.01, and *** = p<0.001 significance compared to vehicle control. 
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2.3.4. Assessing mitotoxicity of FIAU using metabolic modification methods 
2.3.4.1. Acute and chronic modification (7 day incubation) 
Following the 7 day incubation it can be seen that the concentrations at which ATP content 
has been reduced by 50% are also very similar for either modification (Table 2.10, Figure 
2.14 A and B. LDH reserve becomes significant at low concentrations (>18.5µM) for both 
methods with cell death  more apparent  when cells are acutely modified. No significant 
differences are observed between IC50-ATP using either the acute or chronic method 
however ATP content is decreasing in parallel with cell death. 
 
 
Acute (IC50 ± SD) (µM) Chronic (IC50 ± SD) (µM) 
Glucose Galactose Glucose Galactose 
ATP LDH ATP LDH ATP LDH ATP LDH 
16.3 ± 
6.7 
475.6 ± 
181.5 
24.3 ± 
15.1 
307.5 ± 
49.2 
60.2 ± 
17.1 
573.2 ± 
68.7 
68.6 ± 
26.3   
>665 
IC50-ATPglu/ IC50-ATP gal 
0.7  (p 0.176) 0.9 (p 0.299) 
IC50-LDH gal/ IC50-ATP gal 
12.6 (p 0.0024) 9.6 (p 0.0003) 
 
Table 2.10. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely and chronically modified HepG2 cells following treatment 
with FIAU (0 – 665 µM) for 7 d. Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 
ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 
ATP gal >2. 
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Figure 2.14. Cellular ATP determination and LDH reserve in HepG2 cells cultured in 
glucose or galactose, following acute or chronic modification, and treatment with FIAU (0-
665 µM) for 7 d. (A) HepG2 line with acute modification (B) HepG2 line with chronic 
modification. ATP values are expressed as a % of vehicle control normalised to protein 
content. LDH values are expressed as a % of vehicle control. Results are mean ± S.D. of 
three or more independent sets of experiments. * = P<0.05, **= P<0.01, and *** = p<0.001 
significance compared to vehicle control. 
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2.3.4.1.2. Acute and chronic modification (24 hour incubation) 
 
Following 24 h incubation the IC50-ATP values are similar for either modification with no 
significant difference between the cells exposed to FIAU in either glucose or galactose. A 
higher concentration of FIAU is required to achieve to a significant 50 % decrease in ATP 
than was calculated at 24 h (Table 2.11, Figure 2.15 A and B). Additionally, LDH reserve did 
not become significant in either modification system, in comparison to the 7 day 
incubation. No significant differences are observed between IC50-ATP using either the acute 
or chronic method although changes in cellular ATP content are seen in the absence of cell 
death (IC50-LDH glu and gal >665 (µM)). Cellular IC50-ATP gal values for acute and chronically 
modified cells was 250.4 ± 95.5 and 243.4 ± 77.4 respectively 
 
Acute (IC50 ± SD) (µM) Chronic (IC50 ± SD) (µM) 
Glucose Galactose Glucose Galactose 
ATP LDH ATP LDH ATP LDH ATP LDH 
164.0 ± 
150.1 
>665 
250.4 ± 
95.5 
>665 
193.6 ± 
17.13 
>665 
243.4 ± 
77.4 
>665 
IC50-ATPglu/ IC50-ATP gal 
0.5  (p 0.244) 0. 8 (p 0.1667) 
IC50-LDH gal/ IC50-ATP gal 
2.7 (p not calculated) 2.7 (p not calculated) 
 
Table 2.11. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely and chronically modified HepG2 cells following treatment 
with FIAU (0 – 665 µM) for 24 h. Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 
ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 
ATP gal >2. 
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Figure 2.15. Cellular ATP determination and LDH reserve in HepG2 cells cultured in 
glucose or  galactose, following acute or chronic modification, and treatment with FIAU 
(0-665 µM) for 24 h. (A) HepG2 with acute modification (B) HepG2 with chronic 
modification. ATP values are expressed as a % of vehicle control normalised to protein 
content. LDH values are expressed as a % of vehicle control. Results are mean ± S.D. of 
three or more independent sets of experiments. * = P<0.05, **= P<0.01, and *** = p<0.001 
significance compared to vehicle control. 
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2.3.4.1.3. Metabolic modification using 2DG plus a 7 day incubation 
 
The incubation of FIAU with and without 2DG resulted in a significant dose dependent 
decrease in ATP content in both media conditions (Table 2.12, Figure 2.16). LDH reserve 
decreased in a significant dose dependent manner but did not reach 50% for either media 
conditions. No significant differences in IC50-ATP are observed between either media 
condition with ATP and LDH reserve decreasing in parallel. Cellular ATP changes were 
measured in the absence of cell death with an insignificant IC50-ATP No 2DG/ IC50-ATP with 
2DG value of 1.5. 
 
IC50 ± SD (µM) 
No 2DG With 2DG 
ATP LDH ATP LDH 
85.8 ± 81.9 >665 59.1 ± 10.8 >665  
IC50-ATP No 2DG/ IC50-ATP with 2DG 
1.5  (p 0.328) 
IC50-LDH With 2DG/ IC50-ATP with 2DG 
> 7.7 (p not calculated) 
 
Table 2.12. IC50-ATP and IC50-LDH values plus IC50-ATP -2DG/ IC50 ATP +2DG and IC50-LDH 
+2DG/ IC50 ATP +2DG ratios for 2DG (10 mM) modified HepG2 cells following treatment 
with FIAU (0 – 665 µM) for 7 d. Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 
ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 
ATP gal >2. 
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Figure 2.16. Cellular ATP determination and LDH reserve in HepG2 cells co-dosed with 
FIAU (0-665 µM) and with and without 2DG (10 mM) for 7 d. ATP values are expressed as a 
% of vehicle control normalised to protein content. LDH values are expressed as a % of 
vehicle control. Results are mean ± S.D. of three or more independent sets of experiments. 
* = P<0.05, **= P<0.01, and *** = p<0.001 significance compared to vehicle control. 
 
2.3.4.1.4. Metabolic modification using 2DG plus a 24 hour incubation 
 
At the shorter time (24 h) FIAU was less effective with much higher IC50-ATP values 
calculated (Table 2.13, Figure 2.17) when compared to a 7 day dosing duration (Table 2.12). 
The difference equated to approximately 10 times and 2.5 times higher in the presence and 
absence of 2DG respectively. In the presence of 2DG ATP did not decrease to 50 % of 
control and thus only an IC50-ATP >665 (µM) could be assumed.  There was no significant 
LDH reserve decrease in either of the conditions. There was a significant difference 
between both media conditions (p value 0.003) in the absence of cell death with FIAU 
decreasing cellular ATP content more in the absence of 2DG. 
 
 
A
76 
 
 
 
IC50 ± SD (µM) 
No 2DG With 2DG 
ATP LDH ATP LDH 
181.5 ± 
64.7 
>665 >665 >665 
IC50-ATP No 2DG/ IC50-ATP with 2DG 
0.3  (p 0.003) 
IC50-LDH With 2DG/ IC50-ATP with 2DG 
not calculated 
 
Table 2.13. IC50-ATP and IC50-LDH values plus IC50-ATP -2DG/ IC50 ATP +2DG and IC50-LDH 
+2DG/ IC50 ATP +2DG ratios for 2DG (10 mM) modified HepG2 cells following treatment 
with FIAU (0 – 665 µM) for 24 h. Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 
ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 
ATP gal >2. 
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Figure 2.17. Cellular ATP determination and LDH reserve in HepG2 cells co-dosed with 
FIAU (0-665 µM) and with and without 2-DG (10 mM) for  24 h. ATP values are expressed 
as a % of vehicle control normalised to protein content. LDH values are expressed as a % of 
vehicle control. Results are mean ± S.D. of three or more independent sets of experiments. 
* = P<0.05, **= P<0.01, and *** = p<0.001 significance compared to vehicle control. 
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2.3.5. Using metabolic modification to screen for mitochondrial toxicity induced by the 
inactive epimer of FIAU 
 
The non-active epimer had no significant effect on ATP for both media conditions (Table 
2.14, Figure 2.18). LDH reserve did not significantly decrease as the concentration of epimer 
increased. There was no significant drug response for both media’s in the absence of cell 
death. 
 
Acute (IC50 ± SD) (µM) 
Glucose Galactose 
ATP LDH ATP LDH 
>665 >665 >665 >665 
IC50-ATP No 2DG/ IC50-ATP with 2DG 
1 
IC50-LDH With 2DG/ IC50-ATP with 2DG 
1 
 
Table 2.14. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely modified HepG2 cells following treatment with inactive 
epimer of  FIAU (0 – 665 µM) for 7 d. Mitochondrial toxicity is defined when IC50-ATP glu/ 
IC50 ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ 
IC50 ATP gal >2. 
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Figure 2.18. Cellular ATP determination and LDH reserve in HepG2 cells cultured in either 
glucose or galactose, following acute metabolic modification, and following treatment 
with non-active epimer of FIAU (0-665 µM) for 7 days. ATP values are expressed as a % of 
vehicle control normalised to protein content. LDH values are expressed as a % of vehicle 
control. Results are mean ± S.D. of three or more independent sets of experiments. * = 
P<0.05, **= P<0.01, and *** = p<0.001 significance compared to vehicle control. 
 
2.3.6. Western blot analysis of mitochondrial complexes 
Following a 24 h incubation with ADEF (Fig. 2.19 A) and a 0 - 4 day incubation with FIAU 
(Fig. 2.19 B)  there was no decrease in a mitochondrial DNA coded component of complex 
IV by either drug. Additionally, complex II which is nuclear encoded remained unchanged. 
Furthermore, there was no change in the expression of complexs V, III and I following 
exposure to ADEF (24 h) and FIAU (4 days). 
 
 
79 
 
 
 
Figure 2.19. Representative Western blot to demonstrate relative levels of mitochondrial 
respiratory chain complexes of HepG2 whole cell lysates (5µg).  (A) Treatment with ADEF 
(100 µM) for 24 hours (B) Treatment with FIAU (665 µM) for 0 to 4 days  
 
2.3.7. Effect of adefovir upon oxygen consumption measured by seahorse 
 
Following a 24 hour incubation of ADEF a mitochondrial stress test was carried out to 
determine the effects of ADEF on mitochondrial respiration by measuring oxygen 
consumption rates.  Both basal respiration and ATP-linked respiration decreased in a dose 
dependent manner with the top concentration (100 µM) being significantly different from 
vehicle control (Figure 2.20 A and B). Coupling efficiency was not significantly altered with 
increasing ADEF concentration (Figure 2.20 C).  Proton leak, ATP-linked respiration and 
spare respiratory capacity were calculated as a % of maximal respiration to account for 
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changes in basal respiration (Figure 2.20 D). While there was an insignificant effect on 
proton leak, spare respiratory capacity increased while the ATP-linked respiration 
production decreased in a significant dose dependent manner.  
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Figure 2.20. Cellular oxygen consumption rates of HepG2 cells following treatment with 
adefovir (0 - 100 µM) for 24 h. (A) Assessment of basal metabolic rate (B) Assessment of 
ATP production (C) Assessment of coupling efficiency and (D) Assessment of proton leak, 
ATP production plus spare respiratory capacity as a % of maximum respiration. Values are 
expressed as a value per mg of protein. Results are mean ± S.D. of three or more 
independent sets of experiments. * = P<0.05, **= P<0.01, and *** = p<0.001 significance 
compared to vehicle control. 
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2.3.8. Effect of FIAU upon oxygen consumption with HepG2 cells 
 
A mitochondrial stress test was carried following 24 hour incubation with FIAU. Unlike the 
ADEF investigations there was no significant change in basal respiration, ATP-linked 
respiration, nor coupling efficiency (Figure 2.21 A, B, C and D). 
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Figure 2.21. Cellular oxygen consumption rates of HepG2 cells following treatment with 
FIAU (0 - 665 µM) for 24 h. (A) Assessment of basal metabolic rate (B) Assessment of ATP 
production (C) Assessment of coupling efficiency and (D) Assessment of proton leak, ATP 
production plus spare respiratory capacity as a % of maximum respiration. Values are 
expressed as a value per mg of protein. Results are mean ± S.D. of three or more 
independent sets of experiments. * = P<0.05, **= P<0.01, and *** = p<0.001 significance 
compared to vehicle control. 
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2.4. Discussion 
 
In this chapter a number of experimental methods have been used to assess the mitotoxic 
potential of nucleoside analogue FIAU with subsequent elucidation of its mechanism of 
toxicity using liver hepatocellular cells (HepG2). Previous work has demonstrated that ADEF 
induces mitochondrial dysfunction within human proximal tubule cells and thus ADEF was 
included as a positive control for mitochondrial toxicity (Tanji et al., 2001). This is the first 
study of whether ADEF also has a mitochondrial liability when incubated with human 
hepatic cells. 
It has been shown that FIAU can enter the mitochondria via the human equilibrative 
transporter 1 (hENT1). The bi-directional transporter, which transports nucleosides such as 
cytidine, uridine, adenosine, guanosine, thymidine and inosine is expressed within both the 
mitochondrial and plasma membrane of human hepatic cells (Lai et al., 2004a; Lee et al., 
2006a). It is believed that the species specific expression of hENT-1 in the mitochondrial 
membrane underlies its selective toxicity to humans (Govindarajan et al., 2008a). 
Therefore, it was important to demonstrate that the HepG2 line expressed hENT1. Utilising 
a blocking peptide, which prevents the antibody from binding to the epitope site within the 
protein of interest, plus hENT1 recombinant protein a band purporting to hENT1 was 
observed at approximately 50 KDA in line with the literature (Lai et al., 2004a). 
Interestingly, two additional bands were observed within the blocking condition and this 
may be an artefact of non-specific binding of the antibody-blocking peptide complex.  
In order to assess whether either drug (ADEF or FIAU) contained a mitochondrial liability 
several models of metabolic modification were investigated as these have been proposed 
as simple, first-screening methods to detect mitotoxicants. Two of these models relied 
upon the use of galactose media to inhibit the production of ATP via glycolytic pathways; 
one in which media substitution was performed acutely, and the other in which this change 
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was done over 4 weeks (Marroquin et al., 2007). It is hypothesised that this screen should 
identify compounds which directly inhibit electron transport chain activity. The insecticide, 
rotenone is a well-known complex I inhibitor and thus was used to validate whether the 
models were capable of detecting mitotoxicity (Li et al., 2003; Marroquin et al., 2007). The 
glucose analogue 2DG was also tested as a third model of metabolic modification due to its 
ability to inhibit glycolysis via competitive inhibition of glucose-6-PO4 production 
(Woodward et al., 1952; Pelicano et al., 2006).  
In line with the literature HepG2 cells exposed to galactose were more sensitive to 
rotenone following a 2 h incubation compared with cells exposed to glucose and drug 
(Marroquin et al., 2007; Kamalian et al., 2015b). Modification using 2-DG demonstrated 
that the Crabtree effect can be overcome through inhibition of glucose-6-PO4 production 
thus resulting in cells more sensitive to rotenone as shown. While 2-DG modification was 
successful the effect was less pronounced than that seen when using the acute and chronic 
glucose and galactose methods. This is contrary to what was expected as 2-DG should 
completely inhibit glycolysis thus resulting in an even greater sensitivity to rotenone. It 
could be postulated that the complete cessation of glycolysis from 2-DG results in 
diminished cellular health. In this scenario the effect of rotenone would be underestimated, 
leading to a minimal difference in IC50-ATP values in either media condition (With and 
without 2-DG).  
Each of the three screens were utilised to assess whether ADEF has a mitochondrial liability. 
Drug incubation was extended to 7 days as with many nucleoside reverse transcription 
inhibitors (NRTI) mitotoxicity is only observed following long term dosing (Manning et al., 
1995b). However, cell culture problems associated with long term culture including contact 
inhibition and overgrowth which limited any further extended time points. The acute and 
chronic metabolic screens both in short (24 h) and long (7 day) incubations revealed that 
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ADEF was causing a similar decrease in cellular ATP content in both media conditions 
(glucose and galactose) before cell death became apparent. In this respect, ADEF is not 
classified as a mitotoxin as cells exposed to galactose are not more susceptible. However, 
ATP is reduced even though the cells are not dying. This may be due to ADEF not being a 
direct toxin to the ETC which is the pathway of mitotoxicity most commonly picked up by 
this screening method 
35
. Interestingly, the 2DG model exposed to ADEF for shorter periods 
(24 h) demonstrated that cells exposed to drug plus 2DG were more sensitive when 
compared to drug and glucose media. The longer (7 day) time point did not reveal any 
significant difference between the two media conditions in the absence of cell death, which 
may signal an early mitochondria event only evident at early time points. This suggests that 
ADEF may have a mitochondrial effect, but this is only visible in the 2DG model, perhaps 
due to a mechanism which may not directly impact upon the electron transport chain or 
may even have multiple targets.  
It has been demonstrated that ADEF inhibits the activity of DNA polymerase λ. Five DNA 
polymerases exist: α,β,δ,ε, and λ, of which only, λ is located within the mitochondrion with 
the remainder located in the nucleus. The polymerases can inadvertently incorporate an 
NRTI in place of its endogenous substrate, deoxyribonucleotide and thus cause a 
deleterious knock on effect for nuDNA and mtDNA (Kakuda, 2000). Many NRTIs, just like 
ADEF, have the ability to inhibit mtDNA λ (Martin et al., 1994; Cherrington et al., 1995). 
Work using activated DNA as a primer template revealed that ADEF has a KiKM (Kinetic 
inhibition/Kinetic)  ratio of 1.34 while the more potent Zalcitabine has a value of 0.07 
(Cherrington et al., 1995). The smaller the ratio the greater the level of enzyme inhibition. 
This ability of ADEF to inhibit mt polymerase λ would lead to a reduction in ETC subunit 
expression, many components of which are encoded for by mtDNA, therefore leading to a 
situation whereby OXPHOS is impaired at the ETC level.  While the metabolic modification 
screens are very useful it may be that they are unable to identify compounds which have an 
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indirect effect on the ETC via the mitochondrial genome. Western blotting revealed that 
there was no dose dependent decrease in MTC02 expression when compared to vehicle 
control. Protein MTC02 is a mitochondrial encoded component of complex IV and therefore 
it would be expected that its expression may be decreased in the case of mtDNA depletion 
(Schon et al., 2012). This suggests that over a period of 24 h, the effect of ADEF on cellular 
ATP content is not due an inhibitory effect upon mtDNA replication and subsequent 
expression of subunits which make up the ETC. This is in accord with research carried out by 
Birkus et al. in which HepG2 cells treated with ADEF (9 day) did not have significant changes 
in mtDNA content (Birkus et al., 2003). However, further mechanistic investigation of the 
effect of ADEF on mitochondrial respiration using Seahorse technology revealed that ADEF 
does indeed induce a dose dependent decrease in basal respiration during the 24 h 
incubation. Such a decrease can be caused by a number of factors such as: decrease in ATP 
demand, proton leak decrease, ETC or ATP synthase inhibition or a decrease in substrate 
supply (Hill et al., 2012). In addition, ADEF did cause a dose dependent decrease in ATP 
linked respiration during the 24h incubation which could be due to a number of factors: low 
ATP demand, ETC damage and or a decrease in substrate availability (Hill et al., 2012). 
Taken together these findings suggest that ADEF may be disrupting the functioning of the 
ETC or ATP synthase. However, the coupling efficiency, which provides a measure of the 
flow of electrons along the ETC with subsequent proton flow, shows no significant 
alteration from vehicle control, in effect the ETC is working optimally (Brand et al., 2011). If 
the ETC was indeed dysfunctional coupling efficiency would be expected to decrease. This 
could be explained through mitochondrial number or mass. A lower number of 
mitochondria would explain the decreases in basal and ATP linked respiration levels while 
coupling efficiency remains normal. However, western blot data is suggestive of no change 
in mitochondrial number. Therefore, overall these investigations have demonstrated that 
decreases in cellular ATP levels are due to a reduction in oxidative phosphorylation and the 
87 
 
cause of this reduction remains unknown; there is no reduction of mitochondrial mass or 
seeming reduction in mtDNA encoded protein translation. As clinically it is known that ADEF 
toxicity progresses via an effect on mtDNA it can be stated that this HepG2 model does not 
adequately recapitulate clinical toxicity, perhaps as a result of the limited time course. 
Furthermore, as ADEF clinical toxicity is seen to involve the proximal tubule cells and more 
importantly mitochondria then it is feasible that a hepatic cell line is insufficient in 
recapitulating toxicity seen within a renal environment (Tanji et al., 2001).   
FIAU was examined to assess whether it possesses a mitochondrial liability using the same 
experimental methods as above. The acute and chronic long incubation (7 day) metabolic 
screens revealed that FIAU was causing a decrease in cellular ATP content in both media 
conditions (glucose and galactose respectively) while cytotoxicity was increasing; in effect 
both ATP and LDH reserve were decreasing in tandem. This is in contrast to that seen with 
ADEF over the same incubation period where ATP decrease was observed before cell death. 
During the short term (24 h) incubation FIAU caused a decrease in ATP in both media 
conditions (glucose and galactose respectively) in the absence of cell death. Metabolic 
modification using 2DG in either short (24h) or long (7day) incubations did not reveal FIAU 
to be having a deleterious effect within the ETC, as demonstrated by no significant 
difference between 2DG and wildtype media conditions. It could be argued that the ATP 
decreases seen with the longer (7 day) incubation are actually a product of cell death. 
Additionally, there was no increased susceptibility seen within the galactose media for 
either modification or incubation period, indicating that FIAU may not be causing ETC 
dysfunction over this time point. 
After a 4 day incubation there was no change in Protein MTC02 expression compared to 
vehicle control. This is supportive of a lack of mitochondrial dysfunction in these 
experimental conditionals. Research has demonstrated that, like ADEF, FIAU is a potent 
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inhibitor of mtDNA polymerase λ with a Ki value of 0.015 µM  and can result in a relative 
decrease in mtDNA content In HepG2 cells (Lewis et al., 1996a; Birkus et al., 2003). It should 
be noted that both studies used FIAU incubation periods ranging from 9 to 14 days, which 
may explain why neither metabolic modification screens nor western analysis could 
demonstrate FIAU as having a mitochondrial liability, within these studies. In line with the 
above observations, Seahorse analysis revealed that FIAU did not directly interfere with ETC 
activity following 24 h incubation. This may again be a consequence of experimental set up 
in which longer incubations are required in order to fully test the hypothesis that FIAU is a 
mitotoxicant. Indeed in the clinic FIAU toxicity is only apparent after 8 – 13 weeks of dosing. 
This arises due to the phenomenon of mitochondrial heteroplasmy, also known as the 
mitochondrial bottleneck, in which mutant mtDNA will accumulate within the 
mitochondrial genome as drug incubation continues with no alteration in phenotype. 
However, a threshold point can arise by which there is more mutant dysfunctional 
mitochondrial than good. This threshold point has been estimated to be approximately 80% 
(Stewart et al., 2015). Once the threshold has been reached phenotype changes and in the 
case of FIAU this could mean a major reduction in the expression of crucial ETC subunits for 
OXPHOS (Honkoop et al., 1997) . It could be hypothesised that during the longer (7 day) 
incubations these high concentrations of FIAU (in patients the Cmax was approximately 2 – 
2.5 µM) could be targeting several cellular pathways, including nuDNA and thus causing 
overt cell death.  The effects of FIAU on nuDNA have been documented (Colacino, 1996). 
This would explain why ATP and LDH levels decrease in tandem, in effect ATP reduction is a 
product of cell death. This observation has been witnessed within other nucleoside 
analogues such as stavudine which induces apoptosis (Kakuda, 2000). 
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Overall the main findings of this chapter can be summarised as follows: 
•  A number of metabolic modification screens, western blotting and seahorse 
technology have been utilised to test the hypothesis that both ADEF and FIAU are 
mitochondrial toxins.  
• It can be concluded that the limitations of the HepG2 cells in terms of extended 
dosing renders them unsuitable for these investigations as neither drug was 
classified as a direct mitochondrial toxin, despite the clinical evidence that they are 
direct mitochondrial toxins.  
• Coupled with the lack of cell polarisation and CYP450 expression it could be argued 
that while HepG2 are useful in vitro tools they are physiologically distant from 
primary human hepatocytes and thus extrapolation issues may arise.  
• Over the last number of years HepaRG cells have become more prominent and 
may offer a way of bridging the physiological gaps between HepG2s and PHHs 
(Guillouzo et al., 2007; Kanebratt et al., 2008; Marion et al., 2010c; McGill et al., 
2011b; Gerets et al., 2012).  
 
 
 
 
 
 
 
 
90 
 
 
 
 
 
 
 
Chapter 3 
 
An Examination of the Utility of Differentiated 
HepaRG cells to Assess Mitochondrial Toxicity 
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3.1. Introduction 
 
Presently PHH remain the gold standard hepatocyte cell line for investigating DILI. Their 
isolation involves collagenase digestion from either whole livers unsuitable for 
transplantation or from healthy sections during tumour resections (Guguen-Guillouzo et al., 
2010). Hepatocytes cultured in suspension are metabolically viable in short term, with less 
loss of CYP450 activity which is advantageous during clearance studies (Guillouzo, 1998; 
Griffin et al., 2004; Griffin et al., 2005). However, isolation techniques are known to damage 
cellular contents and both cell junctions and membranes (Guillouzo, 1998). Additionally, it is 
believed that collagenase digestion may initiate oxidative stress leading to a significant 
decrease in CYP450 isoform activity with peak losses at 4 to 8 hours post isolation (Duval et 
al., 1995; Wang et al., 1998; Tirmenstein et al., 2000). It has been demonstrated that the 2-
dimensional (2D) culture of PHH on collagen can improve their physiological relevance to 
man. For example, this allows for the formation of specialised junctions and bile canaliculi. 
Furthermore, through 2D culturing CYP450 isoform decline can be slowed, cell polarity can 
be re-initiated, and differentiation and bile canaliculi status restored (Ferrini et al., 1997). 
While 2D culturing of hepatocytes can slow the progression of de-differentiation research 
has concentrated on the use of sandwich cultures composed of either collagen or Matrigel.  
Although, PHH are often used with the anticipation that a xenobiotic will affect or be 
affected by the isolated cell in the same way as in the whole organ as a toxicity prediction 
tool or model there are critical drawbacks to their use in a preclinical screening program 
(DelRaso, 1993). These include donor inter-variability, short term viability the substantial 
loss of phenotypic features over a short period of time, the lack of bile collection plus the 
scarcity of available livers limits their use in high throughput drug toxicity studies (Guguen-
Guillouzo et al., 2010).  
In order to circumvent the limited life span and variability of PHH, hepatocyte cell lines can 
be derived through the oncogenic immortalisation of PHH or from hepatic tumours  
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(Guillouzo, 1998; Guguen-Guillouzo et al., 2010). Some work has displayed promise with 
regard to oncogenic immortalisation of PHH with minimal functional losses compared with 
conventional isolated PHH (Schippers et al., 1997; Ripp et al., 2006).  However, it is 
generally accepted that immortalised human hepatocytes are a long way off replacing PHH 
due to their genetic instability and loss of phenotypic features (Guguen-Guillouzo et al., 
2010). However, hepatocyte lines derived from liver hepatomas offer the advantage of 
unlimited sub-cultivation plus a high cell number (Guillouzo, 1998) . However, they often 
suffer from a reduction in drug metabolising enzymes, lack of polarisation and canaliculi 
formation when compared to their in vivo counterparts (Guillouzo, 1998; Guguen-Guillouzo 
et al., 2010; Hart et al., 2010; Gerets et al., 2012). Both the HepG2 and Hep3B lines have 
been established from hepatomas with the former being used extensively within drug 
toxicity studies (Colacino et al., 1994; Cui et al., 1995b; Tirmenstein et al., 2002; Bova et al., 
2005b; Dykens et al., 2008a; Dykens et al., 2008b; Kenne et al., 2008; Kim et al., 2012).  
In 2002 cells were isolated from a female patient suffering from hepatocarcinoma 
associated with chronic hepatitis C viral infection.  The researchers discovered that the 
cells, unlike many established human hepatoma cell lines, were capable of supporting 
hepatitis B virus (HBV) infection (Marion et al., 2010c). It was observed that initially the 
cells had hepatocyte like morphology but after a few passages they acquired an 
undifferentiated state. Following culturing in the presence of 2% DMSO and hydrocortisone 
for 2 weeks, it was observed that some cells grouped into clusters and once again 
demonstrated hepatocyte like morphology, thus displaying a differentiated state (Gripon et 
al., 2002) . The line was called HepaRG. The HepaRG  cell line is known for its expression of 
many CYP isoforms CYP1A2, 2B6, 2C9, 2E1, 3A4 which the HepG2 line either lacks or is 
expressed at lower levels (Hart et al., 2010; Sison-Young et al., 2015). This advantage is 
especially important when investigating drugs or compounds which require metabolic 
activation such as paracetamol (Mitchell et al., 1973b). Furthermore, the HepaRG cells form 
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polarised hepatocyte like colonies surrounded by biliary-epithelial like cells (Gripon et al., 
2002). The biliary like status opens up the possibility for use with drugs which are believed 
to cause cholestatic liver injury and also bile acid-mediated mitochondrial toxicity such as 
bosentan and tolcapone (Krähenbühl et al., 1994; Fattinger et al., 2001; Kostrubsky et al., 
2003; Morgan et al., 2010; Stieger, 2010). As well as increased CYP and biliary like status 
levels of nuclear receptors constitutive androstane receptor (CAR) and pregnane X receptor 
(PXR) are comparable to those found in cultured primary human hepatocytes (Guillouzo et 
al., 2007; Kanebratt et al., 2008; Marion et al., 2010c; McGill et al., 2011a). Both CAR and 
PXR can be termed xenosensors and as such regulate the expression of phase I and II drug 
metabolising enzymes plus transporters (Wada et al., 2009). Therefore their expression is 
crucial in enabling metabolic capacity of a cell line. It is for these reasons that the HepaRG 
cell line is hypothesised to be a cell line available to bridge the gap between PHH and 
hepatocyte lines derived from hepatomas in the study of hepatotoxicity preclinically.  
In this chapter the hypothesis that the HepaRG line has the metabolic properties to enable 
the assessment of drug-induced mitochondrial injury using the metabolic modification 
model will be investigated. In order to do this the following aims will be carried out: 
• Differentiated HepaRG cells will first be bioenergetically phenotyped using a 
Seahorse bioanalyser to define energy production mechanisms and individual 
respiratory complex activity. HepG2 cells will be used both as a control and 
comparison.   
• Differentiated HepaRG cells will then be assessed for their utility in the acute 
metabolic modification screen to identify mitotoxins.  
• Acute metabolic modification will then be validated using both positive and 
negative controls of mitochondrial toxicity.  
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• Following validation a selection of 12 compounds (Table 3.1.) will be assessed for 
mitochondrial toxicity using ATP and LDH reserve endpoints underpinned by 
protein analysis.  
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Compound Mitochondrial 
Toxicity  
Reference Notes 
Amiodarone Yes 
 
(Kennedy et al., 1996a; 
Spaniol et al., 2001; 
Serviddio et al., 2011) 
Well known mitochondria toxin. 
Mitochondrial oxidative stress and 
respiratory chain dysfunction.  
Nefazodone Yes (Dykens et al., 2008b) Inhibition of complex I and IV. 
Buspirone Yes (Dykens et al., 2008b) Inhibition of complex I. 
Perhexiline Yes (Kennedy et al., 1996a; 
Fromenty et al., 1997) 
ETC uncoupler. 
Inhibits carnitine uptake via CPT1, 
inhibits fatty acid oxidation. 
Diclofenac Yes (Moreno-Sánchez et al., 
1999; Boelsterli, 2003b; 
Chan et al., 2005; Hynes 
et al., 2006) 
Effect on the mitochondrial inner 
membrane, opening of 
mitochondrial membrane 
permeability transition pore. Mild 
OXPHOS uncoupler. Inhibits ATP 
synthase. 
Entacapone Uncertain 
 
 
(Nissinen et al., 1997; 
Haasio et al., 2002b; 
Haasio et al., 2002a; 
Korlipara et al., 2004) 
No disruption to membrane 
potential. No changes to liver 
mitochondria. No impairment of 
mitochondrial energy. However 
other research suggests uncoupler. 
Bosentan Yes (Indirect) (Fattinger et al., 2001) Via bile salts so indirect. 
Ximelagatran No (Kenne et al., 2008)  
Metformin Yes (Dykens et al., 2008a) 
(Owen et al., 2000; 
Brunmair et al., 2004) 
Inhibition of complex I. 
Pioglitazone Yes (Scatena et al., 2004; 
Chan et al., 2005; Julie et 
al., 2008) 
Inhibition of mitochondrial 
complex I.  
Troglitazone Yes (Tirmenstein et al., 
2002; Scatena et al., 
2004; Bova et al., 2005b; 
Konrad et al., 2005; 
Nadanaciva et al., 
2007b; Julie et al., 2008) 
Mitochondrial dysfunction within 
HepG2 cells.  Membrane potential 
disruption within HepG2 cells. 
Inhibitor of complex I, II, III, IV, and 
V. MPTP opener. OXPHOS 
uncoupler. 
Tolcapone Yes 
 
(Haasio et al., 2002b; 
Korlipara et al., 2004; 
Kim et al., 2012) 
Membrane potential disruption. 
Formation of MPTP. Uncoupler. 
Inhibition of the bile salt export 
protein. 
Table 3.1. A summary of the mitochondrial liability posed by the compounds used within 
this chapter. 
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Much previous research has demonstrated that a number of the test compounds contain 
mitochondrial liabilities and thus are mitochondrial toxicants. The chapter will be the first 
description of the validation of the utility of the HepaRG cell line in screening for 
mitotoxicants using metabolic modification. The ultimate aim of the chapter is to 
determine whether the increased hepatic physiological relevance of these cells gives better 
prediction of these compounds over the more commonly utilised HepG2 cells (Dykens et 
al., 2008b; Marion et al., 2010a; Swiss et al., 2011).  
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3.2. Methods and Materials 
3.2.1. Materials 
Foetal bovine serum (FBS), dialysed foetal bovine serum (DFBS), D-MEM high glucose and 
Collagen I Rat Protein were purchased from Life Technologies (Paisley, UK). All Seahorse 
consumables were purchased from Seahorse Bioscience (Boston, USA). HepaRG cells, media 
plus supplements were acquired from Biopredic International (Saint Grégoire, France). 
Williams’ E Medium , w/L-Glutamine w/o Glucose (Powder) manufactured by United States 
Biological was purchased from Stratech Scientific Ltd (Suffolk, UK), HepG2 cells were 
acquired from the European Collection of Cell Cultures (Salisbury, UK), Bradford reagent 
was purchased from Bio-Rad Laboratories Ltd (UK). All other materials and reagents were 
purchased from Sigma Aldrich (Poole, Dorset, UK). 
3.2.2. Cell culture and experimental preparation 
HepaRG cells were defrosted, seeded into a T25 flask (5 ml growth media) and incubated 
(37 
o
C, 5 % CO2). HepaRG Growth media were replenished every 3 days for 2 weeks during 
the growth period. Following this HepaRG cells were washed twice with 1x PBS (5 ml) and 
then harvested using 0.05 % Trypsin-EDTA (1ml) which was then neutralised using HepaRG 
growth media (6 ml). Cells were counted using a trypan blue solution of 0.05 %. Cells were 
seeded into T75 flasks (2 x10
6
/ 14 ml HepaRG growth media) and incubated (37 
o
C, 5 % CO2) 
for two weeks with HepaRG growth media (14 ml) replenished every 3 days.  Following this 
growth period cells were washed twice with 1 x PBS (8 ml) and then harvested using 0.05% 
Trypsin-EDTA (3 ml) which was then neutralised using HepaRG growth media (11 ml). Cells 
were counted using a trypan blue solution of 0.05 % and then seeded in either collagen I 
coated (5 μg/cm
2
) 96 well clear flat bottomed plates (0.009 x 10
6
/well/100 µl HepaRG 
growth medium) or collagen I coated (5 μg/cm
2
) XF Cell Culture Microplate (0.4 10
4
 
cells/well/100 µl growth media). Plates were incubated (37 
o
C, 5 % CO2) for 2 weeks with 
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growth media replenishment every 3 days (Fig. 3.1 A). Following growth period the media 
were changed within the growth plates to a 50:50 media containing 50 % growth and 50 % 
differentiation media. For the remaining incubation time plates were replenished with 
differentiation media (100 µl) every 3 days for 2 weeks. Following this 2 week 
differentiation stage the plates were ready for experimental use and could be used for an 
additional 4 week period, with twice weekly media changed required (Fig. 3.1 B).   
 
Figure 3.1. HepaRG cells 1 day after plating while in growth phase (A) and 14 days after 
differentiation phase (B). 
3.2.3. Acute metabolic modification 
In this chapter one form of metabolic modification has been used to gauge the 
mitochondrial toxic potential of a number of drugs and compounds. The modification 
involved replacing glucose with galactose within the culture media within a 2 hour period 
(acute modification) (Fig. 3.2).  
Figure 3.2. Overview of Acute metabolic modification of HepaRG cells. HepaRG cells were 
exposed to serum free glucose or galactose media (2 h) before exposure to test 
compounds. 
 
 
A B 
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Two media types were used, one containing glucose while the other was glucose free with 
supplemental galactose. Glucose free conditions were achieved using serum free media. 
Glucose serum free media 
William’s E media supplemented with Glucose (11 mM), insulin (5 ug/ ml), L-glutamine (2 
mM), hydrocortisone (50 µM) and sodium bicarbonate (3.7 mg/ ml). 
No Glucose serum free media 
William’s E media supplemented with insulin (5ug/ml), L-glutamine (4 mM), Hydrocortisone 
(50 µM), galactose (1 mM) and sodium bicarbonate (3.7mg/ml).  
Before the addition of drug, differentiation media was removed using an aspirator and the 
cells were washed (HBSS, 200 µL, x3). Either glucose or glucose free media (50 µL) were 
added to the appropriate wells (37
o
C, 5 % CO2, and 2 h). Compounds were prepared in 0.5 
% v/v DMSO in glucose or glucose free media (rotenone, 0 to 100 µM), (antimycin A, 0 to 
100 µM), (CCCP, 0 to 100 µM), (digitonin, 0 to 100 µM), (amiodarone, 0 to 300 µM), 
nefazodone, 0 to 300 µM), (buspirone, 0 to 900 µM), perhexiline (0 to 300 µM), diclofenac 
(0 to 3 mM), entacapone (0 to 1 mM), bosentan (0 to 300 µM), ximelagatran (0 to 2.7 mM), 
metformin (0 to 2.5 mM), troglitazone (0 to 300 µM), tolcapone (0 to 300 µM), and 
pioglitazone (0 to 2 mM). Compounds (50 µL) were added to the cells and returned to the 
incubator (37 
o
C, 5 % CO2) for the appropriate length of incubation.   
3.2.4. Combined assays for assessing cellular ATP, LDH release and protein quantification 
The methodology of the combined assays was used as described before (chapter 2, section 
2.2.4) 
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3.2.5. Seahorse XF Analysis of Oxygen Consumption rates for phenotyping studies 
For background to Seahorse Oxygen Consumption measurements please see Chapter 2. 
Section 2.2.6.1. 
HepaRG cells were seeded into a collagen I coated (5 μg/cm
2
) XF Cell Culture Microplate 
(0.4 10
4
 cells/well), grown and differentiated over a 4 week period as described in section 
3.2.1. Once HepaRG cells were differentiated HepG2 cells were seeded into the remaining 
wells on the same plate (2.5 x 10
4
 cells/well) on collagen I left overnight to adhere (37
o
C, 
5% CO2). Cells were bioenergetically phenotyped by measuring baseline oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) in the absence of drug as 
described previously (chapter 2, section 2.2.5.2). 
3.2.6. In situ complex assay using PMP permeabilized HepG2 and HepaRG cell line 
 
Using permeabilised cells allows the sequential injection of substrates and inhibitors in 
order to assess the individual activity of each of the complexes (1 – IV) of the ETC (Fig.3.3). 
Permeabilization of the cell membrane not only permitted mitochondrial access to all of the 
substrates and inhibitors used but also depleted the cells of all cytosolic stores, ensuring 
that mitochondrial electron transport could be specifically driven by the substrates 
provided. The use of Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP)-
treated (uncoupled) cells ensured that any deviations seen were due to perturbations at 
specific respiratory complexes and not due to inefficiencies in the coupling of OXPHOS (Ball 
et al., 2016).  
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Figure 3.3. In situ respiratory complex assay. How the addition of specific substrates and 
inhibitors allows the individual complexes of the electron transport chain to be either 
stimulated or inhibited to calculate complex activity. Substrates are colour coded blue and 
inhibitors red.  
 
The culture medium on the cells was replaced with mitochondrial assay solution (MAS) 
buffer (MgCl 2 ; 5 mM, mannitol; 220 mM, sucrose; 70 mM, KH 2 PO 4 ; 10 mM, HEPES; 
2 mM, EGTA; 1 mM; BSA; 0.4% w/v) and plasma membrane permeabiliser (PMP) (1 nM) 
containing constituents to uncouple cells and stimulate oxygen consumption via complex I 
(ADP; 4.6 mM, malic acid; 30 mM, glutamic acid; 22 mM, BSA; 30 µM, PMP; 1 nM, FCCP; 8 
µM). All compound concentrations had been optimized to generate the maximum effect in 
the absence of toxicity.  MAS buffer, all constituents and compound injections were used at 
pH 7.2. Following a basal measurement of 3 cycles of mix (30 s), wait (30 s), and measure 
(2 min), sequential injections of A: rotenone (2 µM), B: succinate + rotenone (20 mM, 2 µM, 
respectively), C: antimycin A (2 µM) and D: ascorbic acid + N,N,N ′ ,N ′- tetramethyl- p -
phenylenediamine (TMPD) + antimycin A (20 mM, 0.5 mM, and 2 µM, respectively) were 
performed with a 2 cycle interval between each, allowing for the measurement of changes 
in activity of complexes I II , III and IV (Ball et al., 2016). 
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Following analysis, media were removed from seahorse wells. ATP somatic lysis reagent (40 
µL) was added to each well and the plate was shaken (1 min). Cell lysate (5 µL) was 
transferred to a clear 96 well flat bottomed plate for protein quantification. A standard 
curve was prepared using the ddH2O ATP as the diluent. Ten standard concentrations were 
prepared ranging from 2 mg/ml (Bovine serum albumin) to blank. Protein standards were 
loaded in duplicate (10 µ) alongside protein samples. The Bradford assay reaction mix was 
prepared according to the manufacturer’s standard protocol (1 part Bradford solution: 4 
parts ddH2O) and added (200 µl) to protein samples and standards. The plate was 
immediately read using a Varioskan flask spectrophotometer (Thermo Scientific, 
Loughborough, UK) at an absorbance wavelength of 595 nm. Protein values were used to 
normalise Seahorse data to mg protein. 
3.2.7. Statistical analysis 
 
GraphPad Prism 5 was used for the statistical analysis of data. Data are presented as the 
mean of 3 independent experiments ± standard deviation. The data were tested for 
normality of distribution using the Shapiro-Wilk test. Normal data were tested for statistical 
significance using 1- or 2- way anova as appropriate, non-normal data were tested using 
Mann-Whitney. A result was deemed significant when p-value <0.05%.   
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3.3. Results 
3.3.1. HepaRG cells show a similar bioenergetic phenotype to HepG2 cells 
 
The bioenergetic phenotype of the HepaRG cells in comparison to HepG2 cells was defined 
using Seahorse technology. A significant difference in basal respiration was noted between 
both cell lines with HepaRG cells being approximately 55% less metabolically active 
compared to HepG2 (Fig. 3.4 A). A significant difference in ATP-linked respiration was also 
measured; the HepaRG cells had approximately 66% less ATP-linked respiration than the 
HepG2 line (Fig. 3.4 B). Assessment of coupling efficiency revealed no statistically significant 
difference between the two cell types (Fig. 3.4 C). Coupling efficiency is a measure of how 
efficiently the electron transport chain is operating. 
In order to gain further insight into the metabolic properties displayed by both lines 
assessment of proton leak, ATP production plus spare respiratory capacity were calculated 
as a % of maximum respiration (Fig. 3.4 D). The data confirmed that the HepaRG line carries 
out less ATP-linked respiration but possesses a much larger metabolic spare capacity when 
compared to HepG2 cells. The use of a phenogram confirms the less metabolically active 
state held by the HepaRG line (Fig. 3.4 E). The HepaRG line was demonstrated to be 
glycolytically active, but at a much lower level than the HepG2 cells, approximately 2.5 
compared to 9 ECAR (mpH/min/mg).  
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Figure 3.4. Cellular oxygen consumption rates of HepG2 and HepaRG cells following a 
mitochondrial stress test. (A) Basal respiration (B) ATP-linked respiration (C) Coupling 
efficiency, (D) Proton leak, ATP-linked respiration and spare respiratory capacity expressed 
as a % of maximum respiration and (E) Metabolic phenogram displaying OCR vs ECAR. 
Values are expressed as a value per mg of protein. Results are mean ± S.D. of three or more 
independent sets of experiments. Statistical significance of HepaRG vs HepG2 data: * = 
P<0.05, **= P<0.01, and *** = p<0.001.  
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3.3.2. HepaRG cells have an active electron transport chain when assessed in permeabilised 
cells 
 
An electron flow study was utilised to assess mitochondrial complex activity of both the 
HepG2 and HepaRG lines (Fig. 3.5). Each of the mitochondrial complexes (I to IV) was 
demonstrated to be active. It was also evident that the HepaRG line was more 
metabolically active compared with the HepG2 control when in a permeabilised state. 
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Figure 3.5. Cellular oxygen consumption rates of HepG2 and HepaRG cells in 
permeabilised cells following In situ respiratory complex assays. Injections consisted of 
rotenone (complex I inhibitor), succinate (complex II substrate), antimycin A (complex III 
inhibitor), and TMPD/ascorbate (complex IV substrates) thus allowing the measurement of 
complex I, II, III and IV activity (as described in Fig. 3.3). Values are expressed as a value per 
mg of protein. Results are mean ± S.D. of three or more independent sets of experiments.  
 
3.3.3. HepaRG cells use glycolysis to protect against mitochondrial toxicity. Validation of 
metabolic modification 
 
HepaRG cells were cultured in glucose and galactose media, using the acute metabolic 
modification method, and exposed to mitochondrial poisons to determine whether 
glycolysis is active in these cells. A 24 hour time-course was employed to determine the 
optimal drug/compound incubation period whereby mitochondrial dysfunction was 
apparent in the absence of cell death (Table 3.2 and Fig. 3.6). Mitotoxicity is defined by 
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comparing the ratio between IC50-ATP glu and IC50 ATP gal. A value of >2 or a significant p 
value would indicate that the compound contains a mitochondrial liability. In order to 
gauge whether mitochondrial insult occurs before cell the IC50-LDH gal/ IC50 ATP gal is used. 
A value of >2 or a significant p value indicates mitochondrial insult occurs before and thus is 
not a product of cell death. 
It was demonstrated that a 2 h incubation with rotenone was sufficient for mitochondrial 
toxicity to become apparent (IC50-ATP glu/ IC50-ATP gal = >2) in the absence of cell death as 
determined through LDH reserve (IC50-LDH gal/ IC50 ATP gal >714) (Fig. 3.6 A). At longer 
incubation periods (16 and 24h) LDH reserve (Fig.3.6 D and E) decreased and thus 
mitochondrial toxicity can be attributed to cell death. 
 IC50-ATP (μM) ± S.D. IC50-LDH (μM) ± S.D. IC50-ATP glu/ 
IC50 ATP gal 
(p value) 
IC50-LDH 
gal/ IC50 
ATP gal (p 
value) 
Time 
(h) 
Glucose Galactose Glucose Galactose   
2 100 0.1 ± 0.0 >100 >100 
>714 
(<0.0001) 
>1000 
4 36.5 ±  6.7 0.1 ± 0.1 >100 >100 
>202  
(0.0056) 
>1000 
6 4.5 ± 3.9 0.1 ± 0.1 >100 >100 
>34   
(0.0058) 
>1000 
16 6.1 ± 0.7 0.6 ± 0.2 >100 8.0 ± 2.2 
>10   
(0.0014) 
>14 
(0.0141) 
24 5.7 ± 0.1 0.70 ± 0.5 >100 2.4 ± 1.3 
>8     
(0.0007) 
>3 (0.0695) 
ns 
Table 3.2. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely modified HepaRG cells following treatment with  rotenone 
(0 – 100 µM) following a 24 h time course. Mitochondrial toxicity is defined when IC50-ATP 
glu/ IC50 ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH 
gal/ IC50 ATP gal >2. 
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Figure 3.6. Cellular ATP determination and LDH reserve in HepaRG cells cultured in either 
glucose or galactose, following acute metabolic modification, and treatment with 
rotenone (0 – 100 µM). (A) 2 h incubation (B) 4 h incubation (C) 6 h incubation (D) 16 h 
incubation (E) 24 h incubation . ATP Values are expressed as a % of vehicle control 
normalised to protein content. LDH values are expressed as a % of vehicle control. Results 
are mean ± S.D. of three or more independent sets of experiments. * = P<0.05, **= P<0.01, 
and *** = p<0.001 significance compared to vehicle control. 
 
In order to further validate that differentiated HepaRG cells can undergo acute metabolic 
modification, a number of positive (FCCP, antimycin) and negative (digitonin) mitochondrial 
toxicants were utilised as controls. Antimycin A displayed a clear mitochondrial liability 
C D
E 
B A
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following 2 hour incubation with a IC50-ATP glu/ IC50 ATP gal value of >301 in the absence 
of cell death (IC50-LDH gal/ IC50 ATP gal = >100 µM (Fig. 3.7 A). While CCCP was not as 
potent it also caused mitochondrial toxicity (IC50-ATP glu/ IC50 ATP gal = >67) in the absence 
of cell death (IC50-LDH gal/ IC50 ATP gal = >100 µM) (Fig. 3.7 B). Digitonin, a detergent, was 
included as a negative control for mitotoxicity. It can be seen that there was no significant 
difference between cells cultured in glucose or acutely modified (IC50-ATP glu/ IC50 ATP gal = 
0.98) (Fig. 3.7 C). Additionally LDH reserve decreases at relatively the same rate as cellular 
ATP for modified and non-modified cells. 
 
IC50-ATP (μM) ± S.D. IC50-LDH (μM) ± S.D. 
IC50-ATP 
glu/ IC50 
ATP gal (p 
value) 
IC50-LDH 
gal/ IC50 
ATP gal (p 
value) 
 
Glucose Galactose Glucose Galactose 
  
Antimycin
-A 
28.6  ± 
13.0 
0.1  >100 >100 
>301 
(0.0314) 
>1000 
CCCP >100 1.5 ± 0.1 >100 >100 
>67             
(< 0.0001) 
>67 
Digitonin 11.0 ± 2.6 11.2 ± 1.4 
14.7 ± 
2.3 
13.9 ± 3.3 
0.98 (ns) 
1 
Table 3.3. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely modified HepaRG cells following treatment with  antimycin 
A (0 – 100 µM), CCCP (0 – 100 µM) and digitonin (0 – 100 µM) for 2 h. Mitochondrial 
toxicity is defined when IC50-ATP glu/ IC50 ATP gal >2. Mitochondrial toxicity occurring 
before cell death is defined as IC50-LDH gal/ IC50 ATP gal >2.  
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Figure 3.7. Cellular ATP determination and LDH reserve in HepaRG cells cultured in either 
glucose or galactose, following acute metabolic modification, and treatment with (A) 
antimycin-A (0-100 µM),  (B) CCCP (0-100 µM), and (C) digitonin (0-100 µM) for 2 h. ATP 
Values are expressed as a % of vehicle control normalised to protein content. LDH values 
are expressed as a % of vehicle control Results are mean ± S.D. of three or more 
independent sets of experiments. * = P<0.05, **= P<0.01, and *** = p<0.001 significance 
compared to vehicle control. 
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3.3.4. Using HepaRG cells to assess mitochondrial toxicity of a panel of known 
hepatotoxicants 
 
3.3.4.1. Acute (2 h) exposure 
Twelve known hepatotoxicants were selected as training compounds and assessed using 
both cellular ATP determination plus LDH reserve as a measure of cell death in the presence 
of glucose or galactose in order to determine whether they are mitotoxic (Table 3.4). 
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IC50-ATP (μM) ± S.D. IC50-LDH (μM) ± S.D. 
IC50-ATP 
glu/ IC50 
ATP gal 
 (p value) 
IC50-LDH 
gal/ IC50 
ATP gal 
 (p value) 
 Glucose Galactose Glucose Galactose   
Amiodarone 
139.1  ± 
5.7 
62.4 ± 3.6 >300 >300 
>2 
(<0.0001) 
 
>4.8 
Nefazodone 
83.2 ± 
11.1 
33.5 ± 0.4 >300 >300 
> 2.4 
(0.014) 
>9.0 
Buspirone >900 
320.8 ± 
24.8 
>900 >900 
>2.8 
(0.0003) 
>2.8 
Perhexiline 
44.1 ± 
5.2 
24.4 ± 1.1 
45.8 ± 
1.8 
38.7 ± 0.6 
1.8 
(0.0115) 
1.58 
(0.019) 
Diclofenac >300 >300 >300 >300 1 (ns) 1 (ns) 
Entacapone >300 >300 >300 >300 1 (ns) 1 (ns) 
Bosentan >300 >300 >300 >300 1 (ns) 1 (ns) 
Ximelagatran >300 >300 >300 >300 1 (ns) 1 (ns) 
Metformin >300 >300 >300 >300 1 (ns) 1 (ns) 
Pioglitazone >300 >300 >300 >300 1 (ns) 1 (ns) 
Troglitazone 
33.1 ± 
0.4 
31.4 ± 1.6 
169.4 ± 
6.22 
173.1 ± 
3.7 
1.1 (ns) >5.6 
Tolcapone 
67.7  ± 
3.7 
79.8 ± 
17.8 
>300 >300 0.84 (ns) >3.8 
Table 3.4. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely modified HepaRG cells following treatment with 
amiodarone (0-300 µM), nefazadone (0-300 µM), buspirone (0-900 µM), perhexiline (0-
300 µM), diclofenac (0-300 µM), entacapone (0-300 µM), bosentan (0-300 µM), 
ximelagatran (0-300 µM), metformin (0-300 µM), pioglitazone (0-300 µM), troglitazone 
(0-300 µM), and tolcapone (0-300 µM)  for 2 h. Mitochondrial toxicity is defined when IC50-
ATP glu/ IC50 ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-
LDH gal/ IC50 ATP gal >2. 
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Following the acute exposure all 12 compounds could be classified into 3 groups; 
mitochondrial toxicants (IC50-ATP glu/ IC50 ATP gal >2), non-mitochondrial toxicants (IC50-
ATP glu/ IC50 ATP gal <2) and those whereby ATP nor LDH reserve did not alter with 
increasing concentration of compound. 
Amiodarone (Fig. 3.8 A), nefazodone (Fig. 3.8 B) and buspirone (Fig. 3.8 C) demonstrated 
mitochondrial liabilities (IC50-ATP glu/ IC50 ATP gal >2, >2.4 and >2.8 respectively) with a 
significant difference between the cellular ATP levels of cells cultured in glucose or 
galactose. Cell death was not significant over the dose range of all 3 compounds (IC50-LDH 
gal >300 μM). The data demonstrates that amiodarone, nefazodone and buspirone are 
mitochondrial toxicants and that induced mitochondrial insult is independent of cell death. 
Perhexiline demonstrated that it may be a border line mitochondrial toxicant (IC50-ATP glu/ 
IC50 ATP gal >1.8) (Fig. 3.8 D). While this ratio falls below the standard of >2 the p value was 
0.0115 and thus there was a significant difference in cellular ATP levels in cells cultured in 
glucose or galactose. Unlike amiodarone, nefazodone and buspirone LDH reserve and thus 
cell death became significant at higher concentrations (100 and 300 µM) of perhexiline. 
However mitochondrial dysfunction still occurred before these concentrations (IC50-LDH 
gal/ IC50 ATP gal >1.58). 
Troglitazone and tolcapone demonstrated that neither compound displayed any 
mitochondrial toxicity or liability (Fig. 3.8 K-L). While there was a significant dose-
dependent decrease in cellular ATP in both glucose and galactose cultured cells the IC50-ATP 
glu/ IC50 ATP gal ratio of both compounds was insignificant (1.1 and 0.84 respectively). 
Diclofenac entacapone, bosentan, ximelagatran, metformin and pioglitazone displayed no 
significant change in cellular ATP nor LDH reserve levels in both glucose and galactose 
cultured cells as the concentration of compound increased (Fig. 3.8 E-J).  
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Figure 3.8. Cellular ATP determination and LDH reserve in HepaRG cells cultured in either 
glucose or galactose, following acute metabolic modification, and treatment with (A) 
amiodarone (0-300 µM), (B) nefazadone (0-300 µM), (C) buspirone (0-900 µM), (D) 
perhexiline (0-300 µM), (E) diclofenac (0-300 µM), (F) entacapone (0-300 µM), (G) 
bosentan (0-300 µM),  (H) ximelagatran (0-300 µM), (I) metformin (0-300 µM), (J) 
pioglitazone (0-300 µM), (K) troglitazone (0-300 µM), and (L) tolcapone (0-300 µM) for 2 
h. ATP Values are expressed as a % of vehicle control normalised to protein content. LDH 
values are expressed as a % of vehicle control Results are mean ± S.D. of three or more 
independent sets of experiments. * = P<0.05, **= P<0.01, and *** = p<0.001 significance 
compared to vehicle control.  
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3.3.4.2. Increased incubation duration (24 h) and concentration experiments 
 
Ximelagatran, entacapone, pioglitazone, diclofenac, bosentan and metformin did not alter 
cellular ATP nor LDH levels in glucose and galactose cultured cells following a 2h incubation 
and so the experiments were extended (24 and 48h depending on compound).  
Following dosing (24 h) with ximelagatran both cellular ATP levels in both glucose and 
galactose levels initially increased and decreased at higher concentration (0.83 and 2.5 mM 
respectively) (Fig. 3.9 A). The IC50-ATP glu/ IC50 ATP gal ratio was >1.1 and did not support 
mitochondrial toxicity. LDH reserve levels demonstrated a dose-dependent decrease which 
occurs prior to decreases in ATP content supporting the non-mitochondrial nature of 
toxicity. 
Following dosing (24 h) with entacapone the cells were significantly more sensitive when 
they were in the presence of galactose with IC50s of 0.54 ± 0.2 mM and 0.91 mM 
respectively. The IC50-ATP glu/ IC50 ATP gal ratio was 1.68 (Fig. 3.9 B).  LDH reserve in either 
glucose or galactose media did not reach significant levels until the highest concentration (1 
mM). Mitochondrial toxicity can therefore be postulated to precede cell death. 
No changes in cellular ATP or LDH content were apparent following an extended incubation   
of pioglitazone (24 h, Fig. 3.9  C) However, when the time-course was extended further (48 
h, Fig. 3.9 D) there was a significant dose-dependent increase in cellular ATP levels). 
Interestingly, higher increases were evident in cells in galactose media.  LDH reserve 
remained unchanged as the concentration of compound increased. 
Following dosing (24h) with diclofenac an initial significant increase was seen in cellular ATP 
levels for both media types up to 0.33 mM (Fig. 3.9 E).  As concentration increased cellular 
ATP levels decreased within both media types but this rate was faster in cells cultured in 
galactose. This can be seen in the IC50-ATP glu and gal values which were 1.8  ±  0.7 and 1.0 
mM respectively. Assessing the IC50-ATP glu/ IC50 ATP gal ratio (1.8) demonstrated that 
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diclofenac was causing mitochondrial toxicity. In addition, the IC50-LDH gal/ IC50 ATP gal 
ratio (2.6) demonstrates that mitochondrial toxicity occurred before significant decreases in 
LDH reserve and thus cell death. 
Following dosing (24h) with bosentan cellular ATP levels increased in both media conditions 
which became significant at the highest concentration (300 µM). Cellular ATP levels did not 
reach 50% of vehicle at any concentration (Fig. 3.9 F). LDH reserve levels for either media 
condition remained with increasing compound concentration thus signifying that no cell 
death was apparent. Given the increased cellular ATP levels together with unchanged LDH 
reserve levels in can be stated that at the time point used bosentan does not display any 
mitochondrial liabilities. 
Following dosing (24h) with metformin (Fig. 3.9 F) an initial increase was seen in cellular 
ATP levels within glucose cultured cells up to 0.33 mM, although this increase is less 
marked in cells culture in galactose (Fig. 3.9 F). As concentration increased (>0.33 mM) 
dose-dependent decreases in cellular ATP levels were measured, but this rate was faster in 
cells cultured in galactose. This can be seen in the IC50-ATP glu and gal values which were 
>2.5 and 0.9 mM respectively. Assessing the IC50-ATP glu/ IC50 ATP gal ratio (2.7) 
demonstrated that metformin was causing mitochondrial toxicity. In addition, the IC50-LDH 
gal/ IC50 ATP gal ratio (2.7) demonstrates that mitochondrial toxicity occurred before 
significant decreases in LDH reserve and thus cell death 
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IC50-ATP (μM) ± S.D. IC50-LDH (μM) ± S.D. 
IC50-ATP 
glu/ IC50 
ATP gal 
 (p value) 
IC50-LDH 
gal/ IC50 
ATP gal  
(p value) 
 Glucose Galactose Glucose Galactose   
Ximelagatran 
24 h 
2.1  ± 
0.3 
1.9 ± 0.7 1.1 ± 0.2 1.3 ± 0.1 1.1 (ns) 0.7 (ns)  
Entacapone 
24 h 
0.91 0.54 ± 0.2 >1 mM >1 mM 
1.68 
(0.0411) 
1.85   
(0.0292) 
Pioglitazone 
24 h 
> 2mM > 2mM > 2mM > 2mM 1 (ns) 1 (ns) 
Pioglitazone 
48 h 
> 2mM > 2mM > 2mM > 2mM 1 (ns) 1 (ns) 
Diclofenac 
24 h 
1.8  ±  
0.7 
1.0 
2.2  ± 
0.1 
2.6 ± 0.2 
1.8 
(0.0021) 
2.6     
(0.0033) 
Bosentan 
24h 
>300 
µM 
>300 µM 
>300 
µM 
>300 µM 1 (ns) 1 (ns) 
Metformin 
24h 
>2.5 
mM 
0.9 
>2.5 
mM 
>2.5 mM 
2.7 
(0.0002) 
2.7    
(0.0002) 
Table 3.5. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely modified HepaRG cells following treatment with 
ximelagatran (0-2.7 mM), entacapone (0-1 mM), pioglitazone (0-2 mM), diclofenac (0-3 
mM), bosentan (0-300 µM) and metformin (0-2.5 mM) for either 24 or 48 h. Mitochondrial 
toxicity is defined when IC50-ATP glu/ IC50 ATP gal >2. Mitochondrial toxicity occurring 
before cell death is defined as IC50-LDH gal/ IC50 ATP gal >2. 
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Figure 3.9. Cellular ATP determination and LDH reserve in HepaRG cells cultured in either 
glucose or galactose, following acute metabolic modification, and treatment with with (A) 
ximelagatran (0-2.7 mM), (B) entacapone (0-1 mM), (C) pioglitazone (0-2 mM, 24 h) (D) 
pioglitazone (0-2 mM, 48 h), (E) diclofenac (0-3 mM), (F) bosentan (0-300 µM) and (G) 
metformin (0-2.5 mM) for either 24 or 48 h. ATP Values are expressed as a % of vehicle 
control normalised to protein content. LDH values are expressed as a % of vehicle control 
Results are mean ± S.D. of three or more independent sets of experiments. * = P<0.05, **= 
P<0.01, and *** = p<0.001 significance compared to vehicle control. 
 
3.3.4.3. Decreased incubation (6 and 8 h) duration experiments 
 
Based upon the results from the extended (24 h) compound incubations it was decided  to 
reduce the incubation time with the following compounds; entacapone (6 h), diclofenac (6 
h) and metformin (6 and 8 h) . Following 6h incubation with entacapone cellular ATP levels 
decreased dose-dependently in both glucose and galactose cultured cells (Fig. 3.10 A). The 
decrease was more pronounced within cells cultured in galactose (IC50 ATP gal , 0.52 ±  0.01) 
compared with those cultured within glucose (IC50 ATP glu , 0.93 ±  0.02). Further 
assessment of both IC50 values produced an IC50-ATP glu/ IC50 ATP gal value of 1.78 thus 
confirming entacapone has a mitochondrial liability. There was no significant cell death 
through the concentration range as measured by LDH reserve and thus mitochondrial insult 
was independent of cell death (IC50-LDH gal/ IC50 ATP gal = 1.92). 
 
G 
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The shorter (6h) incubation with diclofenac resulted in an increase in cellular ATP levels in 
both glucose and galactose cultured cells with the effect being more pronounced at 
concentrations; 0.1, 0.33 and 1 mM respectively (Fig. 3.10 B). As the concentration 
increased (1 > 3 mM) ATP levels decreased reaching their lowest levels at the top 
concentration (3 mM). Assessment of the IC50 ATP values revealed the galactose cultured 
cells (IC50-ATP gal 2.34 ±  0.05 mM) were more sensitive to diclofenac than those cultured in 
glucose (IC50-ATP Glu >3 mM). This was further confirmed by an IC50-ATP glu/ IC50 ATP gal 
value of 1.28 with a significant p value.  LDH reserve was unchanged through the 
concentration range for both media conditions thus producing IC50-LDH glu and IC50-LDH gal 
values of >3 mM and 3 mM respectively. Over a 6 h incubation period, diclofenac 
demonstrated having a mitochondrial liability in the absence of cell death. 
Reducing the incubation time (6 h) of metformin resulted in a significant decrease in 
cellular ATP levels within the galactose cultured cells but not the glucose cultured cells (Fig. 
3.10 C). A maximal decrease of approximately 75 % was achieved. LDH reserve was 
unchanged within both media cultures though the concentration range. A further 
experiment was carried out using an 8 h incubation of metformin (Fig. 3.10 D). A significant 
dose-dependent decrease in cellular ATP levels was observed in both glucose and galactose 
media, although this decrease was greater in galactose media. The increased sensitivity of 
the aerobic galactose cultured cells was further demonstrated when comparing the IC50-
ATP values (IC50-ATP glu >2.5 and IC50 ATP gal 1.53 ± 0.44 µM). The IC50-ATP glu/ IC50 ATP gal 
ratio was 0.61 which, while under the >2 standard, produced a significant p value (0.0308). 
LDH reserve was unchanged through the concentration range for both media conditions 
and thus cell death was not apparent. An 8 h incubation was sufficient to demonstrate that 
metformin is a mitochondria toxin and this observed toxicity was independent of cell death 
(IC50-LDH gal/ IC50 ATP gal 0.61). 
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IC50-ATP (μM) ± S.D. IC50-LDH (μM) ± S.D. 
IC50-ATP 
glu/ IC50 
ATP gal 
 (p value) 
IC50-LDH 
gal/ IC50 
ATP gal 
 (p value) 
 Glucose Galactose Glucose Galactose   
Entacapone 
6 h 
0.93 ±  
0.02 
0.52 ±  
0.01 
>1 mM >1 mM 
1.78  
(<0.0001) 
1.92 
(0.0005) 
Diclofenac     
6 h 
>3 mM 
2.34 ±  
0.05 
>3 mM >3 mM 
1.28    
(0.001) 
1.28 
(0.001) 
Metformin   
6 h 
>2.5 mM >2.5 mM 
>2.5 
mM 
>2.5 mM 1 1 (ns) 
Metformin   
8 h 
>2.5 mM 
1.53 ± 
0.44 
>2.5 
mM 
>2.5 mM 
0.61 
(0.0308) 
0.61 
(0.0308) 
Table 3.6. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely modified HepaRG cells following treatment with 
entacapone (0-1 mM), diclofenac (0-3 mM), and metformin (0-2.5 mM) for either 6 or 8 h. 
Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 ATP gal >2. Mitochondrial toxicity 
occurring before cell death is defined as IC50-LDH gal/ IC50 ATP gal >2. 
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Figure 3.10. Cellular ATP determination and LDH reserve in HepaRG cells cultured in 
either glucose or galactose, following acute metabolic modification, and treatment with 
(A) entacapone (0-1 mM),  (B) diclofenac (0-3 mM), (C) metformin (0-2.5 mM, 6 h) and (D) 
metformin (0-2.5 mM, 8 h) for either 6 or 8 h. ATP Values are expressed as a % of vehicle 
control normalised to protein content. LDH values are expressed as a % of vehicle control 
Results are mean ± S.D. of three or more independent sets of experiments. * = P<0.05, **= 
P<0.01, and *** = p<0.001 significance compared to vehicle control. 
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3.4. Discussion 
 
These investigations have tested the hypothesis that the HepaRG line has the metabolic 
properties to enable the assessment of drug-induced mitochondrial injury using the 
metabolic modification model. It is suggested that due to their increased CYP450 
expression, biliary like status and presence of PXR and CAR, which are found within PHH, 
HepaRG cells are a better, more physiologically relevant cell line for testing hepatotoxicity. 
Therefore the aims of the chapter included the bioenergetic phenotyping of the HepaRG 
and HepG2 lines, an electron flow study of both lines, plus the assessment of 12 
compounds for mitochondrial toxicity using an acute metabolic modification glu/gal screen 
in order to inform preclinical testing of the utility of these cells.  
The metabolic phenotyping of the HepaRG cells clearly revealed that these cells have an 
active glycolytic function and that this increases in times of chemical stress upon the 
electron transport chain.  Additionally, probing the electron transport chain using metabolic 
poisons revealed that differentiated HepaRG cells are significantly less metabolically active 
as demonstrated with lower basal and ATP levels when compared to HepG2 cells. Further 
analysis revealed that although the HepaRG cells have a lower basal respiration they are 
capable of greater respiration due to their large spare reserve capacity.  In effect this may 
suggest that the HepaRG line has a greater propensity to deal with mitochondrial insult as 
has been reported in other cell types and furthermore their metabolic phenotype is 
amenable to perform mitochondrial screening based upon metabolic modification 
(Sriskanthadevan et al., 2015).  
Using permeabilised cells it was established that the HepaRG cells retain a fully active 
electron transport chain; with activity at each of the mitochondrial complexes (I to IV) and 
thus overall efficient electron flow activity. It was discovered that the HepaRG line were 
more energetic in terms of higher rates of respiration, as demonstrated by higher levels of 
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OCR than HepG2 in the permeabilised form when compared with the basal respirations of 
the whole cell. This may reflect their large spare reserve capacity and therefore it could be 
postulated that this effect is borne out of a higher number of mitochondria compared to 
the HepG2 line. In the whole cell, limited substrate availability may keep basal respiration 
low, reflecting the differentiated, non-growing status of the cells. However, in the 
permeabilised study excess substrates in the presence of an uncoupler allows the electron-
transport chain to run at its maximum rate.  
It was demonstrated that the glycolytic response is used by HepaRG cells as a protective 
mechanism in times of insult to the electron transport chain using glucose and galactose 
media conditions. The conditions utilised match the recently published mitochondrial 
screening assay by Kamalian et al (Kamalian et al., 2015b). Preliminary experiments with 
rotenone provided an optimal incubation time with drug of 2 h, which maximises the 
differences in cellular ATP content between glucose and galactose media whilst ensuring 
that cell death is reduced, evidenced as no significant release of LDH. Further validation 
that a 2h incubation period could be implemented was achieved using a number of positive 
(Antimycin A and CCCP) and negative (digitonin) controls of mitochondrial toxicity 
(Kamalian et al., 2015a). Importantly these findings demonstrate that metabolic 
modification is possible in HepaRG cells with the same outcome in classifying classic 
mitotoxins as is observed in HepG2 cells (Kamalian et al., 2015a). However, it was noted 
that overall HepaRG cells were less sensitive to the positive controls when compared to 
HepG2 cells. This may be resultant of the large spare respiratory capacity seen within the 
phenotyping studies.  
Following this validation a panel of twelve test compounds, made up of hepatotoxins and in 
some cases matched negative controls, were chosen to assess for mitochondrial liabilities 
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based upon the literature (See Table 3.1). The overall findings compared to the matched 
HepG2 studies and literature are summarised in table 3.7.  
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Compound HepaRG HepG2 (Kamalian et 
al., 2015b) 
 Acute 
 (2 h) 
Extended 
 (> 2 h) 
Acute 
 (2 h) 
Extended  
(>2 h) 
Amiodarone (mi++) 
(Kennedy et al., 1996a; Spaniol et al., 
2001; Serviddio et al., 2011) 
 
Positive 
 
 
 
N/A 
 
 
Positive 
 
 
N/A 
Buspirone (mi++) 
(Dykens et al., 2008b) 
Nefazodone (mi++) 
(Dykens et al., 2008b) 
Tolcapone (mi++) 
(Haasio et al., 2002b; Korlipara et al., 
2004; Kim et al., 2012; Longo et al., 
2016) 
Borderline 
Perhexiline (mi++) 
(Kennedy et al., 1996a; Fromenty et 
al., 1997) 
Negative Negative 
Troglitazone (mi++) 
(Tirmenstein et al., 2002; Scatena et 
al., 2004; Bova et al., 2005b; Konrad 
et al., 2005; Nadanaciva et al., 2007b; 
Julie et al., 2008) 
 
 
 
Negative 
Positive N/A 
Diclofenac (mi++) 
(Moreno-Sánchez et al., 1999; 
Boelsterli, 2003b; Chan et al., 2005; 
Hynes et al., 2006) 
Positive 
(6 h) 
 
 
 
Negative 
 
 
Positive 
Entacapone (mi+) 
(Nissinen et al., 1997; Haasio et al., 
2002b; Haasio et al., 2002a) 
(Korlipara et al., 2004) 
Metformin (mi+) 
(Dykens et al., 2008a) (Owen et al., 
2000; Brunmair et al., 2004) 
Pioglitazone (mi+)  
(Scatena et al., 2004; Chan et al., 
2005; Julie et al., 2008) 
 
Negative 
Ximelagatran  
(Kenne et al., 2008) 
Negative 
Bosentan 
(Fattinger et al., 2001) 
Table 3.7. Comparing designated positive and negative mitochondrial toxins reported 
from HepaRG and HepG2 metabolic modification studies (2 h). Key mi++ indicates known 
strong mitochondrial liability from literature, mi+ indicates known weak mitochondrial 
liability from literature. 
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The 2 h incubation data in HepaRG cells for amiodarone, buspirone and nefazodone is in 
line with literature in demonstrating that they possess a mitochondrial liability. In addition, 
the data match that seen within acutely modified HepG2 cells (Kamalian et al., 2015a). 
Amiodarone is believed to cause electron transport chain dysfunction and thus act as a 
mitochondrial uncoupler (Kennedy et al., 1996a; Spaniol et al., 2001; Serviddio et al., 2011). 
Nefazodone inhibits complex I and IV of the ETC following experiments using both isolated 
rat mitochondria plus metabolically modified HepG2 cells (Dykens et al., 2008b; Kamalian et 
al., 2015a). Research using both isolated rat mitochondria plus metabolically modified 
HepG2 cells has suggested that buspirone is a less potent mitochondrial toxicant compared 
with nefazodone. While nefazodone is believed to inhibit complexes I and IV Dykens et al. 
have demonstrated that buspirone inhibits only complex I (Dykens et al., 2008b). While the 
data within this chapter confirm that buspirone has a mitochondrial liability it does not 
confirm its less potent status (nefazodone IC50-ATP gal = 33.5 ± 0.4 µM vs buspirone IC50-
ATP gal = 320.8 ± 24.8 µM). 
Interestingly the 2 h screen in HepaRG cells identified perhexiline as a weak mitochondrial 
toxin. This is in line with the literature as It is believed that perhexiline can Inhibit both 
carnitine uptake via CPT1 and fatty acid oxidation (Kennedy et al., 1996a; Fromenty et al., 
1997). Work carried out using acutely modified HepG2 cells have classified perhexiline as 
negative for mitochondrial toxicity with a similar profile to that of digitonin (Kamalian et al., 
2015a). The HepaRG screen thus highlights its sensitivity in identifying compounds with 
mitochondrial liabilities associated with fatty acid oxidation. 
Troglitazone is believed to be a mitochondrial toxicant through a number of mechanisms. It 
has been reported to inhibit complex I, II, III, IV, and V, can cause an opening of the MPTP 
plus uncouple OXPHOS (Tirmenstein et al., 2002; Scatena et al., 2004; Bova et al., 2005b; 
Konrad et al., 2005; Nadanaciva et al., 2007b; Julie et al., 2008). Interestingly a 2h hour 
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incubation using the acute metabolic modification system did not reveal troglitazone to 
display a mitochondrial liability. This contradicts research using acutely modified HepG2 
cells whereby it was identified as a clear mitotoxicant (Kamalian et al., 2015a). In keeping 
with the literature, It is possible that an opening of the MPTP could explain why 
mitochondrial toxicity was not evident in HepaRG cells (Okuda et al., 2010). The opening of 
the pore would affect both glucose and galactose cultured cells in an equal manner. This in 
turn would then lead to apoptosis and cell death as seen with the reduction in LDH reserve 
within both media conditions. The difference between HepG2 and HepaRG cells may arise 
due to the metabolic activation of troglitazone leading to the formation of a toxic 
metabolite and lastly inhibition of the bile salt export protein (BSEP) could also explain the 
discrepancy which may only occur in HepaRG cells (Funk et al., 2001b; Dixit et al., 2011). It 
could be postulated that the increased CYP450 expression and biliary status seen with the 
HepaRG would provide the correct phenotypic conditions for both metabolic activation. 
However, despite this, only the HepG2 cells correctly identified troglitazone as a 
mitochondrial toxicant. It  has been demonstrated that the predominant mechanism of cell 
death is apoptosis  and also that the parental compound and its sulfate metabolite are 
potent inhibitors of the bile salt export pump (BSEP) (Funk et al., 2001a; Wang et al., 2011; 
Park et al., 2016; Ogimura et al., 2017). It is thus conceivable that given the HepaRG lines 
increased biliary and metabolic status that cells cultured in either glucose or galactose 
would be equally sensitive to troglitazone. Tolcapone is reported to be a mitochondrial 
toxicant which acts via several mechanisms; mitochondrial membrane potential disruption, 
formation of MPTP, uncoupler of OXPHOS and inhibition of BSEP (Haasio et al., 2002b; 
Korlipara et al., 2004; Kim et al., 2012; Longo et al., 2016). However, in this screen using 
HepaRG cells there was no difference in decreases in cellular ATP content between cells 
cultured in glucose or galactose in the absence of cell death. This therefore suggests that 
there may be a mitochondrial component to the mechanism of cell death but one which is 
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not directly mediated by the ETC. For example, opening of the MPT, as discussed, may not 
have a different effect upon cellular ATP levels in glucose or galactose media. The data 
produced in HepaRG cells are contradictory to the same experiments in HepG2 cells which 
classify tolcapone as being a potent mitochondrial toxicant (Kamalian et al., 2015a). It is 
possible that two different mechanisms of mitochondrial toxicity could be responsible for 
this discrepancy. Specifically, tolcapone is an uncoupler of OXPHOS, thus disrupting the 
normal of flow of electrons and ultimately hindering the production of ATP. This scenario 
would explain the increased sensitivity of galactose cultured HepG2 cells which are 
obtaining a majority of their energy requirements from OXPHOS. Tolcapone is also believed 
to inhibit BSEP which is only possible in lines with biliary like phenotype such as PHHs and 
HepaRG cells (Guillouzo et al., 2007; Kanebratt et al., 2008; Marion et al., 2010c; 
Lübberstedt et al., 2011). This is another example of the increased power of HepG2 cells in 
correctly identifying mitotoxicants despite the lack of physiological relevance. However, it is 
important to consider which the more clinically relevant result is and that possibly the 
HepG2 findings could be considered a false positive.  
Diclofenac, entacapone, bosentan, ximelagatran, metformin and pioglitazone did not alter 
either cellular ATP nor LDH reserve levels during the initial short (2h) incubation period and 
so were investigated for extended periods.  
Ximelagatran is not believed to be a mitochondrial toxin and this was further confirmed 
following a 24 h incubation. Additionally, cell death as measured by LDH reserve occurred 
before decreases in cellular ATP thus confirming the hepatotoxic nature of Ximelagatran is 
independent of mitochondrial insult. 
Bosentan according to the literature is believed  to be an indirect mitochondrial toxicant via 
inhibition of BSEP (Fattinger et al., 2001). In this scenario it is difficult to predict whether 
the acute metabolic modification assay could be successfully used to identify its 
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mitochondrial liability. It is possible that both cells cultured in glucose and galactose could 
be equally affected thus hiding the true mitochondrial toxicant nature. The longer 
incubation point (24 h) employed could not confirm that bosentan displays a mitochondrial 
liability. As aforementioned, the significant increase in cellular ATP levels has been seen in 
other compounds and may the result of cellular defence pathways being unregulated in 
response to the insult (Lofrumento et al., 2011). 
Much research gives mixed views regarding the mitochondrial toxicant potential held by 
entacapone. The literature is contradictory in nature with some authors suggesting no 
mitochondrial liability while others describing entacapone as an uncoupler of OXPHOS 
(Nissinen et al., 1997; Haasio et al., 2002b; Haasio et al., 2002a; Korlipara et al., 2004). 
Following an extended incubation (24 h) period with an increased concentration it was 
demonstrated that entacapone displayed a mitochondrial liability in the absence of cell 
death.  While the IC50-ATP glu/ IC50 ATP gal ratio was less than the standard ≥2 it was 
significant thus suggesting that entacapone is a weak mitochondrial toxin. Even after a 
significant reduction in incubation time (6h) entacapone demonstrated a mitochondrial 
liability with no cell death. The acute metabolic modification method highlights how useful 
the assay is in screening for compounds with potential mitochondrial liabilities and ranking 
their potency. 
Pioglitazone did not demonstrate any mitochondrial liability with the acute modified 
HepaRG system. Interestingly, following a 48 h incubation cellular ATP levels with both 
glucose and galactose cells increased in a significant manner as concentration increased. 
This observation has been seen with other drugs  and may be the result of cellular 
protection mechanisms being upregulated in response to the toxic insult (Lofrumento et al., 
2011). While much research has reported Pioglitazone as a mitochondrial toxin its 
mitochondrial toxicant status could not be confirmed here (Scatena et al., 2004; Chan et al., 
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2005; Julie et al., 2008; Kamalian et al., 2015a). In HepG2 cells pioglitazone was identified as 
a mitotoxin at extended timepoints and it is possible that the increased spare reserve 
capacity that the HepaRG cells display may afford the line with an increased degree of 
protection against mitochondrial insult.  
In line with the literature diclofenac demonstrated a mitochondrial liability following 24 h 
incubation with an increased concentration (Moreno-Sánchez et al., 1999; Boelsterli, 
2003b; Chan et al., 2005; Hynes et al., 2006). As cell death was demonstrated in both media 
conditions it is possible a number of mechanisms of mitochondrial toxicity may be present. 
The significant difference in cellular ATP levels would point to ETC dysfunction such as 
uncoupling and or ATP synthase inhibition. However, research has demonstrated that 
diclofenac can cause an MPTP event following 24 h and much longer incubations 
(Masubuchi et al., 2002; Lim et al., 2006). It is not expected that this event would cause the 
differences in ATP observed here. This may indicate a biphasic mechanism with initial ETC 
effects before MPTP. The total absence of cell death further demonstrates mitochondrial 
dysfunction being the overriding cause of increased sensitivity in the galactose cultured 
cells. The identification of mitochondrial toxicity is in line with experiments carried out 
using acutely modified HepG2 cells which also identified diclofenac as possessing a 
mitochondrial liability at 4 h (Kamalian et al., 2015a). While the acute metabolic 
modification assay is extremely useful it cannot fully differentiate between mechanisms of 
mitochondrial toxicity.  
Complex I can be inhibited by the biguanide, metformin (Owen et al., 2000; Brunmair et al., 
2004; Dykens et al., 2008a). The extended incubation point (24 h) plus increased 
concentration revealed metformin to be a mitochondrial toxicant, in line with earlier 
HepG2 research. Mitochondrial toxicity was independent of cell death thus additionally 
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confirming that ETC dysfunction is a causative event in toxicity.  Shorter incubation (6, 8 h) 
confirmed this finding.  
Overall the main findings of this chapter can be summarised as follows: 
• A form of metabolic modification (acute) was utilised to overcome the Warburg 
effect, thus enabling the timely production of differentiated HepaRG cells which 
obtain a majority of their energy requirements from OXPHOS.  
• The metabolic flexibility of the HepaRG cell in terms of utilising glycolysis in times of 
energy crisis has meant that the glu/gal metabolic modification model for 
identifying mitotoxicants is applicable to these cells. This is a novel finding and has 
a significant potential impact on the pharmaceutical industry who are actively 
seeking more physiologically relevant cell lines for the preclinical investigation of 
mitotoxicity and hepatotoxicity.  
• These studies have revealed that in some cases HepaRG cells identify mitotoxins 
which are not identified by HepG2 cells as mitotoxins, such as perhexiline. 
However, conversely, others are missed such as tolcapone and troglitazone.  
• It is of importance in future work to try to establish the clinical relevance of such 
findings. Specifically, whether hepatotoxicity in humans induced by these 
compounds is truly mitotoxic in origin or whether the mitochondrial liability is not a 
causative factor in DILI. This would provide evidence as to whether HepG2 cells, 
although reporting accurately upon mitochondrial liabilities, are giving false 
positives when placed in the context of DILI (Kamalian et al., 2015b).  
• Overall, the results in this study suggest that although often assumed to be a better 
cell model, in terms of physiological relevance, when compared side by side the 
HepaRG appear no better than the HepG2 cells in detecting mitotoxicity. However, 
the HepaRG cells may offer a significant advantage in their ability to be cultured for 
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up to 4 weeks post differentiation and this long term stability in culture may be 
advantageous in their utilisation during extended dosing periods when assessing 
chronic mitochondrial toxicants such as FIAU (Manning et al., 1995b; McKenzie et 
al., 1995b; Colacino et al., 1996). 
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Evaluating the utility of differentiated HepaRG 
cells in the assessment of fialuridine as a 
mitochondrial toxin 
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4.1. Introduction 
 
The first generation nucleoside analogues Adenine arabinoside (vidarabine) and its 
monophosphate, acyclovir, didanosine, zidovudine and ribavirin have been extensively 
studied for use as anti-virals in chronic hepatitis B therapy, however, they are deemed 
either ineffective or too toxic during prolonged dosing regimes. The next generation of 
nucleoside analogues, which were orally bioavailable, were identified following their 
marked anti-hepatitis B (HBV) activity in both in vivo and in vitro models (McKenzie et al., 
1995a). The second generation included lamivudine, adefovir, entecavir, tenofovir, 
telbivudine and FIAU (McKenzie et al., 1995a; Aspinall et al., 2011). The clinical trials of 
FIAU demonstrated its activity against HBV over two and four weeks; FIAU caused a 
reduction in serum HBV DNA levels by 65 and 95 % respectively. However, this anti-viral 
activity was not sustained and viral load increased following cessation of treatment. 
Subsequently, the clinical trials were extended, planned to be 6 months, however, the trial 
was halted after 13 weeks and 5 out of the 15 volunteers died due to acute liver failure 
(1995b; McKenzie et al., 1995b). The clinical evidence from these studies pointed towards a 
mitochondrial origin of toxicity. Specifically, in the affected patients toxicity was delayed in 
onset. In all cases the patients experienced lactic acidosis and follow-up histopathological 
analysis revealed evidence of hepatic steatosis and abnormal mitochondria within the 
damaged liver (McKenzie et al., 1995a; Kleiner et al., 1997).  
The delayed toxicity seen within the phase II clinical trial is the hallmark of a chronic 
mitochondrial toxicant. Nucleoside analogues such as FIAU work to act as chain terminators 
of viral DNA replication thus decreasing viral load. However, research has demonstrated 
that FIAU is unique in that it possesses a hydroxyl group at the 3’ position of the 
deoxyribose molecule thus allowing its incorporation into nascent DNA chains (McKenzie et 
al., 1995a). It is postulated that this incorporation could occur both within the genomic and 
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mitochondrial DNA thus leading to the translation of abnormal protein either of genomic or 
mitochondrial origin (Colacino et al., 1994; Colacino et al., 1996; Lewis et al., 1996b; Lewis 
et al., 1997). In the case of effects of mtDNA this would lead to dysfunction in the 
translation of proteins of the electron transport chain. In this scenario the negative impact 
of OXPHOS machinery due to the incorporation of FIAU may lead to a situation whereby the 
mitochondria are energetically insufficient for the requirements of the cell. Importantly, 
damage to mtDNA can lead to a situation known as mitochondrial heteroplasmy, where 
multiple versions of the mitochondrial genome exist within the same cell (Fig. 4.1). Each 
copy can have varying degrees of mtDNA damage which delays the onset of toxicity until a 
critical threshold of damage is reached and cell death ensues (Boelsterli et al., 2007). An 
example of this effect is seen with another nucleoside analogue, zidovudine (AZT). AZT has 
been shown to have two effects upon mtDNA as it causes an increase mtDNA mutations 
whilst at the same time depleting native mtDNA thus shifting the heteroplasmic balance 
between mutant vs wildtype mitochondria (Lewis et al., 2003). It has been postulated that 
hepatic cells, which have a high turnover of mitochondria, can endure a high level of 
mtDNA damage but up to a critical point, a point termed the ‘’threshold effect’’ (Boelsterli 
et al., 2007).  
 
Figure 4.1. Mitochondrial heteroplasmy and the threshold effect. Multiple versions of the 
mitochondrial genome exist within the cell. The mitochondrial genomes can vary on their 
degree of mtDNA damage from toxic insult. Once the threshold point is reached cell death 
follows. 
 
It has been estimated that the threshold effect can vary between 90% for small point 
mutations to 60% for large scale deletions within the mtDNA (Pulkes et al., 2001). Once the 
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threshold level has been reached it is thought a rapid phenotypic change occurs from 
normal to abnormal leading to organ failure and in the case of hepatic cells, hepatic failure 
(Shoffner, 1996).  The effect of mitochondrial heteroplasmy and the threshold effect is 
believed to underlie the delayed toxicity of FIAU and the subsequent rapid phenotypic 
change from healthy to individuals with acute hepatic failure.  
The delayed onset of clinical FIAU toxicity has led to the hypothesis that an in vitro model of 
FIAU toxicity requires cells to be dosed with FIAU over extended (>7 days) periods in order 
to demonstrate mitochondrial toxicity. Additionally, it is postulated that the increased PHH 
like properties displayed by the HepaRG cell line will provide a novel model of FIAU toxicity 
which is more clinically relevant compared to the mainstay HepG2 models with are 
commonly used for drug toxicity studies. In order to test this hypothesis the following aims 
will be carried out: 
• HepaRG cell line will be used as they are stable in their differentiated state for 4 
weeks of culture which will enable the accumulation of mtDNA dysfunction to 
occur and induce mitochondrial toxicity.   
• The metabolic flexibility of HepaRG cells, which allows them to utilise glycolysis in 
times of mitochondrial stress, means that the acute metabolic modification model, 
using glu/gal media, can be used to identify mitochondrial toxicity.  
• Specifically, the metabolic modification model will be used to identify 
mitochondrial toxicity over 4 weeks alongside the measurement of the effect of 
FIAU on mtDNA levels. Mitochondrial respiration activity will be monitored over 4 
weeks using Seahorse technology.   
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4.2. Methods and Materials 
 
4.2.1. Materials 
 
Foetal bovine serum (FBS), dialysed foetal bovine serum (DFBS) and NUPAGE 4-12% BT GEL 
1.5 mm gels were purchased from Life Technologies (Paisley, UK). All Seahorse 
consumables were purchased from Seahorse Bioscience (Boston, USA). HepaRG cells and all 
media and supplements were acquired from Biopredic International (Saint Grégoire, 
France). Williams’ Medium E, w/L-Glutamine w/o Glucose (Powder) manufactured by 
United Stated Biological was purchased from Stratech Scientific Ltd (Suffolk, UK). Hep G2 
cells were acquired from the European Collection of Cell Cultures (Salisbury, UK). Total 
OXPHOS Human WB Antibody Cocktail (ab110411), Anti-Rabbit IgG (A9169), and Anti-
Mouse IgG (A9044) was purchased from ABCAM (Cambridge, UK). Western Lightning Plus 
ECL Enhanced Chemiluminesence Substrate was purchased from Perkin Elmer 
(Buckinghamshire, UK). GE Healthcare Hyperfilm ECL, TaqMan® Gene Expression Assay MT-
ND1 and TaqMan® Copy Number Reference Assay human RNaseP was purchased from 
Fisher Scientific UK Ltd (Loughborough, UK). Precision Plus Protein™ Kaleidoscope and 
Bradford reagent were purchased from Bio-Rad Laboratories Ltd (Watford, UK). All other 
remaining materials and reagents were purchased from Sigma-Aldrich (Poole, Dorset, UK). 
 
4.2.2. Cell culture and experimental preparation 
HepaRG cells were cultured, seeded into collagen I coated (5 μg/cm
2
) clear flat bottomed 
96 well, 6 well or Seahorse plates XF 96 plates and differentiated as described (chapter 3, 
section 3.2.2). During FIAU exposure (up to 4 weeks) dosing media were replaced twice 
weekly, every 3 – 4 days. 
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4.2.3. Metabolic modification 
 
FIAU (0 to 300 µM) was prepared in 0.5 % v/v DMSO in glucose or glucose free media. The 
compound was added to the differentiated HepaRG cells, in HepaRG differentiation media 
and returned to the incubator (37 
o
C, 5 % CO2) for the appropriate length of incubation.  
The method of acute metabolic modification has already been described (Chapter 3, section 
3.2.3). In these experiments the modification took place for only the final 2 h of drug 
exposure. 
4.2.4. Combined assays for assessing cellular ATP, LDH release and protein quantification 
 
The combined ATP, LDH release and protein quantification method was performed as 
previously described (chapter 2, section 2.2.4). However, the LDH content of the dosing 
media were quantified after every media change and then totalled over the whole dosing 
period. 
4.2.5. Seahorse XF Analysis of Oxygen Consumption rates 
 
The mitochondrial stress test was carried out in accordance with the protocol described 
(chapter 2, section 2.2.6.1). The differentiated HepaRG cells were exposed to FIAU for 2 and 
4 weeks before the experiment commenced. 
4.2.6. Western blot analysis of mitochondrial complexes 
 
HepaRG cells were dosed with FIAU (0, 10 and 50 µM) for 1, 2, 3 and 4 weeks. Following 
drug incubation cellular lysates were prepared. Briefly, cells were washed (3x) before lysis 
using RIPA buffer (100 µl). Wells were scraped and cells/RIPA buffer solution was 
transferred to a 1.5 ml micro centrifuge tube (on ice). Samples were then centrifuged 
(18,000 g / 10 min). Supernatants were retained and stored at -80
o
c before analysis. Protein 
content of each sample was assessed by BCA assay (Chapter 2, section 2.2.3.3). 
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The formulation of buffers and overall western blotting procedure has already been 
described (Chapter 2, section 2.2.4), with the following changes; For control purposes 
membranes were probed using Beta actin antibody (1:5,000 1hr, RT) as primary , washing 
using 1x TBS-T (6x 5min) then anti-Mouse IgG (whole molecule)–Peroxidase antibody 
produced in rabbit (1:10,000, 1hr, RT) as secondary  and anti-VDAC1 / Porin antibody 
(1:1,000 1hr, RT) as
 
primary, washing using 1x TBS-T (6x 5min) then anti-Rabbit IgG (whole 
molecule)–Peroxidase antibody produced in goat (1:10,000, 1hr, RT) as
 
secondary
  
. 
Membranes were washed with 1x TBT-T (6x 5min) and visualised using ECL reagent and 
imaged using X-ray film. Image J software was used to quantify the blots. 
4.2.7. Real time PCR analysis of mtDNA and nuDNA levels  
 
HepaRG cells were dosed with FIAU (0, 10 and 50 µM) for 1, 2, 3 and 4 weeks before cells 
were scraped and transferred to an eppendorf tube. Cells were centrifuged (300 x g, 5 min) 
and then supernatant was discarded leaving a cell pellet which was re-suspended in PBS 
(200 µl). DNA was then purified using the Qiagen QIAamp DNA Mini and Blood Mini kit to 
the manufacturer’s instructions. Extracted DNA underwent spectrophotometric analysis 
using a Nano drop and subsequently diluted to (5 ng/µl) using Qiagen buffer AE (10 mM 
Tris-Cl, 0.5 mM EDTA; pH 9.0). 
Real time PCR procedure 
 
Unique regions of the mitochondrial genome that are not replicated within the nuclear 
genome and conversely  unique regions of the nuclear genome which are not replicated 
within the mitochondrial genome were identified in accordance with previously reported 
work (Malik et al., 2011).  
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Table 4.1. Genomic and mitochondrially specific primers used.  
MtDNA and nuclear DNA were determined using probes specific to both regions (Table 4.1). 
The RNaseP probe was used as a house keeping gene in order to normalise both the mtDNA 
and nuclear DNA content. A 71-bp fragment of mtDNA was amplified using the following 
primers: ND1 as the hybridisation probe (Applied Biosystems), containing the FAM (6-
carboxy fluorescein) as a fluorescent reporter dye and NFQ as a quencher. Nuclear content 
was quantified by targeting a unique region of the RNaseP gene, using the FAM™ dye–
labelled probe (Applied Biosystems).  
Genomic DNA samples (10 ng) were loaded into a 384 well PCR plate in duplicate, with 
TaqMan genotyping master mix (5 µl), TaqMan copy number assay ND-1 (0.5 µl), copy 
number reference assay RNaseP (0.5 µl) and nuclease free water (2 µl). The plate was 
sealed and centrifuged (1 min, 1,000 rpm, RT). The PCR machine used was the Bio-Rad / MJ 
Research Opticon 2 Real-Time PCR with the following settings hold (95 
o
C, 10 min) with 40 
cycles (95 
o
c/15s and 60 
o
c/60s). Relative gene expression was calculated by comparing CT 
values and thus mtDNA vs. nuclear DNA ratio (Fig. 4.2) 
 
Figure 4.2. An example of how CT values were compared in order to assess mtDNA 
depletion. 
 
Gene accession no. Primer/probe Oligonucleotide sequence Product size (bp)
hRNaseP F1 CCCCGTTCTCTGGGAACTC
hRNaseP R1 TGTATGAGACCACTCTTTCCCATA
MT-NDI F1 dye label  
FAM-MGB
Not dislosed by 
ThermoFisherScientific
MT-NDI R1 dye label  
FAM-MGB
Not dislosed by 
ThermoFisherScientific
175Human RNaseP AF479321
Human MT-ND1 assay no. 
Hs02596873_s1
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4.2.8. Statistical analysis 
 
GraphPad Prism 5 was used for the statistical analysis of data. Data are presented as the 
mean of 3 independent experiments ± standard deviation. The data were tested for 
normality of distribution using the Shapiro-Wilk test. Normal data were tested for statistical 
significance using 1- or 2- way Anova as appropriate, non-normal data were tested using 
Mann-Whitney. A result was deemed significant when p-value <0.05%.   
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4.3. Results 
4.3.1. An acute exposure (2h) to FIAU does not reveal mitochondrial toxicity  
Following a 2 hour incubation with FIAU (Fig. 4.3 and Table 4.2) there was no significant 
change in cellular ATP (IC50-ATP glu = >300 μM and IC50-ATP glu = >300 μM) or cellular LDH 
content (IC50-LDH glu = >300 μM and IC50-LDH gal = >300 μM)   within either media 
condition (cells cultured in glucose or galactose). 
 IC50-ATP ± S.D. (μM) IC50-LDH  ± S.D. (μM) IC50-ATP 
glu/ IC50 
ATP gal (p 
value) 
IC50-LDH 
gal/ IC50 
ATP gal (p 
value) 
Time (h) Glucose Galactose Glucose Galactose   
2 >300 >300 >300 >300 1 (ns)  1 (ns) 
Table 4.3. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios  for acutely modified HepaRG cells incubated with  FIAU (0 – 300 µM) 
for 2 h. Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 ATP gal >2. Mitochondrial 
toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 ATP gal >2. 
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Figure 4.3.  Cellular ATP determination and LDH reserve in HepaRG cells cultured in either 
glucose or galactose, following acute metabolic modification, and treatment with FIAU (0-
300 µM, 2 h). ATP Values are expressed as a % of vehicle control normalised to protein 
content. LDH values are expressed as a % of vehicle control Results are mean ± S.D. of three 
or more independent sets of experiments. * = P<0.05, **= P<0.01, and *** = p<0.001 
significance compared to vehicle control. 
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4.3.2. FIAU induces mitochondrial toxicity in HepaRG cells following extended incubation 
 
An extended time course was undertaken (1 to 5 weeks).  Following a 1 week incubation 
with FIAU (Fig. 4.4 A) cellular ATP levels significantly decrease in both media conditions at 
concentrations above 33 µM, although there was no significant difference between cells 
cultured in glucose and galactose (table 4.3). The decrease in cellular ATP occurred in the 
absence of cell death as indicated by cellular LDH content.  
Following 2 weeks of FIAU treatment (Fig. 4.4 B) there was an increase in the fall of cellular 
ATP levels in both media conditions, which became significant at a lower concentration 
(11.1 µM). It can be seen that cells cultured in galactose were significantly more sensitive to 
FIAU compared with their counterparts cultured in glucose (Table 4.3, IC50-ATP glu = 18.4 ± 
1.6 and IC50 ATP gal = 9.2 ± 3.1). This was further confirmed by assessing the IC50-ATP glu/ 
IC50 ATP gal ratio which was 2 (p 0.015). An increase in cell death, decreased cellular LDH 
content, was observed in both media conditions, from 33.3 µM. However, the decrease in 
LDH cellular content occurred after the decrease in cellular ATP (IC50-LDH gal/ IC50 ATP gal = 
32.6, p value 0.0001) thus providing evidence that mitochondrial insult was independent of 
cell death.  
As incubation time (Fig. 4.4 C) was extended further (3 weeks) a significant decrease in 
cellular ATP in both glucose and galactose cultured cells was seen across every 
concentration. Neither cells cultured in glucose nor galactose demonstrated a significant 
increase in sensitivity to FIAU as demonstrated with similar IC50-ATP values observed (5.3 ± 
2.2 and 5.7 ± 2.8 µM respectively). A similar trend was seen at 4 weeks of incubation (Fig. 
4.4 D) with a significant decrease in cellular ATP across all concentrations but with no 
difference between cells cultured in glucose or galactose (IC50-ATP values of 5.3 ± 2.2 and 
5.7 ± 2.8 μM respectively) . At the final time-point (5 weeks) cell ATP was decreased further 
(IC50-ATP 3.3 ± 0.3 and 3.5 ± 0.4 μM in glucose and galactose respectively) (Fig. 4.4 E). Cells 
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cultured in galactose did not display an increased sensitivity towards FIAU (IC50-ATP glu/ IC50 
ATP gal 0.94, p value 0.3312). Cell death as measured by LDH reserve can be seen to 
increase over 3 – 5 weeks (Table 4.3). At every week cellular ATP content is decreased more 
than LDH release. However, it can be seen that over time the difference becomes less when 
measured by IC50 LDHgal/ATP gal (Table 4.3).  
 IC50-ATP (μM) ± S.D. IC50-LDH (μM) ± S.D. IC50-ATP 
glu/ IC50 
ATP gal (p 
value) 
IC50-LDH 
gal/ IC50 
ATP gal 
 (p value) 
Time 
(wk) 
Glucose Galactose Glucose Galactose   
1 
116.6 ± 
38.3 
107.8 
±17.8 
>300 >300 
1.1 
 (0.3722) 
> 2.8 
(not 
calculated) 
2 18.4 ± 1.6 9.2 ± 3.1 >300 >300 
2  
(0.015) 
32.6 
 (0.0001) 
3 5.3 ± 2.2 5.7 ± 2.8 
172.2 ± 
53.4 
160 ± 61.9 
0.92   
(0.4366) 
28.1 
(0.025) 
4 5.0 ± 1.5 5.2 ± 0.9 
50.1 ± 
15.5 
42.9 ±  
21.2 
0.95 
(0.4352) 
8.3 
(0.0454) 
5 3.3 ± 0.3 3.5 ± 0.4 14.2 ± 0.1 17 ± 3.4 
0.94  
  (0.3312) 
4.8 
0.0098 
Table 4.3. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios  for acutely modified HepaRG cells incubated with  FIAU (0 – 300 µM) 
from 1 to 5 weeks. Mitochondrial toxicity is defined as IC50-ATP glu/ IC50 ATP gal >2. 
Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 ATP gal >2. 
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Figure 4.4. Cellular ATP determination and LDH reserve in HepaRG cells cultured in either 
glucose or galactose, following acute metabolic modification, and treatment with FIAU (0 
– 300 µM) for  (A) 1 week (B) 2 weeks  (C) 3 weeks (D) 4 weeks (E) 5 weeks. ATP Values are 
expressed as a % of vehicle control. LDH values are expressed as a % of vehicle control 
Results are mean ± S.D. of three or more independent sets of experiments. * = P<0.05, **= 
P<0.01, and *** = p<0.001 significance compared to vehicle.  
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4.3.3. FIAU induces a decrease in mitochondrial cellular respiration  
 
FIAU induced a significant, dose- and time-dependent decrease in basal rates of oxygen 
consumption (Fig. 4.5 A). A significant dose- and time-dependent decrease in ATP-linked 
respiration was observed (Fig. 4.5 B). The decrease in ATP rate was more prominent 
following the longer (4 week) incubation reaching a maximum decrease of 0.2 
pmol/min/mg at 300 µM. Coupling efficiency remained unchanged following both 2 and 4 
week exposure (Fig. 4.5 C). Proton leak decreased in a dose- and time-dependent manner 
becoming significant at 11.1 µM at both 2 and 4 weeks (Fig. 4.5 D). Spare respiratory 
capacity decreased in a dose- and time-dependent manner becoming significant at 11.1 µM 
FIAU (Fig. 4.5 E). The longer (4 week) incubation resulted in a significantly greater reduction 
in spare respiratory reserve with no spare capacity measurable at the top two 
concentrations (100 and 300 µM).     
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Figure 4.5. Cellular oxygen consumption rates of HepaRG cells following treatment with 
FIAU (0 – 300 µM) for 24 hours. (A) Assessment of Basal metabolic rate, (B) Assessment of 
ATP production, (C) Assessment of coupling efficiency, (D) Assessment of proton leak and 
(E) Assessment of spare respiratory reserve. Values are expressed as a value per mg of 
protein. Results are mean ± S.D. of three or more independent sets of experiments. * = 2 
week time point ^ = 4 week time point.  * or ^ = P<0.05, ** or ^^= P<0.01, and *** or ^^^ = 
p<0.001 significance compared to vehicle control.  
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4.3.4. FIAU affects the expression of proteins which form part of the respiratory chain 
 
The protein levels of complexes I and IV were assayed in cellular lysate using western blot. 
Complex II is nuclear encoded and complex IV is encoded by the mitochondrial genome. 
Beta actin and VDAC/Porin were included as nuclear and mitochondria control proteins 
respectively (Fig. 4.6). 
 
Figure 4.6. Western blot following probing of mitochondrial complex’s I to V following 
dosing of FIAU (0 to 50 µM) for 1 to 4 weeks in HepaRG cells. Whole cell lysate (5 µg) was 
used. 
 
Densitometric analysis revealed that the expression of Mt complex II (Fig. 4.7 A) can be 
seen be to increase initially at week 1 before decreasing dose dependently over the 
remaining incubation periods (Week 2, 3 and 4) (Fig. 4.7 A). The dose dependent decrease 
in expression becomes significant at week 3. At week 3 and 4 expression is approximately 
60 and 50 % respectively of vehicle control. Increasing the concentration of FIAU (50 µM) 
during the same incubation period (Fig. 4.7 A) results in a much greater dose dependent 
decrease in Mt complex II expression, which becomes significant at week 2. At week 4 
expression of Mt complex II is approximately 5% of vehicle control compared to 40% when 
incubated with a lower concentration (10 µM).  Both incubation time and concentration of 
FIAU effect Mt complex II expression. 
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The expression of Mt complex IV (Fig. 4.7 B) initially increases during weeks 1 and 2 then 
decreases in a significant manner for the remaining incubation points. Expression reaches 
approximately 70 % and 60 % of vehicle control for the final two incubation periods (3 and 
4 weeks).Further increasing the concentration of FIAU (50 µM) during the same incubation 
periods (Fig. 4.7 B) results again in an increase in expression during weeks 1 and 2. 
Expression then dose dependently decreases in a significant manner for the remaining 
incubation periods (3 and 4 weeks). At 3 and 4 weeks the expression of Mt complex IV 
reaches approximately 40 % and 10% of vehicle control. The increased concentration of 
FIAU (50 µM) significantly affected expression at these longer (3 and 4 week) incubation 
periods. Both incubation time and concentration of FIAU effect Mt complex IV expression. 
For normalisation purposes complex II (nuclear encoded) was normalised to the expression 
of beta actin in which its gene is both consecutively conserved and is essential for the 
maintenance of normal  cellular function (Stürzenbaum et al., 2001; Ruan et al., 2007). 
Complex IV (Mt encoded) was normalised to the expression of voltage-dependent anion 
channel (VDAC) which is found within the outer mitochondrial membrane (Lemasters et al., 
2006).  
The expression of complex V, III and I did not alter apart from the top concentration (50 
µM) at week 4. Given the minimal expression of beta-actin it could be postulated that at 
this time and concentration point there is minimal protein within the wells therefore 
leading to a decrease in expression of these complexes (V, III and I) in question. 
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Figure 4.7. Relative expression of complexes II and IV following dosing of FIAU for 1 to 4 
weeks within HepaRG cells. Western blot gels were quantified using densitometry, and the 
amounts of complex II and complex IV were determined as a % of vehicle control 
normalised to VDAC Porin 1 or Beta actin respectively. (A) Complex II expression 1 to 4 
weeks, 10 and 50 µM FIAU. (B) Complex IV expression 1 to 4 weeks, 10 and 50 µM FIAU. 
Results are mean ± S.D. of three or more independent sets of experiments.  * =10 µM FIAU 
^ = 50 µM FIAU. * or ^ = P<0.05, ** or ^^= P<0.01, and *** or ^^^ = p<0.001 significance 
compared to vehicle control.  
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4.3.5. FIAU does not affect the mitochondrial mass over extended exposure periods  
 
Relative changes in mitochondrial mass were assessed by quantification of VDAC/Porin 
expression using western blot. VDAC is a highly conserved pore forming protein found 
within the outer mitochondrial membrane (Lemasters et al., 2006; Sun et al., 2012). 
Following dosing with FIAU (1 - 4 wk) mitochondrial mass remained unchanged with no 
significant alteration following either incubation with 10 or 50 µM FIAU (Fig. 4.8 ).  
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Figure 4.8. Mitochondrial mass following dosing of FIAU (1 - 4 wk) in HepaRG cells. 
Western blot gels were quantified by densitometry, and the amounts of VDAC/Porin were 
determined as a % of vehicle control. VDAC/Porin expression 10 and 50 µM FIAU. Results 
are mean ± S.D. of three or more independent sets of experiments.  * =10 µM FIAU ^ = 50 
µM FIAU. * or ^ = P<0.05, ** or ^^= P<0.01, and *** or ^^^ = p<0.001 significance 
compared to vehicle control. 
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4.3.6 FIAU induces mitochondrial DNA depletion compared to nuclear DNA  
 
Real time PCR was used to assess the relative mt to nuclear DNA ratio. At the earliest time 
points (1 and 2 weeks) both concentrations were seen to increase mtDNA to nuclear DNA 
ratio, although this was not significant (Fig 4.9 A and 4.9 B). Following longer exposure (3 
and 4 wk) there was a significant dose-dependent reduction in mtDNA/nuclear DNA ratio 
compared to vehicle control resulting, with a maximum decrease of 13 and 10 % 
respectively (Fig. 4.9 A). At a higher concentration of FIAU (50 µM, Fig. 4.9 B) the decrease 
in mtDNA was more pronounced over the longer (3 and 4 week) timepoints with decreases 
of approximately 10 and 4 % respectively.  
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Figure 4.9. MtDNA / nuclear DNA ratio following dosing of FIAU for 1 to 4 weeks within 
HepaRG cells. Primers used ND1 and RNaseP. (A) MtDNA / nuclear DNA ratio 1 to 4 weeks, 
10 µm FIAU and (B) MtDNA / nuclear DNA ratio 1 to 4 weeks, 50 µm FIAU. Results are mean 
± S.D. of three or more independent sets of experiments. * = P<0.05, **= P<0.01, and *** = 
p<0.001 significance compared to vehicle control.  
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4.4. Discussion 
 
FIAU is one of the clearest examples of where clinical hepatotoxicity can be attributed 
solely to direct mitochondrial toxicity. It remains one of the most infamous cases of clinical 
trial failure due to the severity of the adverse effects which only developed after 13 weeks 
of dosing. The delayed nature of its toxicity has led to the hypothesis that extended dosing 
periods are required in order to produce an in vitro model with which to examine its 
mitochondrial liability and to elucidate its mechanism of toxicity. HepaRG cells were 
selected for these studies due to their closer physiological phenotype to  PHH, specifically in 
terms of cell polarity, biliary status and extensive expression of CYP450 isoforms (Marion et 
al., 2010a). However, the major practical advantage of HepaRG cells is their extended 
viability in culture, up to 4 weeks due to their differentiated status which is ideal with which 
to model the delayed toxicity of FIAU. It was therefore the aim of this chapter to investigate 
the utility of HepaRG cells as an intro vitro model of FIAU toxicity with a specific focus upon 
recapitulating its effect on mtDNA.   
FIAU induced mitochondrial toxicity was only observed using the acute metabolic 
modification model at 2 weeks.  This finding is based upon the definition of mitochondrial 
toxicity  described by Kamalian et al  in which in an IC50-ATPglu/IC50-ATPgal of ⩾2 indicates 
that the tested compound contains a mitochondrial liability and thus has a more significant 
effect in galactose media due to the absence of ATP production via glycolysis (Kamalian et 
al., 2015b). Before this point, at 7 days no evidence of mitochondrial effects was observed, 
which is in accordance with the findings from chapter 2 when FIAU was tested in HepG2 
cells. This provides the first evidence that mitochondrial toxicity is only observed after 
extended dosing. As the exposure to FIAU increased from 2 weeks both glucose and 
galactose cultured cells became equally sensitive to insult and cell death also became more 
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prominent. This may be indicative of the threshold effect in which cell death becomes 
induced only after a threshold of mitochondrial damage has been reached.  
Following the positive screening for mitotoxicity further analysis was carried out to confirm 
that cell death is mitochondrial in origin by conducting mechanistic investigations. The use 
of real time PCR to provide a semi-quantitative measure of mtDNA levels compared to 
nuclear DNA revealed that there was a significant depletion in mtDNA from 3 weeks of FIAU 
treatment. Previously published research has provided evidence that as a nucleoside 
analogue FIAU can be incorporated into both mtDNA and genomic DNA via the action of 
DNA pol-γ resulting in unfunctional DNA and leading to transcriptionally error prone 
nuclear and mtDNA (Lewis et al., 1994b; Colacino et al., 1996). It is thus interesting to track 
mitochondrial DNA depletion in the HepaRG cells, alongside an examination of the protein 
levels of specific subunits which make up the complexes of the ETC, some of which are 
encoded for by mtDNA. Specifically in this work the proteins MTC02 and NDUFB8 were 
examined. MTC02 is a mitochondrially encoded component of complex IV and therefore its 
expression could be decreased in the case of mtDNA depletion whereas protein NDUFB8 is 
a nuclear encoded component of complex II (Schon et al., 2012). A time and dose-
dependent decrease in Protein MTC02 expression was observed, with a significant decrease 
in expression being observed from week 3. This is an important finding as it supports the 
findings of mtDNA depletion and fits with the reported mechanism (Lewis et al., 1996b; 
Lewis et al., 1997). FIAU also decreased the expression of protein NDUFB8 from week 3. 
Although this may seem unexpected as NDUFB8 is encoded in the nucleus, previous 
research has demonstrated that FIAU can be incorporated into nuclear DNA (Lewis et al., 
1994b; Colacino et al., 1996). This suggests that FIAU may induce dual mechanisms of 
toxicity in the cell and that mitochondria-independent mechanisms may also play a role in 
toxicity. 
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 Seahorse analysis was performed in order to evaluate the functional impact of FIAU-
induced mtDNA effects upon mitochondrial respiration. Overall FIAU caused time- and 
dose-dependent decreases in basal respiration which could arise  due to a number of 
factors such as; decrease in ATP demand, proton leak decrease, ETC or ATP synthase 
inhibition or a decrease in substrate supply (Hill et al., 2012). Further analysis revealed that 
this decrease was accompanied by a decrease in ATP linked respiration, a dose dependent 
decrease in proton leak and a dose dependent decrease in spare respiratory reserve. While 
in combination the decreases in basal respiration, ATP linked respiration and spare 
respiratory capacity data are suggestive of possible ETC dysfunction this would normally be 
accompanied by an increase in proton leak/decreased coupling efficiency to signify a break 
down in the efficiencies of electron transfer (Hill et al., 2012). Instead, it can be postulated 
that the decrease in respiration across bioenergetic parameters signals that rather than 
dysfunctional OXPHOS, FIAU is inducing a decrease in respiration. However, when 
mitochondrial mass was assessed using VDAC as a marker of mitochondrial number (VDAC 
is a highly conserved pore forming protein found within the outer mitochondrial 
membrane, therefore, allows its expression to be correlated with mitochondrial number), 
the expression of VDAC remained unchanged (Lemasters et al., 2006; Sun et al., 2012).This 
can be interpreted as there being no change in the actual number of mitochondria and 
therefore the decrease in respiration is not due to a reduced number of cellular 
mitochondria. Although this appears contradictory the specific effect of FIAU on mtDNA 
should be considered. FIAU would only be expected to reduce the expression of the 37 
proteins which are encoded for by mtDNA. Of these 37 genes, 13 encode for proteins of the 
ETC (CI, III and IV) and the remainder are for transfer RNA and ribosomal RNA (Yoon et al., 
2010). We have demonstrated the reduction in CIV protein MTC02 and therefore such 
depletion of proteins of the ETC would cause a reduction in the activity of complexes in the 
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absence of any decrease in mitochondria mass, thus leading to the reduction in 
mitochondrial respiration.  
Overall, the data within this chapter has provided evidence that the mechanism of FIAU 
toxicity in HepaRG cells matches the clinical mechanism (Fig. 4.10). Briefly, FIAU induces 
mtDNA depletion, leading to a decrease in the expression of complex IV. The loss of 
functional complex IV subunits hinders the efficient flow of electrons through the ETC 
leading to a decrease in OXPHOS and a subsequent decrease in ATP production. 
Additionally, the possible depletion of genomic DNA, as indirectly assessed via NDUFB8 
expression, may impact on organelles beyond the mitochondria and explain why cell death 
is not mitochondrial in origin at high FIAU concentrations or in HepG2 cells, chapter 2 
(Lewis et al., 1994b; Lewis et al., 1996b). The observation opens up further questions 
regarding FIAU and whether the observed toxicity seen within the phase II clinical trial had 
a genomic as well as mitochondrial basis (Manning et al., 1995b; McKenzie et al., 1995a; 
Honkoop et al., 1997) .  While FIAU incorporation was not established the data from the 
chapter provides much evidence that this may be the case, this may be an important 
subject for future work due to the continued use of nucleoside analogues as antiviral 
agents which are still associated with mitochondrial toxicity (Blanche et al., 1999; Brinkman 
et al., 1999; Fleischer et al., 2004). Further work to establish FIAU incorporation could 
involve the use of radiolabelled FIAU in conjunction with a gel-based oligonucleotide 
extension assay (Lim et al., 2001).   
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Figure 4.10. The proposed mechanism of FIAU induced mitochondrial toxicity based on 
data within this chapter. Incorporation of FIAU was not established within this thesis. 
 
Overall the main findings of this chapter can be summarised as follows: 
• Work described in this chapter has confirmed the hypothesis, using HepaRG cells, 
that an in vitro model of FIAU toxicity requires cells to be dosed with FIAU over 
extended (>7 days) periods in order to demonstrate mitochondrial toxicity.  
• Mechanistic investigations have confirmed that FIAU targets the mtDNA leading to 
mitochondrial dysfunction, thus it can be concluded that the HepaRG in vitro model 
is in accord with the clinical mechanism of FIAU hepatotoxicity.  
• The Cmax of FIAU in healthy volunteer receiving 5 mg FIAU was reported to be 1 
µM. During the phase II trial patients received upwards of 10 mg FIAU per day thus 
the measurement of their Cmax can be estimated to be approximately 2.5 µM 
(Bowsher et al., 1994; Manning et al., 1995a; Honkoop et al., 1997; Bell et al., 
2016). Therefore the concentrations at which effects were reported in this chapter, 
starting at around 4 µM, appear to have clinical relevance.  
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• It is therefore concluded that HepaRG cells are a good model with which to study 
delayed mitochondrial toxicity, particularly toxicity induced by nucleoside 
analogues. The use of the HepaRG cell line enabled longer drug incubation times 
which were absent when tested within chapter 2.  
• While the toxicity of any drug or compound is a product of its pharmacokinetics it 
must be appreciated that these factors are difficult to model using in-vitro cell line 
models. However, the characterisation of the HepaRG line as an in vitro model 
which recapitulates the clinical toxicity of FIAU will provide an opportunity to study 
these mechanisms in more detail, potentially providing data for systems 
pharmacology/toxicology projects in order to bridge the gap more effectively.  
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Chapter 5 
 
Evaluating the utility of differentiated HepaRG 
cells in the assessment of paracetamol-induced 
hepatotoxicity 
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5.1. Introduction 
 
Paracetamol is an over–the-counter medication used for its analgesic and antipyretic 
properties. Despite its widespread use and availability paracetamol is responsible for the 
highest number of pharmaceutical product poisonings within the United States Of America 
(USA), with approximately 78,000 people requiring emergency room treatment and 
approximately 500 deaths per year (Litovitz et al., 2002; Budnitz et al., 2011). While 
therapeutic doses of paracetamol are considered safe, overdose can cause centrilobular 
hepatic necrosis which may be fatal (James et al., 2003). Following overdose the toxic 
metabolite N-acetyl-p-benzoquinone imine (NAPQI), formed via CYP450 isoenzymes, binds 
and subsequently depletes hepatic GSH reserves. The accumulating NAPQI can then 
covalently bind to macromolecules resulting in increased ROS production, JNK pathway 
activation, formation of MPTP, depolarization of the mitochondrial membrane potential 
and lastly necrotic cell death (Mitchell et al., 1973a; Latchoumycandane et al., 2007; Win et 
al., 2011). 
Despite the volume of research regarding paracetamol hepatotoxicity, a majority of this 
data has been gathered using in vivo rodent, primary culture models and not humans 
(Jaeschke et al., 2006; Jemnitz et al., 2008; Jaeschke et al., 2012; Xie et al., 2014). 
Specifically, much of the mechanistic information has been derived from mice as rats are 
generally resistant to paracetamol hepatotoxicity as demonstrated by lower levels of 
oxidative stress and mitochondrial protein adducts thus extrapolation to the clinic is 
difficult, whereas the pattern of toxicity seen in mouse models is more comparable to that 
observed within the clinic (McGill et al., 2012a). However key differences are noted with no 
clear understanding of their origin. For example, liver dysfunction is observed far earlier in 
mice following an overdose administration of paracetamol compared to humans. 
Specifically, following an overdose administration of paracetamol aminotransferase activity 
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can be detected in mouse plasma within 2-6 h which in contrast to human is rarely seen 
within the first 12-24 h (Singer et al., 1995; Knight et al., 2001). Furthermore, research using 
the current models, in vitro (HepG2, PHH) and in vivo (mouse), has not adequately defined 
the multi-mechanistic pathway of toxicity induced by paracetamol, in particular the 
interplay between NAPQI-mediated GSH depletion, NAPQI protein binding, the induction of 
reactive oxidant stress, formation of MPTP, activation (phosphorylation) of c-jun NH2-
terminal protein kinase (JNK) and the onset of apoptosis and necrosis is not fully 
understood.  
Currently PHH are considered one of the most advantageous models for the examination of 
the mechanisms of paracetamol hepatotoxicity. This is primarily due to the expression of 
CYP450 metabolic enzymes and key transporters, such BSEP, which allow for a model which 
is physiologically similar to the hepatic in-vivo environment (Kostrubsky et al., 2003; 
Wilkening et al., 2003; Kanebratt et al., 2008). Unfortunately, there remain numerous 
limitations regarding both their isolation and long term viability when in culture, inter-batch 
variation such as in cytochrome P450 isoform expression differences and whether there is 
evidence of an underlying state of liver disease (Guguen-Guillouzo et al., 2010; Bhogal et 
al., 2011). It is for these limitations that much  drug testing and pre-clinical  development 
rely on immortalised cells, derived from tumours, which are cultured in supraphysiological 
glucose conditions, even with their considerable limitations, as discussed in chapter 3 
(Marroquin et al., 2007; Hart et al., 2010). Thus in order to more faithfully recapitulate the 
clinical scenario an ideal in vitro model would require the following characteristics.  
Expression of phase I and II enzymes, more specifically CYP 2E1, 1A2, 3A4, and 2A6 plus 
sulfotransferase, UDP glucuronosyl transferase and glutathione-S-transferases in order to 
allow both metabolic activation plus detoxification (James et al., 2003). A fully functioning 
respiratory chain to allow for the production of reactive oxidative species (ROS) with 
subsequent oxidative stress pathways via iron and calcium metabolism and lastly a 
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functioning JNK pathway (Latchoumycandane et al., 2007; Hinson et al., 2010; Moon et al., 
2010; Win et al., 2011; van Swelm et al., 2012; Sison-Young et al., 2015; Sison-Young et al., 
2017). 
Therefore, the research described in this chapter will examine the utility of HepaRG cells for 
the assessment of paracetamol toxicity, particularly the role of metabolic activation and the 
mitochondria in the transduction of toxicity. Importantly, the pathways delineated will be 
compared to the mechanisms known to be initiated in the paracetamol overdose in 
patients. HepaRG cells were selected due to their increased metabolic competency and 
similarity to hepatocytes  as previously discussed (Troadec et al., 2006; Annand et al., 2009; 
Hart et al., 2010; Gerets et al., 2012; Sison-Young et al., 2015; Sison-Young et al., 2017).  
Therefore, the studies detailed in this chapter will examine the utility of HepaRG cells for 
the elucidation of the mechanism of toxicity induced by paracetamol, in particular via 
mitochondrial dysfunction. In order to do this the following aims will be carried out: 
• The suitability of HepaRG cells for this purpose will be assessed; specifically, the 
chemical metabolism of paracetamol in HepaRG cells will be assessed by the mass 
spectrometric quantification of the phase II adducts formed following bioactivation 
to NAPQI.  
• In order to determine the relevance of toxic pathways induced in HepaRG cell to 
the clinical situation, the role of glutathione and n-acetyl cysteine in the onset of 
toxicity will be examined.  
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5.2. Methods and Materials 
5.2.1. Materials 
Foetal bovine serum (FBS), dialysed foetal bovine serum (DFBS) was purchased from 
LifeTechnologies (Paisley, UK). HepaRG cells and all required media and supplements were 
acquired from Biopredic International (Saint Grégoire, France).Williams’ Medium E, w/L-
Glutamine w/o Glucose (Powder) manufactured from United Stated Biological was 
purchased from Stratech Scientific Ltd (Suffolk, UK). Bradford reagent was purchased from 
Bio-Rad Laboratories Ltd (UK). All remaining materials and reagents were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). 
 
5.2.2. Cell culture and experimental preparation 
 
Cell culture, experimental preparation and metabolic modification has already been 
described (Chapter 3, sections 3.2.2 and 3.2.3). 
Paracetamol (0 to 30 mM) was prepared in 0.5 % v/v DMSO in glucose or glucose free 
media before it was added to the differentiated HepaRG cells and returned to the incubator 
(37 
o
C, 5 % CO2) for the appropriate length of incubation   
5.2.3. Combined assays for assessing cellular ATP, LDH release and protein quantification 
 
The methodology of the combined assays has already been described (Chapter 2, section 
2.2.4), with the exception that protein analysis was determined using the methods 
described by Bradford (Bradford, 1976). 
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5.2.4. Mass spectrometric analysis of chemical activation and detoxification of paracetamol   
 
HepaRG cells were cultured, seeded into clear flat bottomed 96 well plates and 
differentiated in accordance with Biopredic international guidelines. Cells were dosed (100 
µl) in triplicate with paracetamol (0 to 30 mM) and returned to the incubator (37 
o
C, 5 % 
CO2) for 1 and 2 h. Following the dosing period, plates and dosing solutions were stored (24 
h, t -30 
o
C). 
Prior to analysis, plates were defrosted and wells were scraped into media and drug 
supernatant and left in the plate. The cell suspension (50 µl) was then transferred to a 
deep, clear-bottomed96 well plate and sealed. The remaining cell suspension (50 µl) was 
retained for protein analysis by Bradford. Mass spectrometry analysis of the samples was 
carried out by Dr Mark Bayliss, Centre for Drug Safety Science, University of Liverpool. 
5.2.5. Assessment of total GSH content following dosing with paracetamol 
 
HepaRG cells were cultured, seeded into clear flat bottomed 24 well plates and 
differentiated in accordance with Biopredic international guidelines. Cells were dosed (100 
µl) in duplicate with paracetamol (0 to 30 mM in glucose media) and returned to the 
incubator (37 
o
C, 5 % CO2) for 1 and 2 h. 
Following drug incubation cells were scraped into media and drug suspension (500 µl) and 
transferred to a 1.5ml Eppendorf micro centrifuge tube and centrifuged (1000 rpm, 2min). 
Supernatant was discarded. Hydrochloric acid (10 mM, 250 μl) was added to the pellet and 
vortexed. For Bradford analysis a sample (50μl) was removed to a clean 1.5ml micro 
centrifuge tube and placed on ice or stored (-80 
o
C) . To the remaining sample was added 5-
Sulfosalicylic Acid (6.5%, 50μl) before placing on ice to allow precipitation of protein. The 
sample was then centrifuged (18,400 g, 5 mins, 4
o
c) and the supernatant retained for 
testing 
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GSH Stock Buffer 6.3mM EDTA and 143mM NaH2PO4 
8.58g NaH2PO4.2H2O 
1.17g EDTA disodium salt 
500ml dH20 
pH to 7.4 using 5M NaOH 
 
  1mM GSH Stock Solution 
3.07mg GSH in 10ml GSH Stock Buffer 
Dilute the 1mM GSH solution 1:10 to get a 0.1mM GSH 
solution. 
  Daily Assay Reagent 
9.908mg DTNB (5,5-dithiobis-1,2-nitrobenzoic acid) 
7.08mg NADPH 
25ml GSH Stock buffer 
 
GSH Reductase 
Calculate the volume of  GSH reductase required in 
10ml GSH stock buffer at concentration of 6.96 units/ml 
Table 5.1. Buffers and reagents required for total GSH 
assay. 
 
GSH standards (0 to 40 nmoles/ml) were made up in GSH stock buffer. Samples were then 
diluted (1 in 5) in GSH stock buffer. Diluted samples and GSH standards (20 µl) were added 
to a clear 96 well flat plate.  Stock buffer (20 µl) and daily assay reagent (200 µl) were 
added to each well and left to incubate (5 min/RT). GSH reductase (50 µl) was then added 
to each well and plate was immediately read using a Varioskan flask spectrophotometer 
(Thermo Scientific, Loughborough, UK) using a kinetic protocol and an absorbance 
wavelength of 410 nm. 
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5.2.6. Assessing whether N-acetylcysteine (NAC) protects against paracetamol induced 
mitochondrial toxicity  
 
HepaRG cells were cultured, seeded into clear flat bottomed 96 well plates and 
differentiated in accordance with Biopredic international guidelines. 
Cells were acutely metabolically modified and pre-treated with and without NAC (0.25 mM, 
2h). Following modification and NAC pre-treatment cells were dosed (100 µl) in triplicate 
with paracetamol (0 to 30 mM) and returned to the incubator (37 
o
C, 5 % CO2) for 2 hours. 
Acetaminophen concentrations were made up in glucose and galactose media. 
Following incubation the combined assays were carried out. The methodology of the 
combined assays has already been described, (Chapter 2. section 2.2.4) with the exception 
that Bradford protein analysis was used in place of BCA analysis. 
5.2.7. Statistical analysis 
 
GraphPad Prism 5 was used for the statistical analysis of data. Data are presented as the 
mean of 3 independent experiments ± standard deviation. The normality of data were 
tested for normality of distribution using the Shapiro-Wilk test. Normal data were tested 
for statistical significance using 1- or 2- way Anova as appropriate, non-normal data was 
tested using Mann-Whitney. A result was deemed significant when p-value <0.05%.  
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5.3. Results 
5.3.1. An acute (2h) incubation with paracetamol does not reveal mitochondrial toxicity 
 
Following a 2 hour incubation with paracetamol (Fig. 5.1) there was no significant change in 
cellular ATP (IC50-ATP glu = >300 μM and IC50-ATP glu = >300 μM) nor LDH reserve levels 
(IC50-LDH glu = >300 μM and IC50-LDH gal = >300 μM) within either media condition.  
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Figure 5.1. Cellular ATP determination and LDH reserve in HepaRG cells cultured in either 
glucose or galactose, following acute metabolic modification, and treatment with 
paracetamol (0-300 µM) 2 h. ATP Values are expressed as a % of vehicle control normalised 
to protein content. LDH values are expressed as a % of vehicle control. Results are mean ± 
S.D. of three or more independent sets of experiments. * = P<0.05, **= P<0.01, and *** = 
p<0.001 significance compared to vehicle control.  
 
5.3.1.2. High concentrations of paracetamol (0-30 mM) reveal mitochondrial toxicity during 
short term incubations (6 and 2 h)  
 
At short incubation times (6 h) there was no significant change in cellular ATP levels in cells 
cultured in glucose and although cells cultured in galactose were more sensitive, the 
changes were too small to indicate a clear mitochondrial liability: IC50-ATP glu/ IC50 ATP gal 
ratio which was 1.3 (p 0.0386)(Table 5.2) (Fig.5.2). There was no change in LDH reserve over 
the entire concentration range. 
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  IC50-ATP (mM) ± S.D. IC50-LDH (mM) ± S.D. IC50-ATP 
glu/ IC50 
ATP gal (p 
value) 
IC50-LDH 
gal/ IC50 
ATP gal (p 
value) 
Time point 
(h) 
Glucose Galactose Glucose Galactose     
6 >30 23.2 ± 3.5 >30 >30 
1.3 
(0.0386) 
> 1.3  
Table 5.2. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely modified HepaRG cells following treatment with 
paracetamol (0 – 30 mM,6  h). Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 ATP 
gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 ATP 
gal >2 
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Figure 5.2. Cellular ATP determination and LDH reserve in HepaRG cells cultured in either 
glucose or galactose, following acute metabolic modification, and treatment with 
paracetamol (0-30 mM) 6 h. ATP Values are expressed as a % of vehicle control normalised 
to protein content. LDH values are expressed as a % of vehicle control Results are mean ± 
S.D. of three or more independent sets of experiments. * = P<0.05, **= P<0.01, and *** = 
p<0.001 significance compared to vehicle control. 
 
A further reduction of the incubation time (2 h) demonstrated no significant change in 
cellular ATP levels in cells cultured in glucose and although cells cultured in galactose were 
more sensitive, the changes were too small to indicate a clear mitochondrial liability: IC50-
ATP glu/ IC50 ATP gal ratio which was 1.1 (p 0.0016)(Table 5.3) (Fig. 5.3). There was no 
change in LDH reserve.  
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  IC50-ATP (mM) ± S.D. IC50-LDH (mM) ± S.D. IC50-ATP 
glu/ IC50 
ATP gal (p 
value) 
IC50-LDH 
gal/ IC50 
ATP gal (p 
value) 
Time point 
(h) 
Glucose Galactose Glucose Galactose     
2 >30 
 27.9 ± 
0.26 
>30 >30 
1.1 
(0.0016) 
~ 1 
Table 5.3. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios for acutely modified HepaRG cells following treatment with 
paracetamol (0 – 30 mM, 2  h). Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 ATP 
gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 ATP 
gal >2 
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Figure 5.3. Cellular ATP determination and LDH reserve in HepaRG cells cultured in either 
glucose or galactose, following acute metabolic modification, and treatment with 
paracetamol (0-30 mM, 2 h). ATP Values are expressed as a % of vehicle control normalised 
to protein content. LDH values are expressed as a % of vehicle control Results are mean ± 
S.D. of three or more independent sets of experiments. * = P<0.05, **= P<0.01, and *** = 
p<0.001 significance compared to vehicle control. 
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5.3.1.3. High concentrations of paracetamol (0-30 mM) reveal possible indirect 
mitochondrial toxicity during an extended incubation (24 h)  
 
Following an extended (24 h) incubation (Fig. 5.4) with an increased concentration range (0 
to 30 mM) of paracetamol, cellular ATP decreased in both glucose and galactose cultured 
cells, which became significant at the highest concentration (30 mM).  By assessing the IC50-
ATP glu and IC50 ATP gal values it was noted that cells cultured in galactose were more 
sensitive to paracetamol (IC50-ATP glu =  >30  and IC50 ATP gal = 13.64 ± 2.9)(Table 5.4). This 
results in an IC50-ATP glu/ IC50 ATP gal ratio of 2.2 (p 0.0053), indicating mitochondrial 
toxicity. There was no change in LDH reserve over the entire concentration range.    
  IC50-ATP (mM) ± S.D. IC50-LDH (mM) ± S.D. IC50-ATP 
glu/ IC50 
ATP gal (p 
value) 
IC50-LDH 
gal/ IC50 
ATP gal (p 
value) 
Time point 
(h) 
Glucose Galactose Glucose Galactose     
24 >30 
13.64 ± 
2.9 
>30 >30 
2.2 
(0.0053) 
N/A as 
IC50-LDH 
gal >30 
mM 
Table 5.4. IC50-ATP and IC50-LDH values plus IC50-ATP glu/ IC50 ATP gal and IC50-LDH gal/ 
IC50 ATP gal ratios  for acutely modified HepaRG cells following treatment with 
paracetamol (0 – 30 mM) for 24 h. Mitochondrial toxicity is defined when IC50-ATP glu/ IC50 
ATP gal >2. Mitochondrial toxicity occurring before cell death is defined as IC50-LDH gal/ IC50 
ATP gal >2. 
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Figure 5.4. Cellular ATP determination and LDH reserve in HepaRG cells cultured in either 
glucose or galactose, following acute metabolic modification, and treatment with 
paracetamol (0 - 30 mM, 24 h). ATP Values are expressed as a % of vehicle control 
normalised to protein content. LDH values are expressed as a % of vehicle control Results 
are mean ± S.D. of three or more independent sets of experiments. * = P<0.05, **= P<0.01, 
and *** = p<0.001 significance compared to vehicle control. 
 
5.3.2. Mass spectrometric analysis of the bioactivation of paracetamol in HepaRG cells  
 
Paracetamol glucuronide detection increased in a dose-and time dependent manner with 
significant levels reached at 3.3 mM of paracetamol dosed at both time points (1 and 2 h). 
The maximum paracetamol glucuronide detected at the top concentration (30 mM) for 
both time points (1 and 2 h) was approximately 20 µmoles/mg and 50 µmoles /mg 
respectively (Fig 5.5 A and Table 5.5).   The amount of sulphated-paracetamol metabolite 
increased in a dose- and time- dependent manner with significant levels reached at 1 mM 
of paracetamol dosed at both timepoints (1 and 2 h (Fig. 5.5 B and Table 5.5).Cysteine 
adduct detection increased in a dose- and time- dependent manner with significant levels 
reached at 3.3 mM of paracetamol dosed at both time points). The maximum cysteine 
adduct detected at the top concentration (30 mM) for both time points (1 and 2 h) was 
approximately 0.15 µmoles /mg and 0.3 µmoles /mg respectively (Fig 5.5 C and Table 5.5). 
The detection of GSH-paracetamol conjugate detection increased in a dose- and time 
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dependent manner becoming significant during the longer (2 h) timepoint at 3.3 mM). The 
maximum GSH-paracetamol conjugate detected at the top concentration (30 mM) for both 
time points (1 and 2 h) was approximately 0.25 µmoles /mg and 0.4 µmoles /mg 
respectively (Fig 5.5 D and Table 5.5).  
  Glucuronide 
(µmoles) per µg 
protein ± S.D. 
Sulphation 
(µmoles) per µg 
protein ± S.D. 
Cysteine 
adducts 
(µmoles) per µg 
protein ± S.D. 
Glutathione 
conjugate 
(µmoles) per µg 
protein ± S.D. 
Conentration 
(mM) 
1 hour 2 hour 1 hour 2 hour 1 hour 2 hour 1 hour 2 hour 
0.1 0 0 0 0 0 0 0 0 
1 0.7 ± 1.2 
8.9 ± 
2.1 
1.5 ± 
0.1 
2.6 ± 
0.1 
1.5 ± 
0.1 
2.6 ± 
0.1 
0.02 ± 
0.0 
0.03 ± 
0.01 
3 
10.8 ± 
0.5 
17.8 ± 
0.7 
2.4 ± 
0.2 
4.1 ± 
0.3 
2.4 ± 
0.1 
4.1 ± 
0.3 
0.07 ± 
0 
0.08 ± 
0.01 
10 
18.4 ± 
1.7 
26.5 ± 
1.5 
2.7 ± 
0.3 
4.0 ± 
0.2 
2.7 ± 
0.3 
4.0 ± 
0.2 
0.18 ± 
0.06 
0.18 ± 
0.01 
30 
22.2 ± 
11.5 
50.7 ± 
8.1 
1.6 ± 
0.2 
2.8 ± 
0.3 
1.6 ± 
0.2 
2.8 ± 
0.2 
0.26 ± 
0.05 
0.40 ± 
0.06 
Table 5.5. Mass spectrometric analysis of the bioactivation of paracetamol in HepaRG 
cells. Glucuronide, sulphation, cysteine adducts and glutathione conjugates ((µmoles) were 
measured within HepaRG cells after treatment with paracetamol (0 – 30 mM) for 1 and 2 
hours respectively. 
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Figure 5.5. Mass spectrometric analysis of HepaRG cells following incubation of 
paracetamol (0 - 30 mM) for 1 and 2 h. (A) Glucuronide conjugate, (B) sulphated adduct, 
(C) cysteine adducts, and (D) GSH conjugates. Values (µmoles) are normalised to protein 
content. Results are mean ± S.D. of three or more independent sets of experiments. * = 
P<0.05, **= P<0.01, and *** = p<0.001 significance compared to vehicle control.  
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5.3.3. Acute incubation (2 h) with paracetamol did not alter total GSH content 
 
No significant change in total GSH content was observed as the concentration of 
paracetamol was increased over 2 h (Fig. 5.6).  
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Figure 5.6. Total GSH content analysis in HepaRG cells following incubation with 
paracetamol (0-30 mM, 1 and 2 h). Total GSH values are expressed as a % of vehicle control 
normalised to protein content. Results are mean ± S.D. of three or more independent sets 
of experiments. * = P<0.05, **= P<0.01, and *** = p<0.001 significance compared to vehicle 
control. 
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5.3.4. N-acetylcysteine  (NAC) does not protect against paracetamol induced mitochondrial 
toxicity 
 
Cellular ATP levels in cells with pre or no pre-treatment (NAC) did not decrease and become 
significant until the highest concentration (30 mM) of paracetamol (Fig. 5.7). Both pre and 
not pre-treated cells were equally sensitive to paracetamol. LDH reserve did not alter from 
vehicle control for either pre or not pre-treated cells.  
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Figure 5.7. Cellular ATP determination and LDH reserve analysis in HepaRG cells following 
incubation with paracetamol (0-30 mM) and with and without NAC (0.25 mM) for 2 h. 
Cells were cultured in galactose. ATP Values are expressed as a % of vehicle control 
normalised to protein content. LDH values are expressed as a % of vehicle control Results 
are mean ± S.D. of three or more independent sets of experiments. * = P<0.05, **= P<0.01, 
and *** = p<0.001 significance compared to vehicle control.  
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5.4. Discussion 
 
Paracetamol toxicity from overdose is widespread and is currently responsible for one-half 
of acute liver failures within the UK and USA (Hinson et al., 2010). While its hepatotoxicity 
can be described as direct and as such dose dependent, the precise mechanisms of toxicity 
and pathways have not yet been fully elucidated. Much of the mechanistic studies of 
paracetamol toxicity has been gathered using rodent models. However, with interspecies 
differences one cannot have complete confidence in extrapolating from rodents to humans. 
PHHs which provide for a more hepatic like in vivo environment have been utilised but their 
limited life span, coupled with a decrease in the expression of crucial drug metabolising 
enzymes and intra-individual variability highlight their limitations (Guguen-Guillouzo et al., 
2010; Bhogal et al., 2011). The more PHH like phenotypic characteristics held by the 
HepaRG line therefore offers a novel in vitro model which may better represent the 
pathways of toxicity induced in humans due to the increased levels of phase I and II 
enzymes, transporters and polarised membranes than traditional in vitro models. 
Therefore, the aim of this chapter was to undertake a preliminary evaluation of the 
chemical and molecular pathways of toxicity induced by paracetamol in HepaRG cells.  
In order to test the hypothesis whether HepaRG cells could serve as an alternative to PHH 
in investigating paracetamol hepatotoxicity and mitochondrial toxicity a series of 
experiments including testing direct mitochondrial toxicity of paracetamol by assessing the 
effect of the drug on ATP production in a glucose deprived environment; and mass 
spectrometric assessment of metabolic turnover of paracetamol into its main metabolites 
were utilised.      
Following a short (2h) incubation of the cells to low doses of paracetamol in galactose 
media there was no significant alteration in either cellular ATP levels or LDH reserve. This 
was expected because the concentrations used in this experiment (up to 300 uM) were not 
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equivalent to what was reported to produce any evidence of paracetamol toxicity in vitro 
(McGill et al., 2011a). However, when the higher concentrations were applied for 2 hours 
and 6 hours, the paracetamol concentration that caused 50 percent reduction in ATP level 
compared to the vehicle control was significantly lower for cells pre-treated with galactose 
media, those that received glucose.  There was no evidence for the occurrence of cell 
necrosis at this point as was indicated by the steady level of preserved cellular LDH even 
with the highest concentration (30 mM). This indicates a direct mitochondrial damage 
caused by paracetamol and/or its metabolite in the space of 2 hours. When the duration of 
drug exposure was increased to 24 hours, although the ATP level in cells pre-treated with 
glucose media declined in a dose dependent manner it never reached 50% of the vehicle 
control.  Also, there still was a statistically significant difference between ATP-IC50 of the 
drug for cells pre-treated with galactose media and glucose media.  The LDH level was not 
affected even after 24 hours.   
Importantly, the effects observed at the increased concentration range can be rationalised 
to represent the clinical situation during overdose where plasma levels have been recorded 
at levels as high as approximately 340 mg/L, which equates to approximately 2.3 mM 
(Dargan et al., 2001). Interestingly, although at a reduced level and did not reach 50% of 
vehicle control, cellular ATP was also decreased in the presence of glucose exposed cells. In 
this situation ATP decrease is occurring even though glycolytic activity is available to 
compensate for inhibition of OXPHOS. Using prior research findings it could be speculated 
that paracetamol has multiple effects in the mitochondria. The positive result in the glu/gal 
assay is suggestive of a direct effect upon electron transport chain activity (Kamalian et al., 
2015b). However, it has been shown that the binding of NAPQI to critical mitochondrial 
proteins leads to the initiation of an MPTP event with subsequent swelling of the 
mitochondrial and apoptosis (Kon et al., 2004; Kon et al., 2007). It is therefore possible that 
184 
 
at this longer time point mitochondrial dysfunction is increased and two effects may be 
underway; direct ETC insult and initiation of an MPTP event.  
In clinical overdose, toxicity is a result of NAPQI formation following GSH depletion. 
Therefore it was important to investigate whether the same chemical species could be 
responsible for mitotoxicity in the HepaRG cells in the timeframe tested in this study. The 
paracetamol glucuronide and sulphation metabolites which form part of the detoxification 
pathways (Fig. 5.8) of the parent compound were detected, which were seen to increase 
over time.  Importantly, the HepaRG cells were demonstrated to be metabolically sufficient 
in activating paracetamol to NAPQI via CYP-mediated metabolism as GSH conjugates could 
be measured from 1 h, with increases over time. As NAPQI is detoxified by cellular GSH, the 
presence of GSH conjugates provides good evidence of its turnover from parent compound, 
paracetamol. However, at these early timepoints the actual levels of metabolites are very 
low. This suggests that although paracetamol metabolic pathways are functional the 
turnover to NAPQI is very low and the majority of the dose remains as paracetamol. These 
results are supported by research which has shown that the HepaRG cells contain higher 
levels of the CYP enzymes important for paracetamol bioactivation; CYP1A2 (X 2.04), 3A4 (X 
19.1) and 2E1 (X 5.53) expression compared with the HepG2 line (Kanebratt et al., 2008; 
Hart et al., 2010; Gerets et al., 2012).  Further support of paracetamol metabolic activation 
was demonstrated by the presence of cysteine adducts. 
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Figure 5.8. Schematic representing the metabolism of Acetaminophen during toxicity 
Paracetamol undergoes detoxification via the sulphation or glucuronidation pathways. At 
non-toxic doses a small proportion of paracetamol is metabolised by phase I hepatic 
enzymes mostly CYP2E1 and to a lesser extent by CYPs 3A4, 2D6 and CYP1A2 to the toxic 
metabolic NAPQI. NAPQI is detoxified at non-toxic doses by GSH. However, at toxic doses 
the GSH detoxification pathway becomes saturated allowing NAPQI to bind to 
macromolecules, an increase in reactive oxidant stress, JNK activation, formation of MPTP 
and lastly toxicity in the form of necrosis. 
 
It is known that following a toxic dose of paracetamol hepatic GSH reserves are depleted by 
approximately 90% (James et al., 2003). This depletion of the body’s natural protection 
against electrophiles allows for the reactive metabolite to covalently bind to critical 
proteins (Mitchell et al., 1973a). This is the chemical hallmark of clinical paracetamol 
overdose. Therefore, based upon the low level of turnover of paracetamol suggested by 
mass spectrometric study, it was important to examine whether the same pathway was 
responsible for toxicity in HepaRG cells. The assessment of total GSH content in vitro in 
combination with the use of exogenous GSH modulators has enabled a mechanistic 
interrogation of its role in paracetamol toxicity; specifically, whether paracetamol 
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metabolic activation has taken place and moreover whether paracetamol bioactivation  
leads to GSH depletion and toxicity of HepaRG cells.  It was seen that total GSH content did 
not alter from vehicle control at any point including, importantly, at time points where 
mitochondrial effects were observed. This supports the mass spectrometry findings that 
although NAPQI turnover takes place, levels are low and therefore not enough NAPQI is 
produced to deplete GSH stores. This may arise due to the short time points which were 
measured as previous studies have shown turnover of NAPQI in HepaRG cells  following 1 
hour of paracetamol exposure with no significant GSH depletion (McGill et al., 2011b).  
However, it should also be noted, other limitations may impact including  the measurement 
of total GSH, rather than only in sub-cellular compartments such as the mitochondria, and 
that there has been reported increased expression of glutathione-S-transferase (GST) genes 
in HepaRG cells when compared to HepG2 cells which may reduce the effects of NAPQI-
induced depletion of total GSH content (Hart et al., 2010). It could be postulated that a 
higher expression of GSH would lead to a situation whereby NAPQI turnover is 
underestimated. Additionally, it has been reported that HepaRG cells demonstrate a higher 
expression of GST genes compared with PHH following differentiation which could hinder 
the assessment of total GSH (Kanebratt et al., 2008; Sison-Young et al., 2015). 
The accumulated data from the glu/gal assay, mass spectrometric analysis and GSH 
depletion study support the hypothesis that paracetamol is inducing mitochondrial damage 
in the absence of glutathione depletion. Thus suggesting that it may be independent of 
NAPQI. Therefore, in order to confirm the lack of a role of GSH in toxicity, NAC was used. 
NAC was introduced within the 1970s to treat paracetamol overdose. Even today NAC is 
still the antidote of choice as it can be administered up to 48 h post paracetamol ingestion 
(Saito et al., 2010). The mechanism of action involves the promotion of hepatic GSH 
synthesis thus replenishing depleted hepatic GSH reserves and providing enough 
glutathione to scavenge NAPQI and prevent the formation of protein adducts which are the 
187 
 
cause of hepatotoxicity (Lauterburg et al., 1983). The pre-treatment of the galactose 
cultured cells with NAC did not prevent mitochondrial insult, which fits with the lack of 
paracetamol-induced GSH depletion, thus supporting the conclusion that within the short 
(1 and 2 h) time points NAPQI is not responsible for the observed mitochondrial toxicity.  
Overall, these results suggest that the observed mitochondrial injury seen within the short 
incubations maybe due to parent compound (paracetamol) rather than NAPQI. Although 
such a chemical mechanism goes against the accepted mechanism of paracetamol toxicity 
in the clinic this phenomenon of NAPQI-independent effects has also been reported by 
others. For example, Kamalian et al. reported similar observations using an acute metabolic 
screen and incubating HepG2 cells with paracetamol (4 h). The author suggested the 
observed mitochondrial toxicity was primary compound in origin as the lack of CYP450 
expression led to barely detectable levels of NAPQI production (Kamalian et al., 2015b).  
Work using isolated rat mitochondria has also demonstrated that paracetamol induced 
mitochondrial toxicity may also be primary compound in origin. Specifically, Ramsay et al. 
and Meyers et al. propose that paracetamol itself causes a reversible inhibition of NADH 
linked respiration, thus supporting the idea that paracetamol can cause a direct effect upon 
ETC activity (Meyers et al., 1988; Ramsay et al., 1989). More recently, work undertaken by 
Prill et al. using a bioreactor to culture spheroid HepaRG/3A4 cells has demonstrated that 
paracetamol induced CYP450-independent mitochondrial dysfunction via complex III 
inhibition (Prill et al., 2016). In the study ascorbic acid and complex IV reducing substrate, 
N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD), were used and shown to eliminate the 
toxicity of paracetamol. However, it is important to note that such a NAPQI-independent 
mechanism can only be postulated at the early time-points (up to 2 h), for which 
bioactivation and GSH data have been collected.  As incubation length is increased 
paracetamol turnover via NAPQI may be increased inducing different mechanisms of 
toxicity, for example MPTP (Kaplowitz, 2004; Kaplowitz, 2005; Abboud et al., 2007). Such 
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extended incubations (24 h) in HepaRG cells have been reported and  it was demonstrated 
that there was significant decreases in total GSH and cell viability (as measured by LDH) plus 
a significant increase in protein adducts, thus suggesting an increased generation of NAPQI 
(McGill et al., 2011a).  However, McGill reported significant cell death at 24 h which 
contrasts that seen within the initial acute metabolic screen data.  
Overall the main findings of this chapter can be summarised as follows: 
• The glu/gal acute metabolic modification screen in HepaRG cells demonstrates the 
possibility that the paracetamol parent compound may display a mitochondrial 
liability in the course of hepatotoxicity in vitro.  
• This is in direct contrast to the accepted clinical mechanism of toxicity. Whether 
this finding of direct paracetamol toxicity has relevance to the understanding or 
management of clinical paracetamol overdose is currently unknown. However, the 
studies reported in this chapter highlight the power of using in vitro models to 
uncover fine toxicological and mechanistic detail. Many questions still remain 
regarding paracetamol hepatotoxicity even though its toxicology is both direct and 
predictive.    
• The HepaRG are metabolically sufficient as demonstrated by the detection of GSG 
conjugates following a short (1-2 h) incubation with paracetamol. While this 
concentration of GSH conjugate was appreciably low it still provides much evidence 
for NAPQI turnover and thus metabolic sufficiency. 
• Recapitulating hepatotoxicity within an in vitro model is both challenging and 
fraught with limitations, however, defining the utility the HepaRG model is an 
important step in producing more predictive models of DILI for use preclinically.  
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DILI remains of major concern to both clinicians and the pharmaceutical industry due to 
both acute hepatic dysfunction and drug attrition either during development or post 
marketing as with the case of troglitazone (Kohlroser et al., 2000). With a greater onus now 
being placed on mitochondrial toxicity, it has been postulated that DIMD could account for 
cases of DILI which are not adequately explained by the traditional mechanisms. Evidence 
of the link between DILI and DIMD is growing; many drugs which have been implicated with 
DILI are now known to display mitochondrial liabilities (McKenzie et al., 1995b; Colacino, 
1996; Boelsterli, 2003a; Bova et al., 2005a; Chan et al., 2005; Boelsterli et al., 2007).  
Traditionally DIMD testing has often been overlooked or left too late in the drug 
development process thus allowing drugs with mitochondrial liabilities to be approved with 
mitochondrial toxicity discovered post marketing (Dykens et al., 2007b; Dykens et al., 
2007a; Will et al., 2014). Thus it is of great importance that industry has the correct screens 
available which are able to identify compounds with mitochondrial liabilities and do so 
using models which are physiologically relevant.   
The FIAU HepG2 studies carried out within this thesis demonstrate that the detection of 
mitochondrial toxicity in compounds with mitochondrial liabilities is at times both difficult 
and challenging. The data exemplify the above issue and demonstrate why clinically 
relevant models are required for the screening and detection of mitochondrial toxicity. 
While the data contradicted that seen within the clinic it was concluded that experimental 
set up such as drug incubation duration may be key to demonstrating the mitochondrial 
liability held by FIAU.  
The long term stability of HepaRG cells in culture enabled utilisation in the chronic 
screening of FIAU. More specifically the line enabled 5 weeks of drug incubation which as of 
present has not been seen in the literature with respect to FIAU mediated mitochondrial 
toxicity. As aforementioned earlier studies within this thesis could not demonstrate FIAU 
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induced mitochondrial toxicity even following 7 day incubation in HepG2 cells. This 
observation is a real problem as the line is commonly used for drug toxicity studies and thus 
real questions remain as to its suitability. It was demonstrated that the increasingly stable 
nature of HepaRG cells allowed the sufficient accumulation of dysfunctional mtDNA 
following chronic FIAU dosing, with mitochondrial toxicity observed at 2 weeks using the 
acute metabolic screen. This finding was novel because as of the present FIAU induced 
mitochondrial toxicity had not been demonstrated using an acute metabolic screen in 
HepaRG cells nor had any published models demonstrated the downstream mechanistic 
effects of FIAU. While work using 3D PHH had demonstrated FIAU induced mitochondrial 
dysfunction with endpoint analysis being cellular ATP concentration, the lack of cytotoxicity 
assessment gave rise to the question; could the decrease in cellular ATP levels be a product 
of cellular death? (Bell et al., 2016). The novelty of the simultaneous measurement of both 
cellular ATP and LDH reserve allowed for the detection of mitochondrial toxicity in the 
absence of cellular death in this thesis (IC50LDH Gal: Ic50ATP Gal <2). Further mechanistic 
studies within this thesis also demonstrated that FIAU significantly depleted mtDNA and 
significantly caused a decrease in the expression of nuclear encoded complex II and 
mitochondrially encoded complex II. This finding was significant in that much literature has 
proposed that FIAU causes depletion in mtDNA with subsequent mitochondrial dysfunction 
due to abnormal expression of key ETC complex proteins (McKenzie et al., 1995b; Colacino 
et al., 1996; Horn et al., 1997). The utilisation of Seahorse technology allowed for further 
downstream effects to be investigated and thus increased examination of the mechanism 
of toxicity. It was revealed that while direct mitochondrial ETC dysfunction was not 
observed, decreases in basal and ATP levels in the absence of a decrease in mitochondrial 
mass would indicate that the ETC was running at a reduced rate. This observation led to a 
postulation that FIAU incorporation leads to a decrease in mtDNA with a subsequent 
decrease in the expression of crucial proteins which make up the ETC.   The FIAU studies 
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within this thesis highlight that the HepaRG line is able to provide a greater mechanistic 
insight into the observed toxicity seen within the failed phase II clinical trial. Furthermore, 
the Cmax of patients within the phase II FIAU trial was estimated to be approximately 2.5 
µM (Bowsher et al., 1994; Manning et al., 1995a). The data within this thesis demonstrate 
effects occurring at approximately 4 µM thus providing increased clinical relevance. 
Moreover, the novel data highlight that HepaRG can be utilised for long term toxicity 
studies, something for which HepG2 is not suited. This point is especially important in the 
development of new nucleoside analogues whereby HepaRG cells could be utilised for 
these chronic mitochondrial dysfunction studies. More recently an in vivo TK-NOG mouse 
model has been developed whereby mice possess humanised livers in a 3d scaffold. The 
immunodeficient strain expresses a herpes simplex virus type 1 thymidine kinase (TK) 
transgene. Following a nontoxic exposure to ganciclovir the mouse liver cells expressing the 
transgene are ablated, allowing the transplanted human cells to develop into a mature 
human liver organ. Xu et al. demonstrated that following  14 days of FIAU dosing both liver 
and mitochondrial abnormalities were observed more specifically increases in both ALT and 
Lactate, the latter being a hallmark in mitochondrial toxicity (Dykens et al., 2008a; Xu et al., 
2014). The model represents the first rodent model which can replicate that seen within 
the clinic. However, it lacks mechanistic detail such as the assessment of mtDNA depletion 
or assessment of ETC complex expression. Furthermore, the immunocompromised state of 
the mice could hinder the assessment of hepatotoxins due to a lack of potential immune 
mediated effects.  
Through the utilisation of differentiated HepaRG cells a number of drugs, which according 
to the literature possessed mitochondrial liability, were assessed for mitochondrial toxicity 
using the acute metabolic screen. The studies posed the questions; can HepaRG undergo 
metabolic modification and if so are they a better hepatoma line in identifying compounds 
with mitochondrial liabilities. The studies constituted a novel chapter of work as it the first 
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time HepaRG cells have been acutely modified for the purpose of mitochondrial toxicity 
screening. Interestingly when compared with previously published work using acutely 
modified HepG2 cells,  the HepaRG line demonstrated no significant advantage in detecting 
mitochondrial liabilities of the compounds tested (Kamalian et al., 2015b). It could be 
argued that the additional cost in terms both financially and long lead time in the utilisation 
of HepaRG is not outweighed by their phenotypic advantages compared with HepG2. 
HepG2 cells are ideal candidates for acute parent compound and metabolite toxicity 
screening as they still express the majority of phase II enzymes (Westerink et al., 2007; Hart 
et al., 2010). However, their lack of bioactivation capacity and biliary phenotype limits their 
use for compounds which require metabolic activation and those implicated in bile acid 
mediated mitochondrial toxicity (Mitchell et al., 1973b; Mitchell et al., 1973a; Dawson et 
al., 2012).  
While much research has been carried out using rodent models and PHH it was postulated 
that the more PHH like physiological characteristics held by the HepaRG line may be more 
advantageous at recapitulating the toxicity seen within humans and thus provide a better, 
more clinically relevant in vitro model. The aim of chapter 5 was to examine the chemical 
and molecular pathways of toxicity induced by paracetamol within HepaRG cells. The 
studies highlighted that the HepaRG cells have the metabolic capacity to bioactivate NAPQI 
even though the concentrations of adducts and GSH conjugates were incredibly low. This 
was in contrast to previous research in HepG2 cells whereby metabolic activation had not 
been detected at similar timepoints (Kamalian et al., 2015b). Furthermore, studies 
demonstrated that the parent compound may be causing mitochondrial dysfunction, which 
has been previously reported by other authors, but contradicts the main area of thought 
regarding APAP overdose toxicology in that only NAPQI possesses a mitochondrial liability 
(Meyers et al., 1988; Ramsay et al., 1989; Prill et al., 2016). With the limitations of both 
HepG2 and PHH, it could be conceived that the HepaRG line represents a model which is 
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more advantageous in the assessment of APAP overdose. Given the evidence of metabolic 
activation plus the ability of metabolic switching the line represents a model which can 
provide an increased mechanistic insight in terms of mitochondrial dysfunction. However, 
the lack of an activated JNK pathway during APAP toxicity which has been proposed as a 
crucial component could hinder their utility moving forward (Xie et al., 2014). To this extent 
it has been proposed that 2d PHH still remain the best model for investigating APAP 
induced hepatotoxicity (Xie et al., 2014). Hepatocyte lines cultured in 3d may provide a way 
of circumventing the limitations of 2d PHH and thus providing the optimal extrapolation 
back to the clinic. Recent work by Bell et al. has demonstrated the development of a 3d 
PHH model which is viable in culture for up to 5 weeks. Additionally, CYP450 expression 
plus bile phenotype was demonstrated not to significantly decrease during the 5 week 
duration (Bell et al., 2016). Owing to the limited availability of PHH, 3d hepatoma models 
such as HepG2 show promise in their utility in drug toxicity studies with increased phase I 
and II expression plus biliary like structures (Ramaiahgari et al., 2014). It has been reported 
that the 3d HepG2/C3A model is metabolically competent in the turnover of NAPQI in 
which native 2d HepG2 lack (Kamalian et al., 2015b; Prill et al., 2016).  In the direct 
assessment of mitochondrial dysfunction it could be postulated that the utilisation of 
permeabilised cells coupled with Seahorse technology may be advantageous and provide 
greater mechanistic insight, more specifically assessing which complexes of the ETC are 
inhibited by drugs or compounds (Salabei et al., 2014; Ball et al., 2016). In this scenario a 
compound testing positive within the acute metabolic screen could then be further 
interrogated to identify where in the respiratory chain is the target of toxicity.  
It should be appreciated that even if a drug has a mitochondrial liability, for example, an 
uncoupler or an inhibitor of the ETC this may not necessarily result in a severe 
manifestation of DILI. This point is important when considering recent work carried out by 
Aleo et al., whereby it was discovered that drugs with dual toxicities; mitochondrial and 
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BSEP inhibitors result in a higher degree of associated hepatic injury (Aleo et al., 2014). The 
work carried out by Aleo et al., highlights the fact the DILI is multifactorial and many factors 
need to be assessed in the study of DILI.    
The studies within this thesis highlight that metabolic modification is a powerful tool for 
identifying compounds and drugs with mitochondrial liabilities. Coupled with Seahorse 
technology, western blotting and Rt-PCR increased mechanistic integration is possible 
thereby delineating the mechanism of toxicity of drugs such as FIAU. It is also true that 
selection of the appropriate cell line must be taken into account as certain lines may be 
more advantageous than others in drug toxicity studies. For example, HepaRG are best 
suited for long term chronic dosing whereas HepG2 can be utilised for short term exposure 
studies. Furthermore, the lack of metabolic capacity held by HepG2 plus their lack of biliary 
structures hinders their use in studies requiring metabolic activation and or BSEP toxicity. It 
can thus be concluded that in order to assess both DILI and DIMD, models and assays need 
to be tailored or modified in order to replicate the in vivo environment thus enabling more 
accurate extrapolation to the clinic. 
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